

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5:

A61K 47/48

(11) International Publication Number:

WO 92/02257

(43) International Publication Date:

20 February 1992 (20.02.92)

(21) International Application Number:

PCT/US91/05476

A2

(22) International Filing Date:

6 August 1991 (06.08.91)

(30) Priority data:

566,208

10 August 1990 (10.08.90) US

(60) Parent Application or Grant

(63) Related by Continuation

Filed on

566,208 (CIP) 10 August 1990 (10.08.90)

(71) Applicant (for all designated States except US): G.D. SEARLE & CO. [US/US]; P.O. Box 5110, Chicago, IL 60680-5110 (US).

(72) Inventors; and
(75) Inventors/Applicants (for US only): MANNING, Robert, E. [US/US]; 1298 South Mason Road, St. Louis, MO 63131 (US). REITZ, David, B. [US/US]; 14814 Pleasant Ridge Court, Chesterfield, MO 63017 (US).

(74) Agents: KEANE, J., Timothy et al.; G.D. Searle & Co., Corporate Patent Department, P.O. Box 5110, Chicago, IL 60680-5110 (US).

(81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CG (OAPI patent), CG (OAPI patent), CD (OAPI p CH, CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE, DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MN, MR (OAPI patent), MW, NL, NL (European patent), NO, PL, RO, SD, SE, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US.

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: RENAL-SELECTIVE ANGIOTENSIN II ANTAGONISTS FOR TREATMENT OF HYPERTENSION

(57) Abstract

Renal-selective compounds are described which, in one embodiment, are prodrugs preferentially converted in the kidney to compounds capable of blocking angiotensin II (AII) receptors. These prodrugs are conjugates formed from two components, namely, a first component provided by an AII antagonist compound and a second component which is capable of being cleaved from the first component when both components are chemically linked within the conjugate. The two components are chemically linked by a bond which is cleaved selectively in the kidney, for example, by an enzyme. The liberated AII antagonist compound is then available to block AII receptors within the kidney. Conjugates of particular interest are glutamyl derivatives of biphenylmethyl 1H-substituted imidazole compounds, of which N-acetyl-L-glutamic acid, 5-[[4'-[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-ylmethyl] [1,1'-biphenyl]-2-yl]carbonyl]hydrazide shown above is an example.

+ DESIGNATIONS OF "SU"

It is not yet known for which States of the former Soviet Union any designation of the Soviet Union has effect.

12	Codes used to identify States party to the PCT on the front pages of pamphlets publishing internati					
арри	cations under the PCT.	-				
ΑT	Austria	ES	Spain	MG	Madagascar	
AU	Australia	Fl	Finland	ML	Mali	
BB	Barbados	FR	France	MN	Mongolia	
BE	Belgium	GA	Gabon	MR	Mauritania	
BF	Burkina Faso	GB	United Kingdom	MW	Malawi	
BG	Bulgaria	GN	Guinea	NL	Netherlands	
BJ	Benin	GR	Greece	NO	Norway	
BR	Brazil	HU	Hungary	PL	Poland	
CA	Canada	lT	İtaly	RO	Romania	
CF	Central African Republic	JР	Japan	SD	Sudan	
CG	Congo	KP	Democratic People's Republic	SE	Sweden	
CH	Switzerland		of Korea	SN	Senegal	
CI	Côte d'Ivoire	KR	Republic of Korea	su+	Soviet Union	
СМ	Cameroon	Ll	Liechtenstein	TD	Chad	
CS	Czechoslovakia	ŁK	Sri Lanka	TG	Togo	
DE	Germany	LU	Luxembourg	US	United States of America	
DK	Denmark	MC	Monaco			

WO 92/02257 PCT/US91/05476

1

RENAL-SELECTIVE ANGIOTENSIN II ANTAGONISTS FOR TREATMENT OF HYPERTENSION

Field of the Invention

5

10

30

35

This invention is in the field of cardiovascular therapeutics and relates to a class of compounds useful in control of hypertension. Of particular interest is a class of prodrugs of angiotensin II antagonists which, when selectively hydrolyzed in the kidney, provide hypertension control.

Background of the Invention

The renin-angiotensin system is one of the hormonal 15 mechanisms involved in regulation of pressure/volume homeostasis and in expression of hypertension. Activation of the renin-angiotensin cascade begins with renin secretion from the juxtaglomerular apparatus of the kidney and culminates in the formation of angiotensin II, an octapeptide which is the 20 primary active species of this system. Angiotensin II is a potent vasoconstrictor agent and also produces other physiological effects such as promoting aldosterone secretion, promoting sodium and fluid retention, inhibiting renin secretion, increasing sympathetic nervous system activity, 25 increasing vasopressin secretion, causing positive cardiac inotropic effect and modulating other hormonal systems.

Previous studies have shown that antagonizing angiotensin II at its receptors is a viable approach to inhibit the renin-angiotensin system, given the pivotal role of this octapeptide which mediates the actions of the renin-angiotensin system through interaction with various tissue receptors. There are several known angiotensin II antagonists, most of which are peptidic in nature. Such peptidic compounds are of limited use due to their lack of

oral bioavailability or their short duration of action. Also, commercially-available peptidic angiotensin II antagonists (e.g., Saralasin) have a significant residual agonist activity which further limit their therapeutic application.

5

10

15

20

25

30

35

Non-peptidic compounds with angiotensin II antagonist properties are known. For example, the sodium salt of 2-n-butyl-4-chloro-1-(2-chlorobenzyl)imidazole-5-acetic acid has specific competitive angiotensin II antagonist activity as shown in a series of binding experiments, functional assays and in vivo tests [P. C. Wong et al, J. Pharmacol. Exp. Ther., 247 (1), 1-7 (1988)]. Also, the sodium salt of 2-butyl-4-choloro-1-(2-nitrobenzyl)imidazole-5-acetic acid has specific competitive angiotensin II antagonist activity as shown in a series of binding experiments, functional assays and in vivo tests [A. T. Chiu et al, European J. Pharmacol., 157, 3121 (1988)]. A family of 1benzylimidazole-5-acetate derivatives has been shown to have competitive angiotensin II antagonist properties [A. T. Chiu et al, J. Pharmacol. Exp. Ther., 250 (3), 867-874 (1989)]. U.S. Patent No. 4,816,463 to Blankey et al describes a family of 4,5,6,7-tetrahydro-1H-imidazo(4,5-c)-tetrahydro-pyridine derivatives useful as antihypertensives, some of which are reported to antagonize the binding of labelled angiotensin II to rat adrenal receptor preparation and thus cause a significant decrease in mean arterial blood pressure in conscious hypertensive rats. EP No. 253,310, published 20 January 1988, describes a series of aralkyl imidazole compounds, including in particular a family of biphenylmethyl substituted imidazoles, as antagonists to the angiotensin II receptor. EP No. 323,841 published 12 July 1989 describes four classes of angiotensin II antagonists, namely, biphenylmethylpyrroles, biphenylmethylpyrazoles, biphenylmethyl-1,2,3-triazoles and biphenylmethyl 4substituted-4H-1,2,4-triazoles, including the compound 3,5WO 92/02257 PCT/US91/05476

3

dibutyl-4-[(2'-carboxybiphenyl-4-yl)methyl]-4H-1,2,4-triazole. U.S. Patent No. 4,880,804 to Carini et al describes a family of biphenylmethylbenzimidazole compounds as angiotensin II receptor blockers for use in treatment of hypertension and congestive heart failure.

5

10

15

20

25

30

35

One disadvantage of these angiotensin II antagonist compounds is that the desired hypertension-reducing effect may be offset by hypotension-induced compensatory stimulation of the renin-angiotensin system or stimulation of the sympathetic nervous system, either of which may result in promotion of sodium and water retention. Also, some angiotensin II antagonists may have toxicological effects systemically which precludes their use at doses necessary to be effective in reducing blood pressure.

To avoid such systemic side effects, drugs may be targetted to the kidney by creating a conjugate compound that would be a renal-specific prodrug containing the targetted drug modified with a chemical carrier moiety. Cleavage of the drug from the carrier moiety by enzymes predominantly localized in the kidney releases the drug in the kidney. Gamma glutamyl transpeptidase and acylase are examples of such cleaving enzymes found in the kidney which have been used to cleave a targetted drug from its prodrug carrier within the kidney.

Renal targetted prodrugs are known for delivery of a drug selectively to the kidney. For example, the compound L- γ -glutamyl amide of dopamine when administered to dogs was reported to generate dopamine in vivo by specific enzymatic cleavage by γ -glutamyl transpeptidase [J. J. Kyncl et al, Adv. Biosc., 20, 369-380 (1979)]. In another study, γ -glutamyl and N-acyl- γ -glutamyl derivatives of the anti-bacterial compound sulfamethoxazole were shown to deliver relatively high

concentrations of sulfamethoxazole to the kidney which involved enzymatic cleavage of the prodrug by acylamino acid deacylase and γ -glutamyl transpeptidase [M. Orlowski et al, J. Pharmacol. Exp. Ther., 212, 167-172 (1980)]. The N- γ glutamyl derivatives of 2-, 3-, or 4-aminophenol and p-fluoro-L-phenylalanine have been found to be readily solvolyzed in vitro by γ -glutamyl transpeptidase [S.D.J. Magnan et al, <u>J. Med. Chem.</u>, 25, 1018-1021 (1982)]. The hydralazine-like vasodilator 2-hydrazino-5-n-butylpyridine (which stimulates guanylate cyclase activity) when substituted with the 10 N-acetyl- γ -glutamyl residue resulted in a prodrug which provided selective renal vasodilation [K. G. Hofbauer et al, J. Pharmacol. Exp. Ther., 212, 838-844 (1985)]. The dopamine prodrug γ -L-glutamyl-L-dopa ("gludopa") has been shown to be relatively specific for the kidney and to increase renal blood 15 flow, glomerular filtration and urinary sodium excretion in normal subjects [D. P. Worth et al, Clin. Sci., 69, 207-214 (1985)]. In another study, gludopa was reported to be an effective renal dopamine prodrug whose activity can be blocked by the dopa-decarboxylase inhibitor carbidopa [R. F. Jeffrey 20 et al, Br. J. Clin. Pharmac., 25, 195-201 (1988)]. A class of 4-ureido derivatives of isoquinolin-3-ol has been investigated for renal specific effects such as increases in renal vasodilation and renal blood flow [R. M. Kanojia et al, J. 25 Med. Chem., 32, 990-997 (1989)].

BRIEF DESCRIPTION OF THE DRAWING FIGURES

3) Fig. 1 is a graph showing reduction in mean arterial pressure by intravenous administration of a conjugate of the invention to a spontaneously hypertensive rat.

Fig. 2 is a graph showing angiotensin II pressor response in a spontaneously hypertensive rat infused by

WO 92/02257 PCT/US91/05476

5

intravenous administration with a conjugate of the invention over a period of three days.

Fig. 3 is a graph showing urinary sodium excretion response to angiotensin II infusion in concious normotensive rats followed by administration of a saline vehicle, an angiotensin II antagonist, or a renal-selective conjugate of the invention.

Fig. 4 is a graph showing mean arterial pressure response to angiotensin II infusion in conscious normotensive rats followed by administration of a saline vehicle, an angiotensin II antagonist, or a renal-selective conjugate of the invention.

15

DESCRIPTION OF THE INVENTION

retaining disorders such as congestive heart failure, cirrhosis and nephrosis, may be accomplished by administering to a susceptible or afflicted subject a therapeutically-effective amount of a renal-selective prodrug capable of causing blood-pressure reducing effects by selective action in the kidney. An advantage of such renal-selective prodrug therapy resides in reduction or avoidance of adverse side effects associated with systemically-acting drugs.

Advantages of a renal-selective antihypertensive compound are several. First, the renal-selective compound is targetted at those pathophysiological mechanisms which occur primarily in the kidney. Second, the regulation of other organ systems is unaffected; thus, normal physiological regulation of other organ systems is maintained. Third, fewer side-effects may be anticipated, since the compound remains

inactive until cleaved in the kidneys. Similarly, fewer negative drug-drug interactions may be anticipated. Finally, since a renal-selective accumulation of active compound may occur, which is not dependent on plasma levels of the parent compound, lower doses of the renal-selective compound compared to active parent compound may be used.

A renal-selective prodrug is provided by a conjugate comprising a residue of an angiotensin II antagonist compound, which conjugate is renal selective. The conjugate 10 will typically comprise a first component and a second component connected together by a cleavable or hydrolyzable The term "renal-selective", as used to characterize a conjugate of the invention, embraces any of the following four pharmacological events: (1) the conjugate is selectively 15 taken up by the kidney and is selectively cleaved in the kidney; (2) the conjugate is not taken up selectively by the kidney, but is selectively cleaved in the kidney; (3) the conjugate is selectively taken up by the kidney and then cleaved in the kidney; or (4) where the conjugate itself is 20 active as an angiotensin II antagonist, the conjugate is selectively taken up by the kidney without cleavage of the hydrolyzable bond.

25 The first component of a conjugate of the invention is a residue derived from an antagonist compound capable of inhibiting angiotensin II (AII) receptors, especially those AII receptors located in the kidney. The second residue is capable of being cleaved from the first residue

30 preferentially. Cleaving of the first and second residues may be accomplished by a variety of mechanisms. For example, the bond may be cleaved by an enzyme in the kidney.

The residue providing the first component may be characterized as the "AII antagonist active" residue. Such

WO 92/02257 PCT/US91/05476

7

"active" residue may be provided by a compound having AII antagonist activity or by a metabolite of such compound having AII antagonist activity. The residue providing the second component may be characterized in being capable of forming a cleavable bond connecting the "active" first residue and the second residue. Such bond is cleavable by an enzyme located in the kidney. In a preferred embodiment, this cleavable bond is typically a hydrolyzable amide bond, that is, a bond between a carbonyl-terminated moiety and a reactive nitrogenterminated moiety, such as an amino-terminated moiety, which may be cleaved by an enzyme found in the kidney, but which is not cleaved substantially by enzymes located in other organs or tissues of the body. Preferred bond-cleaving enzymes would be found predominantly in the kidney.

15

20

25

30

35

10

The conjugate containing the residue of an AII antagonist compound and containing the cleavable fragment or residue may possess AII antagonist activity comparable to, or more than, or less than, the AII antagonist compound which forms the conjugate. In one embodiment of the invention, the conjugate will have AII receptor blocking activity comparable to the AII antagonist component forming the conjugate. another embodiment of the invention, the conjugate will have AII receptor blocking activity less than the AII receptor blocking activity forming the conjugate. One advantage of such differential activity between the conjugate and the AII antagonist component is that certain side effects associated with non-renal, systemic AII receptor blocking may be avoided or reduced. For example, at least one conjugate of the invention has been found to have a very large differential in AII receptor blocking activities between the conjugate and the AII antagonist component forming the conjugate. differential activity is advantageous in that therapeuticallyeffective antihypertensive doses of the conjugate may be administered to give renal-selective AII receptor blocking

action resulting from kidney-specific enzyme hydrolysis or metabolism of the conjugate to free the active AII receptor blocker within the kidney. Inasmuch as this renal-selective conjugate has relatively low AII receptor blocking activity, compared to the AII receptor compound forming the conjugate, this conjugate will have fewer adverse side effects associated with unwanted systemic interaction with non-renal AII receptors such as found in the vascular bed.

10

15

DETAILED DESCRIPTION OF THE INVENTION

The first residue of the conjugate may be selected from any class of compounds, or metabolites thereof, having angiotensin II antagonist activity. An example of one such class of angiotensin II antagonist compounds is provided by a class of biphenylmethyl 1H-substituted-1,3-imidazole compounds defined by Formula I:

20

wherein m is a number selected from one to four, inclusive;

wherein each of R⁰ through R¹¹ is independently selected from hydrido, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkyl, formyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkylcarbonyloxyalkyl,

mercaptocarbonyl, mercaptothiocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, alkylthiocarbonyl, alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio, alkylthiothiocarbonyl,

- alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy, arylthiocarbonylthio, arylthiothiocarbonyl, arylthiothiocarbonylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy, aralkylthiocarbonylthio,
- alkylthiocarbonyl, aralkylthiocarbonylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, and
- cycloheteroalkylcarbonylalkyl wherein each of said heteroaryland cyclohetero-containing groups has one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of \mathbb{R}^0 through \mathbb{R}^{11} may be further independently selected from amino and amido radicals of the formula

wherein X is oxygen atom or sulfur atom;

wherein each n is a number independently selected from zero to six, inclusive;

wherein each of R^{12} through R^{24} is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein ${\bf R}^{12}$ and ${\bf R}^{13}$ taken together, ${\bf R}^{14}$ and R^{15} taken together, R^{16} and R^{17} taken together, R^{19} and ${\rm R}^{20}$ taken together and ${\rm R}^{21}$ and ${\rm R}^{22}$ taken together may each form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical and which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen 10 and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein \mathbb{R}^{12} and \mathbb{R}^{13} taken together, R^{14} and R^{15} taken together, R^{19} and R^{20} taken together and R^{21} and R²² taken together may each form an aromatic heterocyclic group having five ring members including the nitrogen atom of 15 said amino or amido radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms;

20 and wherein each of R³ through R¹¹ may be further independently selected from hydrido and haloalkyl, and from acidic moieties of the formula

$-Y_nA$

25

30

wherein n is a number selected from zero through three, inclusive, and wherein A is an acidic group selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms;

35 and wherein any of the foregoing R^1 through R^{24} , Y and A

groups having a substitutable position may be substituted with one or more groups selected from hydroxy, alkyl, alkenyl, alkynyl, aralkyl, hydroxyalkyl, trifluoromethyl, difluoroalkyl, oxo, alkoxy, aryloxy, aralkoxy, aralkylthio, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aroyl, cycloalkenyl, cyano, cyanoamino, nitro, alkylcarbonyloxy, alkoxycarbonyloxy, alkylcarbonyl, alkoxycarbonyl, carboxyl, mercapto, mercaptocarbonyl, alkylthio, arylthio, alkylthiocarbonyl, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfinyl, arylsulfinyl, arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and amino and amido radicals of the formula

$$X$$
 \parallel
 $-C-R^{25}$, $-N$
 R^{26}
 R^{27}
and
 $-NC-R^{28}$

15

wherein X is selected from oxygen atom and sulfur atom; wherein R^{25} is selected from hydrido, alkyl, cycloalkyl, cycloalkyl, aralkyl, aryl, DR 30 and

20

25

30

$$-N < R^{31}$$

wherein D is selected from oxygen atom and sulfur atom and R^{30} is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R^{25} , R^{26} , R^{27} , R^{28} , R^{29} , R^{31} and R^{32} is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl, arylsulfonyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein each of R^{26} , R^{27} , R^{28} , R^{29} , R^{31} and R^{32} is further

independently selected from amino and amido radicals of the formula

$$-N < R^{33} \qquad X R^{35} \qquad X R^{35} \qquad X R^{37} \\ R^{34} \qquad -CN < R^{36} \qquad \text{and} \qquad -NC-R^{37} \\ R^{38}$$

5

30

wherein X is oxygen atom or sulfur atom;

wherein each of R^{33} , R^{34} , R^{35} , R^{36} , R^{37} and R^{38} is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, 10 cycloalkylalkyl, alkoxyalkyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein R^{26} and R^{27} taken together and \mathbf{R}^{28} and \mathbf{R}^{29} taken together may each form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical, which 15 heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein \mathbf{R}^{26} and \mathbf{R}^{27} taken together and R^{31} and R^{32} taken together may each form an aromatic 20 heterocyclic group having five ring members including the nitrogen atom of said amino or amido radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and 25 sulfur atoms;

with the proviso that at least one of said R¹ through R²⁴, Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;

WO 92/02257 PCT/US91/05476

13

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

Conjugates of the invention are therapeutically

effective in treatment of cardiovascular disorders by acting directly, or by providing cleavable components selected from Formula I compounds which act directly, as antagonists to, or blockers of, the angiotensin II (AII) receptor. Thus, conjugates of Formula I would be therapeutically effective in treatment of cardiovascular disorders or would be precursors to, or prodrugs of, therapeutically-effective compounds.

Preferred compounds of Formula I, from which a cleavable component may be selected, are all characterized in having a substituent, other than hydrido, at each of the fourand five-positions of the imidazole ring. Such substituents are selected from the aforementioned R¹ and R² groups.

The phrase "acidic group selected to contain at 20 least one acidic hydrogen atom", as used to define the $-Y_nA$ moiety, is intended to embrace chemical groups which, when attached to any of the \mathbb{R}^3 through \mathbb{R}^{11} positions of Formula I, confers acidic character to the compound of Formula I. "Acidic character" means proton-donor capability, that is, the 25 capacity of the compound of Formula I to be a proton donor in the presence of a proton-receiving substance such as water. Typically, the acidic group should be selected to have protondonor capability such that the product compound of Formula I has a pKa in a range from about one to about twelve. More 30 typically, the Formula I compound would have a pKa in a range from about two to about seven. An example of an acidic group containing at least one acidic hydrogen atom is carboxyl group (-COOH). Where n is zero and A is -COOH, in the $-Y_{\mathrm{n}}A$ moiety, such carboxyl group would be attached directly to one of the $\ensuremath{\mathrm{R}^3}$ through $\ensuremath{\mathrm{R}^{11}}$ positions. The Formula I compound may have one 35

-YnA moiety attached at one of the R³ through R¹¹ positions, or may have a plurality of such -YnA moieties attached at more than one of the R³ through R¹¹ positions, up to a maximum of nine such -YnA moieties. There are many examples of acidic groups other than carboxyl group, selectable to contain at least one acidic hydrogen atom. Such other acidic groups may be collectively referred to as "bioisosteres of carboxylic acid" or referred to as "acidic bioisosteres". Specific examples of such acidic bioisosteres are described hereinafter. Compounds of Formula I having the -YnA moiety attached at one of positions R⁵, R⁶, R⁸ and R⁹ would be expected to have preferred properties, while attachment at R⁵ or R⁹ would be more preferred.

A preferred class of compounds within the sub-class 15 defined by Formula I consists of those compounds wherein m is one; wherein each of R^0 through R^{11} is independently selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, 20 alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl, mercaptothiocarbonyl, mercaptoalkyl, 25 alkoxycarbonyloxy, alkylthio, cycloalkylthio, alkylthiocarbonyl, alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio, alkylthiothiocarbonyl, alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, 30 arylthiocarbonyloxy, arylthiocarbonylthio, arylthiothiocarbonyl, arylthiothiocarbonylthio, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy, aralkylthiocarbonylthio,

aralkylthiocarbonyl, aralkylthiocarbonylthio, mercapto,

alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkylalkyl and

- 5 cycloheteroalkylcarbonylalkyl wherein each of said heteroaryland cycloheteroalkyl-containing groups has
 one or more hetero ring atoms selected from oxygen, sulfur
 and nitrogen atoms, and wherein each of R⁰ through R¹¹ may be
 further independently selected from amino and amido radicals
 10 of the formula
- wherein X is selected from oxygen atom or sulfur atom;
 wherein each n is a number independently selected from zero to six, inclusive;
- wherein each of R¹² through R²⁴ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl;
- 25 and wherein each of \mathbb{R}^3 through \mathbb{R}^{11} may be further independently selected from hydrido and haloalkyl, and from acidic moieties of the formula

 $-Y_nA$

15

20

wherein n is a number selected from zero through three, inclusive; wherein A is an acidic group selected from acids containing one or more atoms selected from oxygen, sulfur, phosphorus and nitrogen atoms, and wherein said acidic group is selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms;

and wherein any of the foregoing R¹ through R²⁴, Y and A groups having a substitutable position may be substituted with one or more groups selected from alkyl, alkenyl, aralkyl, hydroxyalkyl, trifluoromethyl, difluoroalkyl, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, mercaptocarbonyl, alkylthio, alkylthiocarbonyl, and amino and amido radicals of the formula

X $-C-R^{25}$, -N R^{26} R^{27} and $-NC-R^{28}$

wherein X is selected from oxygen atom and sulfur atom; wherein R²⁵ is selected from hydrido, alkyl, cycloalkyl, cycloalkyl, aralkyl, aryl, and DR³⁰ and

$$-N$$
 R^{31}
 R^{32}

wherein D is selected from oxygen atom and sulfur atom, and \mathbb{R}^{30} is selected from hydrido, alkyl, cycloalkyl,

cycloalkylalkyl, aralkyl and aryl; wherein each of R^{26} , R^{27} , R^{28} , R^{29} , R^{31} and R^{32} is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkanoyl, alkoxycarbonyl, carboxyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein each of R^{26} , R^{27} , R^{28} , R^{29} , R^{31} and R^{32} is further independently selected from amino and amido radicals of the formula

$$-N < R^{33}$$
 $X < R^{35}$ $X < R^{35}$ $X < R^{37}$ and $-NC-R^{37}$

10

wherein X is selected from oxygen atom or sulfur atom;

wherein each of R²⁶ through R³¹ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl;

with the proviso that at least one of said R¹ through R²⁴, Y

and A substituents contains a terminal primary or secondary
amino moiety or a moiety convertible to a primary or secondary
amino moiety;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

A more preferred class of compounds within the subclass defined by Formula I consists of those compounds wherein m is one; wherein each of R⁰ through R¹¹ is independently selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl,

of the formula

alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, mercaptocarbonyl, alkoxycarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl,

5 aralkylcarbonyloxyalkyl, alkylthio, cycloalkylthio, arylthio, aralkylthio, aralkylthiocarbonylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl— and cycloheteroalkyl—containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R⁰ through R¹¹ may be further independently selected from amino and amido radicals

20 wherein X is selected from oxygen taom or sulfur atom;

wherein each n is a number independently selected from zero to six, inclusive;

wherein each of R¹² through R²⁴ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl;

and wherein each of ${\bf R}^3$ through ${\bf R}^{11}$ may be an acidic moiety further independently selected from hydrido and haloalkyl, and from acidic moieties of the formula

 $-Y_nA$

wherein n is a number selected from zero through three, inclusive;

wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from

-OH, -SH, -NR³⁹, -C-WH, -S-WH, -S-WH, -P-WH, -P-NH and -P-WH
$$\stackrel{\parallel}{\parallel}$$
 $\stackrel{\parallel}{\parallel}$ $\stackrel{\parallel}{\parallel}$

wherein each W is independently selected from oxygen atom, sulfur atom and NR ⁴³; wherein each of R³⁹, R⁴⁰, R⁴¹, R⁴² and R⁴³ is independently selected from hydrido, alkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, cycloalkylalkyl, aryl and aralkyl; wherein each of R³⁹, R⁴⁰, R⁴¹ and R⁴² may be further independently selected from amino radicals of the formula

$$-N < R^{44}$$

wherein each of R⁴⁴ and R⁴⁵ is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R⁴⁴ and R⁴⁵ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further

10

30

35

contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein R⁴⁴ and R⁴⁵ taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; wherein each of R⁴⁰ and R⁴¹ may be further independently selected from hydroxy, alkoxy, alkylthio, aryloxy, arylthio, aralkylthio and aralkoxy; and the amide, ester and salt derivatives of said acidic groups;

wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which 15 heterocyclic ring contains at least one hetero atom selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from ${\bf R}^3$ through ${\bf R}^{11}$ or may be 20 attached at any two adjacent positions selected from ${\ensuremath{\mathtt{R}}}^3$ through R^{11} so as to form a fused-ring system with one of the phenyl rings of the biphenyl moiety of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic 25 groups;

wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl;

and wherein any of the foregoing R¹ through R²⁴, Y and A groups having a substitutable position may be substituted by one or more groups selected from alkyl, difluoroalkyl, alkenyl, aralkyl, hydroxyalkyl, trifluoromethyl, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl,

carboxyl, mercaptocarbonyl, alkylthio, alkylthiocarbonyl, and amino and amido radicals of the formula

$$X$$
 $-C-R^{25}$, $-N$
 R^{26}
 R^{27}
and $-NC-R^{28}$
 R^{29}

5

wherein X is selected from oxygen atom and sulfur atom; wherein R^{25} is selected from hydrido, alkyl, cycloalkyl, cycloalkyl, aralkyl, aryl and DR^{30} and

$$-N < R^{31}$$

10

wherein D is selected from oxygen atom and sulfur atom, wherein R^{30} is selected from hydrido, alkyl, cycloalkyl, cycloalkyl, aralkyl and aryl;

15

wherein each of R²⁶, R²⁷, R²⁸, R²⁹, R³¹ and R³² is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkanoyl, alkoxycarbonyl, carboxyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl;

20

with the proviso that at least one of said R^1 through R^{24} , Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;

25

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

An even more preferred class of compounds within the sub-class defined by Formula I consists of those compounds wherein m is one; wherein each of ${\bf R}^0$, ${\bf R}^1$ and ${\bf R}^2$ is independently selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, 10 mercaptocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, arylthio, aralkylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, 15 cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryland cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of ${\bf R}^0$ through ${\bf R}^{11}$ may be further 20 independently selected from amino and amido radicals of the formula

wherein X is selected from oxygen atom and sulfur atom;

wherein each n is a number independently selected from zero to six, inclusive;

wherein each of R¹² through R²⁴ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl;

wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, alkylthio, aralkylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms;

and wherein each of \mathbb{R}^3 through \mathbb{R}^{11} may be an acidic moiety 20 further independently selected from acidic moieties of the formula

$$-Y_nA$$

wherein n is a number selected from zero through three, 25 inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from

30 wherein each W is independently selected from oxygen atom, sulfur atom and NR 43 ; wherein each of R 39 , R 42 and R 43 is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl,

cycloalkylalkyl, aryl and aralkyl; wherein each of ${\bf R}^{39}$ and ${\bf R}^{42}$ may be further independently selected from amino radical of the formula

 $-N < \frac{R^{44}}{R^{45}}$

5

10

15

20

25

30

wherein each of ${\bf R}^{44}$ and ${\bf R}^{45}$ is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein ${\it R}^{44}$ and ${\it R}^{45}$ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms, and which heterocyclic group may be saturated or partially unsaturated; wherein R44 and ${\rm R}^{45}$ taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from \mathbb{R}^3 through \mathbb{R}^{11} or may be attached at any two adjacent positions selected from ${\bf R}^3$ through ${\bf R}^{11}$ so as to form a fused-ring system with one of the phenyl rings of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups;

WO 92/02257 PCT/US91/05476

25

wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl;

5

10

wherein each of R^1 through R^{24} , Y and A independently may be substituted at any substitutable position with one or more groups selected from alkyl, cycloalkyl, cycloalkylalkyl, hydroxy, oxo, trifluoromethyl, difluoroalkyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy;

with the proviso that at least one of said R^1 through R^{24} , Y and A substituents contains a terminal primary or secondary 15 amino moiety or a moiety convertible to a primary or secondary amino moiety;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

20

25

35

A highly preferred class of compounds within the sub-class defined by Formula I consists of those compounds wherein m is one; wherein each of R^0 , R^1 and R^2 is independently selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, benzoyl, phenoxy, phenoxyalkyl, phenalkyloxy, phenylthio, phenalkylthio, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,

30 aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl-

and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of ${\bf R}^0$ through ${\bf R}^{11}$ may be further independently selected from amino and amido radicals of the formula

10 wherein X is selected from oxygen atom and sulfur atom;

wherein each n is a number independently selected from zero to six, inclusive;

wherein each of R^{12} through R^{24} is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl;

wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenalkyl, phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio, mercapto and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms;

and wherein each of ${\bf R}^3$ through ${\bf R}^{11}$ may be an acidic moiety further independently selected from acidic moieties of the formula

20

25

30

$$-Y_nA$$

wherein n is a number selected from zero through two,
inclusive; wherein A is selected from carboxylic acid and
bioisosteres of carboxylic acid selected from

wherein each W is independently selected from oxygen atom, sulfur atom and NR ⁴³; wherein each of R³⁹, R⁴² and R⁴³ is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, phenyl and benzyl; wherein each of R³⁹ and R⁴² may be further independently selected from amino radical of the formula

$$-N < R^{44}$$

wherein each of R^{44} and R^{45} is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, alkoxyalkyl, benzyl and phenyl; and the amide, ester and salt derivatives of said acidic groups;

wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from \mathbb{R}^3 through \mathbb{R}^{11} or may be attached at any two adjacent positions selected from \mathbb{R}^3 through \mathbb{R}^{11} so as to form

a fused-ring system with one of the phenyl rings of the biphenyl moiety of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups;

5 wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, phenyl, phenalkyl and aralkyl;

wherein each of R¹ through R²⁴, Y and A and independently may be substituted at any substitutable position with one or more groups selected from alkyl, cycloalkyl, cycloalkylalkyl, hydroxy, oxo, trifluoromethyl, difluoroalkyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy;

with the proviso that at least one of said R¹ through R²⁴, Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

An even more highly preferred class of compounds
within Formula I consists of those compounds wherein m is one;
wherein R⁰ is selected from alkyl, alkenyl, phenyl, alkylthio,
cycloalkyl, cycloalkylalkyl and cycloalkylthio; wherein each
of R¹ and R² is independently selected from alkyl, aminoalkyl,
hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl,
alkoxy, aralkyl, aryl, benzoyl, phenoxy, phenoxyalkyl,
phenalkyloxy, phenylthio, phenalkylthio, aralkoxy,
alkoxyalkyl, acetyl, alkoxycarbonyl, alkenyl, cycloalkenyl,
alkynyl, cyano, nitro, carboxyl, carboxyalkyl,
alkylcarbonyloxy, mercaptoalkyl, mercaptocarbonyl,
alkoxycarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,

aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, phthalimido, phthalimidoalkyl, imidazoalkyl, tetrazole, tetrazolealkyl, alkylthio, cycloalkylthio, and amino and amido radicals of the formula

5

wherein X is selected from oxygen atom and sulfur atom;

10

20

wherein each n is a number independently selected from zero to six, inclusive;

wherein each of R¹² through R²⁴ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl;

wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenalkyl, phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, acetyl, alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio and mercapto;

and wherein each of R^3 through R^{11} may be an acidic moiety further independently selected from acidic moieties consisting of CO_2H , CO_2CH_3 , SH, CH_2SH , C_2H_4SH , PO_3H_2 , $NHSO_2CF_3$, $NHSO_2C_6F_5$, SO_3H , $CONHNH_2$, $CONHNHSO_2CF_3$, $CONHOCH_3$, $CONHOC_2H_5$, $CONHCF_3$, OH, CH_2OH , C_2H_4OH , OPO_3H_2 , OSO_3H ,

10

wherein each of R^{46} , R^{47} and R^{48} is independently selected from H, Cl, CN, NO₂, CF₃, C₂F₅, C₃F₇, CHF₂, CH₂F, CO₂CH₃, CO₂C₂H₅, SO₂CH₃, SO₂CF₃ and SO₂C₆F₅; wherein Z is selected from O, S, NR⁴⁹ and CH₂; wherein R^{49} is selected from hydrido, CH₃ and CH₂C₆H₅; and wherein said acidic moiety may be a heterocyclic acidic group attached at any two adjacent positions of R^3 through R^{11} so as to form a fused ring system so as to include one of the phenyl rings of the biphenyl moiety of Formula I, said biphenyl fused ring system selected from

and the esters, amides and salts of said acidic moieties;

- with the proviso that at least one of said R¹ through R²⁴ substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;
- or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

A class of compounds of particular interest within Formula I consists of those compounds wherein m is one; wherein R^0 is selected from $C_4H_9(n)$, $CH_3CH_2CH=CH$, $C_3H_7(n)$,

$$SC_{3}H_{7}$$
, $C_{2}H_{5}$, $C_{5}H_{11}(n)$, $C_{6}H_{13}(n)$,

 SC_4H_9 , CH_2S , $CH_3CH=CH$ and $CH_3CH_2CH=CH-$; wherein

each of ${\bf R}^1$ and ${\bf R}^2$ is independently selected from amino, aminomethyl, aminoethyl, aminopropyl, ${\bf CH_2OH}$, ${\bf CH_2OCOCH_3}$, ${\bf CH_2Cl}$,

20 C1, $CH_{2}OCH_{3}$, $CH_{2}OCH_{3}$ (CH_{3}) 2, I, $CH_{2}OCH_{3}$

CH₂CO₂H, CH (CH₃)CO₂H, NO₂, Cl,
$$\stackrel{N-N}{\downarrow}$$
N

-CH₂OCOCH₂CH₂
$$\longrightarrow$$
 , -CO₂CH₃, -CONH₂, -CONHCH₃, CON (CH₃) ₂,

-CH 2NHCO 2CH2 (CH 3) 2, -CH2NHCO 2C4H9, CH2NHCO 2-adamantyl,

5 -CH₂NHCO₂-(1-napthyl), -CH₂NHCONHCH₃, -CH₂NHCONHC₂H₅,

-CH 2NHCONHC 3H7, -CH2NHCONHC 4H9, -CH2NHCONHCH (CH3) 2,

-CH₂NHCONH(1-napthyl), -CH₂NHCONH(1-adamantyl), CO₂H,

10 -CH₂CH₂CH₂F, -CH₂ONO₂, -CH₂ONO₂, -CH₂SH, -CH₂O- \bigcirc

H, Cl, NO₂, CF₃, CH₂OH, Br, F, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-

oxopentyl, 1,1-dimethoxypropyl, 1,1-dimethoxybutyl, 1,1-dimethoxypentyl, hydroxyalkyl, halo, difluoromethyl, 1,1-difluoromethyl, 1,1-difluoropropyl, 1,1-difluorobutyl and 1,1-difluoropentyl; wherein each of R³ through ¹¹ is hydrido, with the proviso that at least one of R⁵, R⁶, R⁸ and R⁹ is an

20 acidic group selected from CO_2H , SH, PO_3H_2 , SO_3H , $CONHNH_2$, $CONHNHSO_2CF_3$, OH,

10

20

25

wherein each of R^{46} and R^{47} is independently selected from Cl, CN, NO 2, CF 3, CO 2CH 3 and SO 2CF 3;

with the proviso that at least one of said R¹ through R¹¹ substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

A class of compounds of more particular interest within Formula I consists of those compounds wherein m is one; wherein R^0 is selected from $C_4H_9(n)$, $CH_3CH_2CH=CH$, $C_3H_7(n)$,

$$SC_3H_7$$
, C_2H_5 , $C_5H_{11}(n)$, $C_6H_{13}(n)$,

 SC_4H_9 , CH_2S , $CH_3CH=CH$ and $CH_3CH_2CH=CH-$; wherein R^1

is selected from amino, aminomethyl, aminoethyl, aminopropyl, CH₂OH, CH₂OCOCH₃, CH₂CCl, Cl, CH₂OCH₃, CH₂OCH(CH₃)₂, I, CHO, CH₂CO₂H, CH(CH₃)CO₂H, -CO₂CH₃, -CONH₂, -CONHCH₃, CON(CH₃)₂, -

$$CH_2-NHCO_2C_2H_5$$
, $-CH_2NHCO_2$ $-CH_2NHCO_2CH_3$, $-CH_2NHCO_2C_3H_7$, $-CH_2NHCO_2C_3H_$

CH₂NHCO₂CH₂(CH₃)₂, -CH₂NHCO₂C₄H₉, CH₂NHCO₂-adamantyl, -

CH2NHCO₂-(1-napthyl), -CH₂NHCONHCH₃, -CH₂NHCONHC₂H₅, -CH₂NHCONHCH₃H₇, -CH₂NHCONHCH₄H₆, -CH₂NHCONHCH₄CH₂) -

CH₂NHCONHC₃H₇, -CH₂NHCONHC₄H₉, -CH₂NHCONHCH(CH₃)₂, -CH₂NHCONH(1-napthyl), -CH₂NHCONH(1-adamantyl), CO₂H,

-CH₂CH₂F, -CH₂OCONHCH₃, -CH₂CH₂F, -CH₂SH and -CH₂O-O; wherein R² is selected from H, Cl, NO₂, CF₃, CH₂OH, Br, F, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl, 1,1-dimethoxypropyl, 1,1-dimethoxybutyl, 1,1-dimethoxypentyl, hydroxyalkyl, halo, difluoromethyl, 1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl and 1,1-difluoropentyl; wherein each of R³ through R¹¹ is hydrido, with the proviso that at least one of R⁵, R⁶, R⁸ and R⁹ is an acidic group selected from CO₂H, SH, PO₃H₂, SO₃H, CONHNH₂, CONHNHSO₂CF₃, OH,

15

25

wherein each of R^{46} and R^{47} is independently selected from Cl, CN, NO₂, CF₃, CO₂CH₃ and SO₂CF₃;

with the proviso that at least one of said R¹ through R¹¹

20 substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

A class of compounds of even more particular interest within Formula I consists of those compounds wherein m is one; wherein R^0 is selected from $C_4H_9(n)$, $CH_3CH_2CH=CH$,

-CH₂NHCONH(1-napthyl), -CH₂NHCONH(1-adamantyl), CO₂H,
-CH₂CH₂-CO-NO, -CH₂CH₂CO₂H, -CH₂CH₂F, -CH₂OCONHCH₃, -

-CH 2NHCONHC 3H7, -CH2NHCONHC 4H9, -CH2NHCONHCH (CH3) 2,

20 $CH_2CH_2CH_2F$, $-CH_2SH$ and $-CH_2O-CO$;

wherein each of $\rm R^3$ through 11 is hydrido, with the proviso that at least one of $\rm R^5$, $\rm R^6$, $\rm R^8$ and $\rm R^9$ is an acidic group selected from $\rm CO_2H$, $\rm SH$, $\rm PO_3H_2$, $\rm SO_3H$, $\rm CONHNH_2$, $\rm CONHNHSO_2CF_3$, $\rm OH$,

wherein each of R^{46} and R^{47} is independently selected from Cl, CN, NO₂, CF₃, CO₂CH₃ and SO₂CF₃;

with the proviso that at least one of said R¹ through R¹¹

5 substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;

or a tautomer thereof or a pharmaceutically-acceptable salt 10 thereof.

The second component of a conjugate of the invention is provided by a residue which forms a kidney-enzyme-cleavable amide bond with the residue of the first-component AII antagonist compound. Such residue is preferably selected from a class of compounds of Formula II:

$$\begin{array}{c|c}
O & & & \\
\parallel & & \\
C-G & & \\
C-G & & \\
\gamma & \beta & \alpha & N
\end{array}$$

$$\begin{array}{c|c}
C - G & & \\
R^{50} & & \\
R^{51} & & \\
\end{array}$$
(II)

wherein each of R⁵⁰ and R⁵¹ may be independently selected from hydrido, alkylcarbonyl, alkoxycarbonyl, alkoxyalkyl, hydroxyalkyl and haloalkyl; and wherein G is selected from hydroxyl, halo, mercapto, -OR⁵², -SR⁵³ and NR⁵⁴ wherein each of R⁵², R⁵³ and R⁵⁴ is independently selected from hydrido and alkyl; with the proviso that said Formula II compound is selected such that formation of the cleavable amide bond occurs at carbonyl moiety attached at the gamma-position carbon of said Formula II compound.

More preferred are compounds of Formula II wherein each G is hydroxy.

A more highly preferred class of compounds within 5 Formula II consists of those compounds wherein each G is hydroxy; wherein \mathbb{R}^{50} is hydrido; and wherein \mathbb{R}^{51} is selected from

-CR⁵⁵ wherein R⁵⁵ is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, neopentyl, n-hexyl and chloromethyl.

A most highly preferred compound of Formula II is N-acetyl- γ -glutamic acid which provides a residue for the second component of a conjugate of the invention as shown below:

The phrase "terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino terminal moiety" characterizes a structural requirement for selection of a suitable angiotensin II antagonist compound as the "active" first residue of a conjugate of the invention.

Such terminal amino moiety must be available to react with a terminal carboxylic moiety of the cleavable second residue to form a kidney-enzyme-specific hydrolyzable bond.

In one embodiment of the invention, the first component used to form a conjugate of the invention provides a first residue derived from an AII antagonist compound

30

containing a terminal primary or secondary amino moiety. Examples of such terminal amino moiety are amino and linear or branched aminoalkyl moieties containing linear or branched alkyl groups such as aminomethyl, aminoethyl, aminopropyl, aminoisopropyl, aminobutyl, aminosecbutyl, aminoisobutyl, aminotertbutyl, aminopentyl, aminoisopentyl and aminoneopentyl.

In another embodiment of the invention, the first component used to form the conjugate of the invention provides 10 a first residue derived from an AII antagonist compound containing a moiety convertible to a primary or secondary amino terminal moiety. An example of a moiety convertible to an amino terminal moiety is a carboxylic acid group reacted with hydrazine so as to convert the acid moiety to carboxylic 15 acid hydrazide. The hydrazide moiety thus contains the terminal amino moiety which may then be further reacted with the carboxylic acid containing residue of the second component to form a hydrolyzable amide bond. Such hydrazide moiety thus constitutes a "linker" group between the first and second 20 components of a conjugate of the invention.

Suitable linker groups may be provided by a class of diamino-terminated linker groups based on hydrazine as defined by Formula III:

$$-N - (CH2)n N - (III)$$

wherein each of R²⁰⁰ and R²⁰¹ may be independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, hydroxyalkyl, aralkyl, aryl, haloalkyl, amino, monoalkylamino, dialkylamino, cyanoamino, carboxyalkyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl and arylsulfonyl; and wherein n is

zero or a number selected from three through seven, inclusive. In Table I there is shown a class of specific examples of diamino-terminated linker groups within Formula III, identified as Linker Nos. 1-73. These linker groups would be suitable to form a conjugate between a carbonyl moiety of an AII antagonist (designated as "I") and a carbonyl moiety of a carbonyl terminated second residue such as the carbonyl moiety attached to the gamma carbon of a glutamyl residue (designated as "T").

TABLE I

I = inhibitor $T = acetyl-\gamma-glutamyl$

LINKER NO.	n	R ²⁰⁰	R ²⁰¹
1	0	Н	H
2	0	CH3	Н
3	0	С2Н5	Н
4 .	0	С3Н7	Н
5	0	CH (CH3) 2	Н
6	0	C4H9	Н
7	0	СН (СН3)СН2СН3	Н
8	0	C(CH3)3	Н
9	0	С5Н9	Н
10	0	C6H ₁₁ (cyclo)	Н
11	0	С6Н5	Н

LINKER NO.	n	R ²	200 R ²⁰¹
12	0	CH ₂	2С6Н5 Н
13	0	Н	CH3
14	0	Н	C ₂ H ₅
15	0	Н	С3Н7
16	0	Н	СН (СН3) 2
17	0	Н	C4H9
18	0	Н	СН (СН3) СН 2СН3
19	0	Н	C(CH3)3
20	0	Н	С5Н9
21	0	Н	C6H ₁₃
22	0	Н	C6H5
23	0	Н	CH2C6H5
24	0	Н	C ₆ H ₁₁ (cyclo)
2 5	0	С6Н13	L3 H
26	0	СН3	CH3
27	0	C ₂ H ₅	С2Н5

SUBSTITUTE SHEET

LINKER NO.	n	R ²⁰⁰	R ²⁰¹
28	0	С3Н7	С3Н7
29	0	CH (CH ₃) ₂	CH (CH3) 2
30	0	C4H9	C4H9
31	0	CH (CH3) CH 2CH3	CH(CH3)CH2CH3
32	0	C(CH3)3	C(CH3)3
33	0	С5Н9	С5Н9
34	0	C6H13	C6H13
35	0	C ₆ H ₁₁ (cyclo)	C ₆ H ₁₁ (cyclo)
36	0	C6H5	C6H5
37	0	CH ₂ C ₆ H ₅	CH2C6H5
38	3	Н	Н
39	3	СН3	H
40	3	Н	СНЗ
41	3	C6H5	H
42	3	Н	C ₆ H ₅


LINKER NO.	n	R ²⁰⁰	R ²⁰¹
43	3	СНЗ	C6H5
44	3	C ₆ H ₅	СНЗ
45	3	CH2C6H5	Н
46	3	Н	CH2C6H5
47	4	Н	Н
48	4	CH3	Н
49	4	Н	CH3
50	4	С6Н5	Н
51	4	Н	C ₆ H ₅
52	4	СНЗ	C6H5
53	4	C6H5	СНЗ
54	4	CH2C6H5	Н
55	4	Н	CH2C6H5
56	5	Н	Н
57	5	СНЗ	Н
58	5	Н	CH3

SUBSTITUTE SHEET

LINKER NO.	n	R ²⁰⁰	R ²⁰¹
59	5	C6H5	Н
60	5	H	C6H5
61	5	CH3	C6H5
62	5	С6Н5	CH3
63	5	CH2C6H5	Н
64	5	Н	CH2C6H5
65	6	Н	Н
66	6	CH3	Н
67	6	Н	CH3
68	6	C6H5	Н
69	6	н	C6H5
70	6	, СН3	C6H5
71	6	C6H5	CH3
72	6	CH ₂ C ₆ H ₅	Н
73	6	Н	CH2C6H5

SUBSTITUTE SHEET

Another class of suitable diamino terminal linker groups is defined by Formula IV:



5

wherein each of ${\tt Q}$ and ${\tt T}$ is one or more groups independently selected from


$$\begin{bmatrix}
R^{202} \\
C \\
R^{203}
\end{bmatrix}$$
and
$$\begin{bmatrix}
R^{204} & R^{205} \\
C & C
\end{bmatrix}$$

10

15

wherein each of R²⁰² through R²⁰⁵ is independently selected from hydrido, hydroxy, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, alkoxy, aralkoxy, aryloxy, alkoxyalkyl, haloalkyl, hydroxyalkyl, halo, cyano, amino, monoalkylamino, dialkylamino, carboxy, carboxyalkyl, alkanoyl, alkenyl, cycloalkenyl and alkynyl.

A preferred class of linker groups within Formula IV is defined by Formula V:



wherein each of R²⁰² and R²⁰³ is independently selected from hydrido, hydroxy, alkyl, phenalkyl, phenyl, alkoxy, benzyloxy, phenoxy, alkoxyalkyl, hydroxyalkyl, halo, amino, monoalkylamino, dialkylamino, carboxy, carboxyalkyl and alkanoyl; and wherein each of p and q is a number independently selected from one through six, inclusive; with the proviso that when each of R²⁰² and R²⁰³ is selected from halo, hydroxy, amino, monoalkylamino and dialkylamino, then the carbon to which R²⁰² or R²⁰³ is attached in Formula V is not adjacent to a nitrogen atom of Formula V.

A more preferred class of linker groups of Formula

V consists of divalent radicals wherein each of R²⁰² and R²⁰³ is independently selected from hydrido, hydroxy, alkyl, alkoxy, amino, monoalkylamino, carboxy, carboxyalkyl and alkanoyl; and wherein each of p and q is a number independently selected from two through four, inclusive. Even more preferred are linker groups wherein each of R²⁰² and R²⁰³ is independently selected from hydrido, amino, monoalkylamino and carboxyl; and wherein each of p and q is independently selected from the numbers two and three. Most preferred is a linker group wherein each of R²⁰² and R²⁰³ is hydrido; and wherein each of p and q is two; such most preferred linker

group is derived from a piperazinyl group and has the structure

5

10

In Table II there is shown a class of specific examples of cyclized, diamino-terminated linker groups within Formula V. These linker groups, identified as Linker Nos. 74-95, would be suitable to form a conjugate between a carbonyl moiety of an AII antagonist (designated as "I") and a carbonyl moiety of carbonyl terminated second residue such as the carbonyl moiety attached to the gamma carbon of a glutamyl residue (designated as "T").

TABLE II

I = inhibitor $T = acetyl-\gamma-glutamyl$

		•						
LINKER NO.	R ²⁰⁶	R ²⁰⁷	R ²⁰⁸	R ²⁰⁹	R ²¹⁰	R ²¹¹	R ²¹²	R ²¹³
74	Н	Н	Н	Н	Н	H	Н	Н
75	CH3	Н	Н	Н	Н	Н	Н	H
76	н.	Н	Н	Н	СНЗ	Н	Н	Н
77	СНЗ	Н	н -	Н	CH3	Н	Н	Н
78	СНЗ	Н	СНЗ	Н	Н	Н	Н	Н
79	СНЗ	Н	Н	Н	Н	Н	СНЗ	Н
80	СНЗ	СНЗ	Н	Н	Н .	Н	Н	Н
81	Н	Н	H	Н	СНЗ	СНЗ	Н	Н
82	СНЗ	СН3	Н	Н	CH3	СНЗ	Н	Н
83	CH3	CH3	CH3	CH3	Н	Н	Н	Н

LINKER NO.	R R ²⁰⁶	R ²⁰⁷	R ²⁰⁸	R ²⁰⁹	R ²¹⁰	R ²¹	1 _R 212	R ²¹
84	СНЗ	СНЗ	н	Н	Н	Н	СНЗ	СН3
85	Н	Н	Н	Н	СНЗ	CH3	3 CH ₃	СНЗ
86	С6Н5	Н	Н	Н	н	Н	Н	Н
87	Н	Н	Н	Н	С6Н5	Н	н	Н
88	С6Н5	Н	Н	Н	C6H5	Н	Н	Н
89	С6Н5	Н	Н	Н	Н	Н	C6H5	Н
90	C6H5	Н	C6H5	Н	Н	Н	н	Н
91	CH2C6H5	H	Н	Н	Н	Н	Н	Н
92	Н	Н	Н	Н	CH2C6H5	Н	Н	Н
93	CH ₂ C ₆ H ₅	Н	Н	Н	CH 2C 6H5	Н	Н	Н
94	CH2C6H5	Н	Н	Н	Н	н с	CH2C6H5	Н
95	CH2C6H5	Н	CH ₂ C ₆ H ₅	Н	Н	Н	н	Н

Another class of suitable diamino terminal linker groups is defined by Formula VI:

$$\begin{array}{c|c}
R^{214} & R^{216} \\
-N & C \\
 & N
\end{array}$$

$$\begin{array}{c|c}
R^{215} \\
N \\
\end{array}$$
(VI)

5

10

wherein each of R²¹⁴ through R²¹⁷ is independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, aralkyl, aryl, haloalkyl, amino, monoalkylamino, dialkylamino, cyanoamino, carboxyalkyl, alkylsulfino, alkylsulfonyl, arylsulfinyl and arylsulfonyl; and wherein p is a number selected from one through six inclusive.

A preferred class of linker groups within Formula VI consists of divalent radicals wherein each of ${\rm R}^{214}$ and ${\rm R}^{215}$ 15 is hydrido; wherein each of ${\rm R}^{62}$ and ${\rm R}^{63}$ is independently selected from hydrido, alkyl, phenalkyl, phenyl, alkoxyalkyl, hydroxyalkyl, haloalkyl and carboxyalkyl; and wherein p is two or three. A more preferred class of linker groups within Formula VI consists of divalent radicals wherein each of ${\tt R}^{214}$ 20 and R^{215} is hydrido; wherein each of R^{216} and R^{217} is independently selected from hydrido and alkyl; and wherein p is two. A specific example of a more preferred linker within Formula VI is the divalent radical ethylenediamino. III there is shown a class of specific examples of diamino-25 terminated linker gorups within Formula VI. These linker groups, identified as Linker Nos. 96-134, would be suitable to form a conjugate between a carbonyl moiety of an AII antagonist (designated as "I") and a carbonyl moiety of carbonyl terminated second residue such as the carbonyl moiety attached to the gamma carbon of a glutamyl residue (designated as "T").

TABLE III

I = inhibitor
G = acetyl-γ-glutamyl

LINKER NO.	R ²¹⁸	R ²¹⁹	R ²²⁰	R ²²¹	R ²²²	R ²²³
96	Н	Н	Н	Н	Н	Н
97	Н	Н	Н	Н	Н	CH3
98	Н	Н	Н	СНЗ	Н	Н
99	Н	Н	Н	СНЗ	Н	CH3
100	СНЗ	Н	Н	Н	Н	Н
101	Н	СНЗ	Н	Н	Н	Н
102	Н	Н	H	Н	СНЗ	СНЗ
103	Н	Н	СНЗ	CH3	Н	Н

SUBSTITUTE SHEET

						·, ···
LINKER NO.	R ²¹⁸	R ²¹⁹	R ²²⁰	R ²²¹	R ²²²	R ²²³
104	CH3	CH3	Н	Н	Н	Н
105	Н	Н	Н	Н	H	C ₆ H ₅
106	Н	Н	Н	C6H5	Н	Н
107	Н	H	Н	С6Н5	Н	C6H5
108	C6H5	Н	Н	Н	Н	Н
109	H	С6Н5	Н	Н	Н	Н
110	H	Н	Н	Н	С6Н5	C ₆ H ₅
111	Н	Н	C6H5	C6H5	Н	Н
112	C6H5	С6Н5	Н	Н	Н	Н
113	H	Н	Н	Н	Н	С2Н5
114	Н	Н .	Н	C2H5	Н	Н
115	Н	Н	Н	С2Н5	Н	C2H5
116	C ₂ H ₅	Н	Н	Н	Н	Н
117	Н	C ₂ H ₅	Н	Н	H	Н
118	Н	H	Н	Н	С2Н5	С2Н5

SUBSTITUTE SHEET

LINKER NO.	R ²¹⁸	R ²¹⁹	R ²²⁰	R ²²¹	R ²²²	R ²²³
119	Н	Н	C2H5	C2H5	H	Н
120	C ₂ H ₅	C2H5	Н	Н	Н	H
121	СНЗ	Н	С6Н5	Н	Н	Н
122	СНЗ	Н	Н	Н	С6Н	5 H
123	Н	СНЗ	C6H5	Н	Н	Н
124	Н	CH3	Н	Н	С6Н	5 H
125	CH3	CH3	Н	C6H5	Н	Н
126	СНЗ	CH3	Н	Н	Н	С6Н5
127	Н	Н	Н	Н	Н	CH2C6H5
128	Н	Н	Н	CH2C6H	5 H	Н
129	CH2C6H5	Н	Н	Н	Н	Н
130	Н	CH2C6H5	Н	Н	Н	Н
131	СНЗ	Н	CH2C6H5	Н	Н	Н
132	СНЗ	Н	Н	н с	H2C6H5	Н
133	Н	СНЗ	СН2С6Н5	Н	Н	Н

LINKER NO.	R ²¹⁸	R ²¹⁹	R ²²⁰	R ²²¹	R ²²²	R ²²³	
134	ŭ	CH3	Н	Н	CH2C6H5	Н	

The term "hydrido" denotes a single hydrogen atom (H) which may be attached, for example, to a carbon atom to form a hydrocarbyl group or attached to an oxygen atom to form an hydroxyl group. Where the term "alkyl" is used, either alone or within other terms such as "haloalkyl" and "hydroxyalkyl", the term "alkyl" embraces linear or branched radicals having one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkyl radicals are "lower alkyl" radicals having one to about ten carbon atoms. Most preferred are lower alkyl radicals having one to about five carbon atomms. The term "cycloalkyl" embraces cyclic radicals having three to about ten ring carbon atoms, preferably three to about six carbon atoms, such as cyclopropyl and cyclobutyl. The term "haloalkyl" embraces radicals wherein any one or more of the alkyl carbon atoms is substituted with one or more halo groups, preferably selected from bromo, chloro and fluoro. Specifically embraced by the term "haloalkyl" are monohaloalkyl, dihaloalkyl and polyhaloalkyl groups. A monohaloalkyl group, for example, may have either a bromo, a chloro, or a fluoro atom within the group. Dihaloalkyl and polyhaloalkyl groups may be substituted with two or more of the same halo groups, or may have a combination of different halo groups. A dihaloalkyl group, for example, may have two fluoro atoms, such as difluoromethyl and difluorobutyl groups, or two chloro atoms, such as a dichloromethyl group, or one fluoro atom and one chloro atom, such as a fluoro-chloromethyl group. Examples of a polyhaloalkyl are trifluoromethyl, 1,1-difluoroethyl, 2,2,2trifluoroethyl, perfluoroethyl and 2,2,3,3-tetrafluoropropyl

groups. The term "difluoroalkyl" embraces alkyl groups having two fluoro atoms substituted on any one or two of the alkyl group carbon atoms. Preferably, when the difluoroalkyl group is attached at the triazole ring \mathbb{R}^1 and \mathbb{R}^2 positions of 5 Formula I, the two fluoro atoms are substituted on the carbon atom which is attached directly to the triazole ring. Such preferred difluoroalkyl group may be characterized as an "alpha-carbon difluoro-substituted difluoroalkyl group" The terms "alkylol" and "hydroxyalkyl" embrace linear or branched 10 alkyl groups having one to about ten carbon atoms any one of which may be substituted with one or more hydroxyl groups. The term "alkenyl" embraces linear or branched radicals having two to about twenty carbon atoms, preferably three to about ten carbon atoms, and containing at least one carbon-carbon 15 double bond, which carbon-carbon double bond may have either cis or trans geometry within the alkenyl moiety. The term "alkynyl" embraces linear or branched radicals having two to about twenty carbon atoms, preferably two to about ten carbon atoms, and containing at least one carbon-carbon triple bond. 20 The term "cycloalkenyl" embraces cyclic radicals having three to about ten ring carbon atoms including one or more double bonds involving adjacent ring carbons. The terms "alkoxy" and "alkoxyalkyl" embrace linear or branched oxy-containing radicals each having alkyl portions of one to about ten carbon 25 atoms, such as methoxy group. The term "alkoxyalkyl" also embraces alkyl radicals having two or more alkoxy groups attached to the alkyl radical, that is, to form monoalkoxyalkyl and dialkoxyalkyl groups. The "alkoxy" or "alkoxyalkyl" radicals may be further substituted with one or 30 more halo atoms, such as fluoro, chloro or bromo, to provide haloalkoxy or haloalkoxyalkyl groups. The term "alkylthio" embraces radicals containing a linear or branched alkyl group, of one to about ten carbon atoms attached to a divalent sulfur atom, such as a methythio group. The term "aryl" embraces

aromatic radicals such as phenyl, naphthyl and biphenyl. The

15

20

25

term "aralkyl" embraces aryl-substituted alkyl radicals such as benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, phenylbutyl and diphenylethyl. The terms "benzyl" and "phenylmethyl" are interchangeable. The terms "aryloxy" and "arylthio" denote radical respectively, aryl groups having an oxygen or sulfur atom through which the radical is attached to a nucleus, examples of which are phenoxy and phenylthio. terms "sulfinyl" and "sulfonyl", whether used alone or linked to other terms, denotes respectively divalent radicals SO and The term "aralkoxy", alone or within another term, embraces an aryl group attached to an alkoxy group to form, for example, benzyloxy. The term "acyl" whether used alone, or within a term such as acyloxy, denotes a radical provided by the residue after removal of hydroxyl from an organic acid, examples of such radical being acetyl and benzoyl. The term "heteroaryl" embraces aromatic ring systems containing one or two hetero atoms selected from oxygen, nitrogen and sulfur in a ring system having five or six ring members, examples of which are thienyl, furanyl, pyridinyl, thiazolyl, pyrimidyl and isoxazolyl. Such heteroaryl may be attached as a substituent through a carbon atom of the heteroaryl ring system, or may be attached through a carbon atom of a moiety substituted on a heteroaryl ring-member carbon atom, for example, through the methylene substituent of imidazolemethyl moiety. Also, such heteroaryl may be attached through a ring nitrogen atom as long as aromaticity of the heteroaryl moiety is preserved after attachment.

Specific examples of alkyl groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, methylbutyl, dimethylbutyl and neopentyl. Typical alkenyl and alkynyl groups may have one unsaturated bond, such as an allyl group, or may have a plurality or unsaturated bonds, with such plurality of bonds either adjacent, such as allene-type structures, or in conjugation, or separated by several saturated carbons.

Conjugates of the invention formed from compounds 5 of Formula I have been found to inhibit the action of angiotensin II in mammals. For example, specific biphenylmethyl 1H-substituted-imidazole compounds within Formula I have been evaluated for angiotensin II receptor binding and antihypertensive effects in renal hypertensive rats, as shown in EP #253,310 published 20 January 1988. 10 Thus, conjugates of Formula I are therapeutically useful in methods for treating hypertension by administering to a hypertensive patient a therapeutically-effective amount of a conjugate containing a compound of Formula I, such that the conjugate is hydrolyzed by an enzyme found predominantly in 15 the kidney so as to release an active angiotensin II antagonist species. The phrase "hypertensive patient" means, in this context, a mammalian subject suffering from the effects of hypertension or susceptible to a hypertensive 20 condition if not treated to prevent or control such hypertension.

Included within the invention are conjugates of compounds of Formula I which are tautomeric forms of the described compounds, isomeric forms including 25 diastereoisomers, and the pharmaceutically-acceptable salts The term "pharmaceutically-acceptable salts" embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. 30 of the salt is not critical, provided that it is pharmaceutically-acceptable. Suitable pharmaceuticallyacceptable acid addition salts of compounds of Formula I may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and 35

phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, example of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, p-hydroxybenzoic, salicyclic, phenylacetic, mandelic, embonic (pamoic), methansulfonic, ethane sulfonic, 2-hydroxyethane sulfonic, pantothenic, benzenesulfonic, toluenesulfonic, sulfanilic, mesylic, 10 cyclohexylaminosulfonic, stearic, algenic, β -hydroxy butyric, malonic, galactaric and galacturonic acid. Suitable pharmaceutically-acceptable base addition salts of compounds of Formula I include metallic salts made from aluminium, calcium, lithium, magnesium, potassium, sodium and zinc or 15 organic salts made from N, N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. All of these salts may be prepared by conventional means from the corresponding compound of Formula I by reacting, for example, 20 the appropriate acid or base with the compound of Formula I. Also, such pharmaceutical salts may be formed with either a compound of Formula I which is contained in the conjugate, or such salts may be formed with the conjugate itself.

25

30

35

Conjugates of the invention can possess one or more asymmetric carbon atoms and are thus capable of existing in the form of optical isomers as well as in the form of racemic or non-racemic mixtures thereof. The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example by formation of diastereoisomeric salts by treatment with an optically active acid or base. Examples of appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric and camphorsulfonic acid and then separation of the mixture of

diastereoisomers by crystallization followed by liberation of the optically active bases from these salts. A different process for separation of optical isomers involves the use of a chiral chromatography column optimally chosen to maximize 5 the separation of the enantiomers. Still another available method involves synthesis of covalent diastereoisomeric molecules by reacting conjugates with an optically pure acid in an activated form or an optically pure isocyanate. The synthesized diastereoisomers can be separated by conventional 10 means such as chromatography, distillation, crystallization or sublimation, and then hydrolyzed to deliver the enantiomerically pure compound. The optically active conjugates can likewise be obtained by utilizing optically active starting materials. These isomers may be in the form of 15 a free acid, a free base, an ester or a salt.

Conjugates of the invention may be prepared using precursors of highly active angiotensin II antagonists of Formula I. Examples of lesser active, suitable precursors are acid chloride, esters and amides of angiotensin II antagonists 20 of Formula I. For example, ester precursors of angiotensin II antagonists, such as the methyl ester precursor made in Step 1 of Example 81, may be reacted with hydrazine to provide an amino terminal moiety which then can be reacted with a 25 glutamic acid derivative to form a conjugate of the invention. Such precursors or intermediates themselves may be relatively strong, relatively weak, or inactive as AII antagonists. Also, conjugates of the invention may be prepared using angiotensin II antagonists lacking a reactive terminal amino moiety. Such angiotensin II antagonists, as shown in Example 30 Nos. 78-80 of Table IV, lack a terminal amino moiety. AII antagonist compounds may be modified as described in

Example Nos. 711 and 712 to contain a terminal acid moiety which then may be connected to a glutamyl residue through a diamino-terminated linker group, such as shown in Tables I-III.

5

Synthetic Procedures

Conjugates of the invention are synthesized by 10 reaction between precursors of the first and second residues. One of such precursors must contain a reactive acid moiety, and the other precursor must contain a reactive amino moiety, so that a conjugate is formed having a cleavable bond. Either precursor of the first and second 15 residues may contain such reactive acid or amino moieties. Preferably, the precursors of the first residue are angiotensin II antagonists and will contain a reactive amino moiety or a moiety convertible to a reactive amino moiety. Inhibitor compounds lacking a reactive amino 20 moiety may be chemically modified to provide such reactive amino moiety. Chemical modification of these inhibitor compounds lacking a reactive amino group may be accomplished by reacting an acid or an ester group on an AII antagonist compound with an amino compound having at 25 least one reactive amino moiety. A suitable amino compound would be a diamino compound such as hydrazine, urea or ethylenediamine. Hydrazine, for example, may be reacted with a carboxylic acid or ester moiety of an AII antagonist compound to form a hydrazide derivative of such AII 30 antagonist compound.

In the following general Synthetic Procedures, there is described firstly in Scheme I, methods for making suitable angiotensin II antagonists of Formula I for selection as the first component of the conjugate. Then, in Schemes II- VII, there are described general methods for making a conjugate by reacting a first component AII antagonist of Formula I with a cleavable second component represented by N-acetyl- γ -glutamic acid.

Scheme I

SUBSTITUTE SHEET

Synthetic Scheme I shows the coupling reaction of trisubstituted imidazoles 1 with the appropriate alkylating reagent 2. In the first step, 1 and 2 are reacted in 5 dimethylformaide (DMF) in the presence of base, such as cesium carbonate, and a dehydrating agent, such as molecular seives, to give a mixture of coupled regioisomers 3a and 3b. isomer mixture may be converted to mixtures of the corresponding acids 4a and 4b or tetrazoles 5a and 5b. Or, the isomers <u>3a</u> and <u>3b</u> may be separated by chromatographic methods, and each isomer may be reacted with the appropriate reagent to provide the acid- or tetrazole-substituted end product.

Scheme II

Synthetic Scheme II shows the preparation of the renal-selective angiotensin II antagonists by coupling γ glutamic acid with one of the angiotensin II antagonist regiosiomers 3a (the synthesis of the other regioisomer is 5 shown in Scheme III); the biphenyl R^5 acid moiety of the AII antagonist is coupled to the γ -acid moiety of glutamic acid via an hydrazine linker. In step 1, the methyl ester of the AII antagonist 3a is converted to the hydrazide 6a by the action of hydrazine. In step 2, the hydrazide 6a is first 10 reacted with the symmetrical anhydride of the protected γ glutamic acid $\underline{\mathbf{7}}$ and subsequently reacted with trifluoroacetic acid (TFA) to give the deprotected coupled material 8a. Step 3, the free amino group of 8a is acetylated with acetic anhydride in the presence of base to give the renal-selective 15 angiotensin II antagonist 9a.

Scheme III

Synthetic Scheme III shows the preparation of renal-selective angiotensin II antagonists by coupling γ glutamic acid with one of the angiotensin II antagonist regioisomers 3b (the synthesis of the other regioisomer is shown in Scheme II); the biphenyl ${\bf R}^5$ acid moiety of the AII 5 antagonist is coupled to the γ -acid moiety of glutamic acid via an hydrazine linker. In step 1, the methyl ester of the AII antagonist 3b is converted to the hydrazide 6b by the action of hydrazine. In step 2, the hydrazide 6b is first 10 reacted with the symmetrical anhydride of the protected γ glutamic acid $\ensuremath{\textit{7}}$ and subsequently reacted with TFA to give the deprotected coupled material 8b. In step 3, the free amino group of 8b is acetylated with acetic anhydride in the presence of base to give the renal-selective angiotensin II 15 antagonist 9b.

PCT/US91/05476

Scheme IV

Synthetic Scheme IV shows the preparation of renal-selective angiotensin II antagonists by coupling γ -glutamic acid with one of the angiotensin II antagonist regiosiomers 3a which contains an amino moiety in the imidazole R^1 group (the synthesis of the other regioisomer is shown in Scheme V). In step 1, the AII antagonist 3a is reacted with the symmetrical anhydride of the protected γ -glutamic acid 7 to give 10a. In step 2, the protected material 10a is reacted with TFA to give the deprotected coupled material 11a. In step 3, the free amino compound 11a is acetylated with acetic anhydride in the presence of base to give the renal-selective angiotensin II antagonist 12a.

5

Scheme V

Synthetic Scheme V shows the preparation of renalselective angiotensin II antagonists by coupling γ -glutamic acid with one of the angiotensin II antagonist regioisomers 3b which contains an amino moiety in the imidazole R¹ group (the synthesis of the other regioisomer is shown in Scheme IV). In step 1, the AII antagonist 3b is reacted with the symmetrical anhydride of the protected γ -glutamic acid 7 to give 10b. In step 2, the protected material 10b is reacted with TFA to give the deprotected coupled material 11b. In step 3, the free amino compound 11b is acetylated with acetic anhydride in the presence of base to give the renal-selective angiotensin II antagonist 12b.

Scheme VI

Synthetic Scheme VI shows the preparation of renalselective angiotensin II antagonists by coupling $\gamma\text{-glutamic}$ 5 acid with one of the angiotensin II antagonist regioisomers 3a which contains an acid moiety in the imidazole ${\ensuremath{\mathtt{R}}}^1$ group (the synthesis of the other regioisomer is shown in Scheme VII); the imidazole ${\bf R}^{\bf 1}$ acid moiety of the AII antagonist is coupled to the γ -acid moiety of glutamic acid via an hydrazine linker. In step 1, the methyl ester of the AII antagonist 3a is 10 converted to the hydrazide 13a by the action of hydrazine. step 2, the hydrazide 13a is first reacted with the symmetrical anhydride of the protected γ -glutamic acid $\overline{2}$ and subsequently reacted with TFA to give the deprotected coupled material 14a. In step 3, the free amino group of 14a is 15 acetylated with acetic anhydride in the presence of base to give the renal-selective angiotensin II antagonist 15a.

Scheme VII

Synthetic Scheme VII shows the preparation of renal-selective angiotensin II antagonists by coupling γ glutamic acid with one of the angiotensin II antagonist regioisomers 3b which contains an acid moiety in the imidazole \mathbb{R}^1 group (the synthesis of the other isomer is shown in Scheme VII); the imidazole R^1 acid moiety of the AII antagonist is coupled to the γ -acid moiety of glutamic acid via an hydrazine linker. In step 1, the methyl ester of the AII antagonist 3b is converted to the hydrazide 13b by the action of hydrazine. 10 In step 2, the hydrazide 13b is first reacted with the symmetrical anhydride of the protected γ -glutamic acid $\underline{7}$ and subsequently reacted with TFA to give the deprotected coupled material 14b. In step 3, the free amino group of 14b is acetylated with acetic anhydride in the presence of base to 15 give the renal-selective angiotensin II antagonist 15b.

The following Examples 1-80 shown in Table IV are angiotensin II antagonists suitable for selection as precursors to provide the first residue of a conjugate of the invention. These angiotensin II antagonists may be prepared generally by the procedures outlined above in Scheme I. Also, specific procedures for preparation of Examples 1-80 of Table IV may be found in EP #253,310 published 20 January 1988.

25

20

TABLE IV

Ex. #	R ⁰	R ²	R ¹	_R 5
				-
1	C4H9 (n)	CH2OCOCH3	Cl	CO ₂ H
2	C4H9 (n)	CH ₂ OH	NO ₂	CO ₂ H
3	C4H9 (n)	CH ₂ OH	CF3	CO ₂ H
4	SC3H7	СН2ОН	H	CO ₂ H
5	C4H9 (n)	CH ₂ OH	Cl	CO ₂ H
6	C4H9 (n)	Cl	CH ₂ OH	CO ₂ H

Ex.	#	R ⁰	R ²	R ¹	R ⁵
7		C4H9 (n)	Н	CH2 OH	CO ₂ H
8		C4H9 (n)	CH20H	Н	CO ₂ H
9		C4H9 (n)	CH2OCH3	Cl	CO ₂ H
10		C4H9 (n)	CH ₂ OCH (CH ₃) ₂	Cl	CO ₂ H
11		C4H9 (n)	CH ₂ OH	Br	CO ₂ H
12		C4H9 (n)	CH ₂ OH	F	CO ₂ H
13		C4H9 (n)	СН2ОН	I	CO ₂ H
14		CH₂	СН2ОН	Cl	CO ₂ H
15			CH ₂ OH	Cl	CO ₂ H
16		C4H9 (n)	I	СН ₂ ОН	CO ₂ H
17		C3H7 (n)	CH ₂ OH	C1	CO ₂ H

Ex. #	R ⁰	R ²	R ¹	_R 5
18	C2H5	CH ₂ OH	Cl	СО2Н
19	C3H7 (n)	CH ₂ OH	Cl	CO ₂ H
20	C5H ₁₁ (n)	CH ₂ OH	Cl	CO ₂ H
21	C ₆ H ₁₃ (n)	CH ₂ OH	Cl	CO ₂ H
22	C4H9 (n)	CH ₂ SH	Cl	CO ₂ H
23	C4H9 (n)	CH2OC6H5	Cl	CO ₂ H
24	C3H7 (n)	CHO	Cl	CO ₂ H
25	C4H9 (n)	CH2CO2H	Cl	CO ₂ H
26	C4H9 (n)	СН (СН3)СО2Н	Cl	CO ₂ H
27	C4H9 (n)	NO ₂	CH ₂ OH	СО ₂ Н
28	C4H9 (n)	CH2OCOCH3	Cl	CO ₂ H

WO 92/02257

79

Ex. #	R ⁰	R ²	R ¹	_R 5
29	C4H9 (n)	CH ₂ OCOCH ₂ CH ₂	Cl	CO ₂ H
30	SC4H9 (n)	CH ₂ OH	Н	CO ₂ H
31	V—cH₂s	СН ₂ ОН	Н	CO ₂ H
32	C4H9 (n)	CHO	Cl	CO ₂ H
33	C4H9 (n)	CO ₂ CH ₃	Cl	CO ₂ H
34	C4H9 (n)	CONH 2	Cl	CO ₂ H
35	^	CH ₂ OH	Cl	CO ₂ H
36	^	СНО	Cl	CO ₂ H
37	C4H9 (n)	СНО	Н	СО ₂ н
38	C4H9 (n)	СНО	CF3	СО ₂ Н
9	C4H9 (n)	CONHCH 3	Cl	CO ₂ H

Ex. #	_R 0	R ²	R ¹	_R 5
40	C4H9 (n)	CON (CH 3) 2	Cl	CO ₂ H
41	\	CH2OH	Cl	CO ₂ H
42	^	. СН2ОН	CF3	CO ₂ H
43		CHO	Cl	СО2Н
44	C4H9 (n)	O CH ₂ -N-C-OC ₂ H ₅ H	Cl	CO ₂ H
45	C4H9 (n)	CH2NHCO2	Cl	CO ₂ H
46	C4H9 (n)	CH2NHCO2CH3	Cl	CO ₂ H
47	C4H9 (n)	CH2NHCO2C3H7	Cl	CO ₂ H
48	C4H9 (n)	CH2NHCO2CH2(CH3)2	Cl	CO ₂ H

WO 92/02257 PCT/US91/05476

81

Ex. #	R ⁰	R ²	R ¹	_R 5
49	C4H9 (n)	CH2NHCO2C4H9	Cl	СО2Н
50	C4H9 (n)	CH2-NHCO2-adamanty	'l Cl	CO ₂ H
51	C3H7 (n)	CH2NHCO2CH3	Cl	СО ₂ н
52	C4H9 (n)	CH2NHCO2CH3	Cl	CO ₂ H
53	C4H9 (n)	CH2NHCO2C2H5	Cl	CO ₂ H
54	C4H9 (n)	CH2NHCO2C3H7	Cl	CO ₂ H
55	C4H9 (n)	CH2NHCO2C4H9	Cl	CO ₂ H
56	C4H9 (n)	CH2NHCO2CH(CH3)2	Cl	CO ₂ H
57	C4H9 (n)	CH ₂ NHCO ₂ (1-naphthyl)	Cl	CO ₂ H
58	C4H9 (n)	CH2NHCONHCH3	Cl	CO ₂ H
9	C4H9 (n)	CH2NHCONHC2H5	Cl	CO ₂ H

Ex. #	R ⁰	R ²	R1	R ⁵
60	C4H9 (n)	CH2NHCONHC3H7	Cl	CO ₂ H
61	C4H9 (n)	CH2NHCONHC4H9	Cl	CO ₂ H
62	C4H9 (n)	CH2NHCONHCH (CH3)2	Cl	CO ₂ H
63	C4H9 (n)	CH2NHCONH(1-napthyl)	Cl	CO ₂ H
64	C3H7 (n)	CH_2CH_2 $ C-N$ O	H	CO ₂ H
65	C3H7 (n)	CH ₂ OH	Cl	CO ₂ H
66	C3H7 (n)	CH ₂ OH	Cl	CO ₂ H
67	C4H9 (n)	CH_2CH_2 $ C-N$ O	Cl	CO ₂ H
68	C4H9 (n)	CH2CH2CO2H	Cl	CO ₂ H
69	C4H9 (n)	CH2CH2CH2CH2CO2H	Cl	CO ₂ H

Ex. #	R ⁰	R ²	R ¹	_R 5
70	^_	— CH ₂ OH	Cl	CO ₂ H
71	C4H9 (n)	O -CH ₂ -O-C-N-CH ₃ H	Cl	CO ₂ H
72	C4H9 (n)	S ∥ -CH ₂ -O-C-NHCH ₃	Cl	CO ₂ H
73	C4H9 (n)	S -CH ₂ N-C-OC ₃ H ₇ H	Н	СО ₂ Н
74	C4H9 (n)	S -CH ₂ -O-C-NHCH ₃	Н	CO ₂ H
75	C4H9 (n)	-CH2CH2CH2F	Cl	CO ₂ H
76	C4H9 (n)	-CH 2 ONO 2	Cl	CO ₂ H
77	C4H9 (n) -	-CH ₂ -CH ₂ -N	Cl	CO ₂ H

Ex. #	R ⁰	R ²	R ¹	_R 5
78	C4H9 (n)	CH ₂ OH	Cl	CN4H
79	C4H9 (n)	Cl	CH ₂ OH	CN4H
80	C4H9 (n)	СНО	Cl	CN4H

A class of highly preferred specific conjugates of the invention is provided by conjugates formed from a biphenylmethyl 1H-substituted imidazole AII antagonist compound linked to a cleavable glutamyl residue. 5 conjugate contains a diamino linker moiety which connects a terminal carboxylic acid moiety on the biphenylmethyl portion of the AII antagonist compound with a terminal carboxylic acid moiety on the gamma carbon of the cleavable glutamyl residue. Such conjugates are shown herein as Examples 81-146. General 10 procedures for preparation of the conjugates of Examples 81-146 are described in Schemes II-III. Detailed procedures for preparation of representative conjugates are described in Examples 81 and 82. Similar procedures may be used for preparation of the conjugates identified as Examples 83-146 15 shown in Table V.

Example 81

N-acetyl-L-glutamic acid, 5-[[4'-[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-ylmethyl][1,1'-biphenyl]-2yl]carbonyl]hydrazide

Step 1: Preparation of 1-[(2'-methoxycarbonyl-biphenyl-4-yl)methyl]-2-butyl-4-chloro-5-hydroxymethylimidazole.

10

15

Under nitrogen, a solution of 6.69 g (36 mmol) of 2-butyl-4-chloro-5-hydroxymethylimidazole in 100 mL of anhydrous dimethylformamide (DMF) was treated with molecular seives and 11.0 g (36 mmol) of 4-bromomethyl-2'-methoxycarbonylbiphenyl. The reaction was allowed to stir at ambient temperature overnight and then was filtered. The DMF was removed in vacuo and the residue was partitioned between water and chloroform; the chloroform extracts were combined, dried (MgSO₄), and concentrated in vacuo giving 17.4 g of

crude material. Purification by silica gel chromatography (Waters Prep-500A) using ethyl acetate/hexane (40:60) gave the 4-hydroxymethyl isomer as the regioisomer with the lower R_f value and 6.27 g (42%) of the 5-hydroxymethyl isomer: NMR (CDCl₃) δ 0.91 (t, \underline{J} =7Hz, 3H), 1.29-1.44 (m, 2H), 1.52 (t, \underline{J} =8Hz, 1H), 1.63-1.76 (m, 2H), 2.62 (t, \underline{J} =7Hz, 2H), 3.65 (s, 3H), 4.54 (d, \underline{J} =8Hz, 2H), 7.02-7.08 (m, 2H), 7.25-7.36 (m, 3H), 7.38-7.47 (m, 1H), 7.50-7.58 (m, 1H), 7.83-7.90 (m, 1H).

Step 2: Preparation of 1-[(2'-hydrazinylcarbonyl-biphenyl-4-yl)methyll-2-butyl-4-chloro-5-hydroxymethylimidazole.

Under nitrogen, 6.27 g (15 mmol) of the 5hydroxymethyl ester from step 1 was dissolved in 100 mL of 5 methanol and trated with 15 mL (480 mmol) of anhydrous The reaction was allowed to stir at reflux hydrazine. overnight; concentration in vacuo gave 4.83 g of crude material. Purification by silica gel chromatography (Waters Prep-500A) using isopropanol/ethyl acetate (20:80) gave 4.27 g 10 (68%) of the hydrazide as a colorless glass: NMR (CDCl3) δ 0.81 (t, \underline{J} =7Hz, 3H), 1.18-1.34 (m, 2H), 1.42-1.56 (m, 2H), 2.50 (t, J=Hz, 2H), 4.15-4.35 (br s, 2H), 4.35 (d, J=8Hz, 2H), 5.24 (t, \underline{J} =8Hz, 1H), 7.05-7.13 (m, 2H), 7.32-7.44 (m, 5H), 7.45-7.54 (m, 1H), 9.34 (s, 1H). 15

Step 3: Preparation of N-acetyl-L-glutamic acid, 5-[[4'-[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-ylmethyl][1,1'-biphenyl]-2-yllcarbonyl|hydrazide.

5 To a solution of 1.70 g (5.60 mmol) of N-Boc-Lglutamic acid- α -tertbutyl ester (BACHEM) in 50 mL of methylene chloride under nitrogen was added 580 mg (2.8 mmol) of solid dicyclohexylcarbodiimide (DCC). The reaction was allowed to stir for 2 h and filtered under nitrogen. The anhydride 10 solution was then added to a solution of 1.0 g (2.4 mmol) of hydrazide from step 2 in 75 mL of methylene chloride under nitrogen. The reaction was stirred overnight, concentrated to a volume of 25 mL, cooled to 0°C, and treated with 25 mL of TFA under nitrogen. The stirred reaction was allowed to warm 15 to abmient temperature overnight and concentrated in vacuo. The crude product wad dissolved in 100 mL of acetonitrile/water (1:1) and the pH adjusted to 8 with 1 M K₂CO₃. The solution was cooled to 0°C and 0.23 mL (2.4 mmol) of acetic anhydride and 2.4 mL (2.4 mmol) of 1 M K_2CO_3 was 20 added every 30 min for 5 h; the pH was maintained at 9 and the reaction temperature kept below 5°C. After the last addition, the reaction was allowed to warm to ambient temperature overnight. The pH was adjusted to 4 with 3 M HCl and the reaction was concentrated to 100 mL. Purification by reverse 25 phase chromatography (Waters Deltaprep-3000) using isocratic 25% acetonitrile/water (0.05% TFA) gave 1.0 g (75% overall yield from the hydrazide of step 2) of colorless product: NMR (DMSO-d₆) δ 0.81 (t, \underline{J} =7Hz, 3H), 1.20-1.30 (m, 2H), 1.42-1.55 (m, 2H), 1.75-1.84 (m, 2H), 1.85 (s, 3H), 1.89-2.05 (m, 2H), 30 2.21 (t, J=7Hz, 2H), 4.13-4.24 (m, 1H), 4.35 (s, 2H), 7.05-7.12 (m, 2H), 7.37-7.58 (m, 6H), 8.12-8.17 (m, 2H); MS (FAB) m/e (rel. intensity) 584 (18), 568 (100), 225 (64); HRMS. Calcd for M+H: 584.2276. Found: 584.2240.

Example 82

N-acetyl-L-glutamic acid, 5-[[4'-[2-butyl-5-chloro-4-(hydroxymethyl)-1H-imidazol-1-ylmethyl][1,1'-biphenyl]-2-yl]carbonyl]hydrazide

Step 1: Preparation of 1-[(2'-hydrazinylcarbonyl-biphenyl-4-yl)methyl]-2-butyl-5-chloro-4-hydroxymethylimidazole.

10 Under nitrogen, 4.13 g (10 mmol) of the 4-hydroxymethyl ester from step 1 of Example 81 is dissolved in 100 mL of methanol and is treated with 15 mL of (480 mmol) of anhydrous hydrazine. The reaction is allowed to stir at reflux overnight; concentration in vacuo gives the crude 15 material. Purification by silica gel chromatography (Waters Prep-500A) gives the pure hydrazide.

Step 2: Preparation of N-acetyl-L-glutamic acid, 5-[[4'-[2-butyl-5-chloro-4-(hydroxymethyl)-1H-imidazol-1-ylmethyl][1,1'-biphenyl]-2-yllcarbonyl]hydrazide

5 To a solution of 1.70 g (5.6 mmol) of N-Boc-Lglutamic acid- α -tertbutyl ester (BACHEM) in 50 mL of methylene chloride under nitrogen is added 580 mg (2.8 mmol) of solid dicylcohexylcarbodiimide (DCC). The reaction is allowed to stir for 2 h and is filtered under nitrogen. The anhydride 10 solution is then added to a solution of 1.0 g (2.4 mmol) of the hydrazide from step 1 in 75 mL of methylene chloride under nitrogen. The reaction is stirred overnight, is concentrated to a volume of 25 mL, is cooled to 0°C, and is treated with 25 mL of TFA under nitrogen. The stirred reaction is allowed 15 to warm to ambient temperature overnight and is concentrated in vacuo. The crude product is dissolved in 100 mL of acetonitrile/water (1:1) and the pH is adjusted to 8 with 1 ${\tt M}$ K_2CO_3 . The solution is cooled to 0°C and 0.23 mL (2.4 mmol) of acetic anhydride and 2.4 mL (2.4 mmol) of 1 M K_2CO_3 is 20 added every 30 min for 5 h; the pH is mainained at 9 and the reaction temperature is kept below 5°C. After the last addition, the reaction is allowed to warm to ambient temperature overnight. The pH is adjusted to 4 with 3 M HCl and the reaction is concentrated to 100 mL. Purification by 25 reverse phase chromatography (Waters Deltaprep-3000) gives the product.

Ex. #	R ²	R ¹	L	В	E	P
83	CH ₂ OH	Cl	-NH-	Н	Н	Н
84	CH ₂ OH	Cl	-NH-	Н	CH3	Н
85	CH ₂ OH	Cl	-NH-	Н	CH3	COCH 3
86	CH ₂ OH	Cl	-NH-	Н	C ₂ H ₅	COCH 3
87	CH ₂ OH	Cl	-NH-	Н	C ₂ H ₅	Н
88	CH ₂ OH	Cl	-NH-	Н	Н	COCH ₂ Cl
89	CH ₂ OH	Cl	-NH-	Н	Н	COC 4H9 (n)

Ex. #	R ²	R ¹	L B	E	P
90	Cl	CH ₂ OH	-NH- Н	Н	Н
91	CH ₂ OH	Cl	-NHCH ₂ CH ₂ - H	н	COCH 3
92	CH ₂ OH	Cl	-NHCH ₂ CH ₂ - H	Н	Н
93	CH ₂ OH	Cl	-NHCH ₂ CH ₂ - H	CH ₃	Н
94	CH ₂ OH	Cl	-NHCH ₂ CH ₂ - H	CH ₃	COCH 3
95	CH ₂ OH	Cl	-NHCH ₂ CH ₂ - H	C ₂ H ₅	COCH 3
96	CH ₂ OH	Cl	-NHCH ₂ CH ₂ - н	C ₂ H ₅	Н
97	CH ₂ OH	Cl	-NHCH ₂ CH ₂ - H	Н	COCH ₂ Cl
8	СН ₂ ОН	Cl	-NHCH ₂ CH ₂ - H	Н	COC 4H9 (r.
9	Cl	CH ₂ OH	-NHCH ₂ CH ₂ - H	Н	COCH ₃
00	Cl	CH ₂ OH	-NHCH ₂ CH ₂ - H	Н	Н

Ex. #	R ²	R ¹	L	В	E	P
101	CH ₂ OH	Cl	-N	- *	Н	COCH 3
102	CH ₂ OH	Cl	-N N	*	Н	Н
103	CH ₂ OH	Cl	-N N	*	СНЗ	Н
104	CH ₂ OH	Cl	-N N	⊹	СНЗ	COCH 3
105	CH ₂ OH	Cl	-N	- *	C ₂ H ₅	COCH ₃
106	CH ₂ OH	Cl	-N	- *	C ₂ H ₅	Н
107	CH ₂ OH	Cl	-N	- *	Н	COC 4H9
108	CH ₂ OH	Cl	-N	- *	Н	COC 4H9

Ex. #	R ²	R ¹	L	В	E	P
109	Cl	СН ₂ ОН	.N	N- *	Н	COCH 3
110	Cl	СН ₂ ОН	-N	N- *	Н	Н
111	CH ₂ OCH ₃	Cl	-NH-	Н	Н	COCH 3
112	CH ₂ OCH 3	Cl	- NH-	Н	H	Н
113	Cl	СН ₂ ОСН 3	-NH-	Н	Н	COCH ₃
114	Cl	СН ₂ ОСН 3	-NH-	Н	Н	Н
15	CH ₂ OH	CF ₃	-NH-	Н	Н	COCH 3
.16	CH ₂ OH	CF3	-NH-	Н	Н	Н
17	CH ₂ OH	C ₂ F ₅	-NH-	Н	Н	COCH 3
18	СН ₂ ОН	C ₂ F ₅	-NH-	Н	Н	Н
19	CH ₂ OH	C3F7	-NH-	Н	Н	COCH 3

Ex. #	R ²	R1	L	В	E	P
120	CH ₂ OH	C ₃ F ₇	-NH-	H	Н	H
121	CHO	Cl	-NH-	H	Н	COCH 3
122	СНО	Cl	-NH-	H	Н	Н
123	Cl	СНО	- NH-	Н	Н	COCH 3
124	Cl	СНО	NH	H	Н	H
125	СО ₂ Н	Cl	-NH-	Н	Н	COCH 3
126	CO ₂ H	Cl	-NH-	H	Н	COCH 3
127	Cl	CO ₂ H	- NH-	Н	Н	COCH 3
128	Cl	CO ₂ H	-NH-	H	Н	Н
129	CH ₂ OH	Br	-NH-	H	Н	COCH 3
130	CH ₂ OH	Br	-NH-	Н	Н	Н

Ex. #	R ²	R ¹	L B	E	P
131	Cl	CHO	-NHCH ₂ CH ₂ - H	Н	COCH 3
132	Cl	CHO	-NHCH ₂ CH ₂ - H	Н	Н
133	CO ₂ H	Cl	-NHCH ₂ CH ₂ - H	Н	COCH 3
134	CO ₂ H	Cl	-NHCH ₂ CH ₂ - H	Н	Н
135	Cl	CO ₂ H	-NHCH ₂ CH ₂ - H	Н	COCH 3
136	C1	CO ₂ H	-NHCH ₂ CH ₂ - H	Н	Н
137	СН ₂ ОН	Br	-NHCH ₂ CH ₂ - H	Н	COCH 3
138	CH ₂ OH	Br	-NHCH ₂ CH ₂ - H	Н	Н
139	Cl	СНО	-N *	Н	COCH 3
140	Cl	СНО	_N *	Н	Н

Ex. #	R ²	R ¹	L	В	E	P
141	CO ₂ H	Cl	-N	N- *	Н	COCH 3
142	CO ₂ H	Cl	-N	N- *	Н	H
143	Cl	CO ₂ H	-N	*	Н	COCH 3
144	Cl	CO ₂ H	-N	*	Н	Н
145	CH ₂ OH	Br	-N	N- *	Н	COCH ₃
146	CH ₂ OH	Br	-N	N- *	Н	Н
		* B * e	quals pipera	azinyl		

Another class of highly preferred specific conjugates of the invention is provided by conjugates formed from a biphenylmethyl 1H-substituted imidazole AII antagonist compound having a terminal amino group attached to the imidazole nucleus. In this family of conjugates, 5 the cleavable glutamyl residue is attached through an amide bond formed between the carbonyl at the gamma carbon of the glutamyl residue and the terminal amino nitrogen of the AII antagonist imidazole nucleus. Such conjugates are shown as 10 Examples #147-#710. General procedures for preparation of the conjugates of Examples #147-#710 are described in Schemes IV-V. Detailed procedures for preparation of representative conjugates are described in Examples #147 and #148. Procedures similar to these aforementioned 15 general and specific procedures may be used for preparation of the conjugates identified as Examples #149-#710 shown in Table VI.

100

Example 147

N2-acetyl-N-[[2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazol-5-yl]methyl]-L-glutamine

Step 1: Preparation of 5-aminomethyl-2-butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-methyllimidazole.

A solution of 4.20 g (10 mmol) of the compound of Example 80, 7.7 g (100 mmol) of ammonium acetate, and 439 mg (7 mmol) of NaBH₃CN in 30 mL of absolute methanol is stirred at ambient temperature for 48 h. Concentrated HCl is added until pH<2, and the methanol is removed in vacuo.

- The residue is dissolved in water and is extracted with ethyl acetate. The aqueous solution is brought to pH>10 with 50% NaOH, is saturated with NaCl, and is extracted with methylene chloride. The extracts are combined, are dried (MgSO₄), and are evaporated in vacuo to give the
- 20 crude product. Purification by reverse phase chromatography (Waters DeltaPrep-3000) provides the pure 5aminomethyl product.

Step 2: Preparation of N2-acetyl-N-[[2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1Himidazol-5-yl]methyl]-L-glutamine

5

To a solution of 1.70 g (5.6 mmol) of N-Boc-Lglutamic acid- α -tertbutyl ester (BACHEM) in 50 mL of methylene chloride under nitrogen is added 580 mg (2.8 mmol) of solid dicylcohexylcarbodiimide (DCC). The 10 reaction is allowed to stir for 2 h and is filtered under nitrogen. The anhydride solution is then added to a solution of 1.01 g (2.4 mmol) of the 5-aminomethyl compound of step 1 in 75 mL of methylene chloride under nitrogen. The reaction is stirred overnight, is concentrated to a 1.5 volume of 25 mL, is cooled to 0°C, and is treated with 25 mL of TFA under nitrogen. The stirred reaction is allowed to warm to ambient temperature overnight and is concentrated in vacuo. The crude product is dissolved in 100 mL of acetonitrile/water (1:1) and the pH is adjusted 20 to 8 with 1 M K_2CO_3 . The solution is cooled to 0°C and 0.23 mL (2.4 mmol) of acetic anhydride and 2.4 mL (2.4 mmol) of 1 M K₂CO₃ is added every 30 min for 5 h; the pH is mainained at 9 and the reaction temperature is kept below 5°C. After the last addition, the reaction is allowed to 2.5 warm to ambient temperature overnight. The pH is adjusted to 4 with 3 M HCl and the reaction is concentrated to 100 mL. Purification by reverse phase chromatography (Waters Delta- prep-3000) gives the pure product.

Example 148

N2-acetyl-N-[[2-butyl-5-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazol-4-yl]methyl]-L-glutamine

Step 1: Preparation of 2-butyl-5-chloro-4-formyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-methyl]imidazole.

A mixture of 2.11 g (5.0 mmol) of the compound of Example 79 and 3.08 g (35 mmol) of activated manganese dioxide in 30 mL of methylene chloride at ambient temperature is stirred for 40 h. The reaction mixture is filtered through celite, and the filtrate is concentrated in vacuo. Purification by reverse phase chromatography provided the pure 4-formyl product.

Step 2: Preparation of 4-aminomethyl-2-butyl-5-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-methyl]imidazole.

20

5

A solution of 4.20 g (10 mmol) of the aldehyde from step 1, 7.7 g (100 mmol) of ammonium acetate, and 439

mg (7 mmol) of NaBH3CN in 30 mL of absolute methanol is stirred at ambient temperature for 48 h. Concentrated HCl is added until pH<2, and the methanol is removed in vacuo. The residue is dissolved in water and is extracted with ethyl acetate. The aqueous solution is brought to pH>10 with 50% NaOH, is saturated with NaCl, and is extracted with methylene chloride. The extracts are combined, are dried (MgSO4), and are evaporated in vacuo to give the crude product. Purification by reverse phase chromatography (Waters Deltaprep-3000) provides the pure product.

Step 3: Preparation of N2-acetyl-N-[[2-butyl-5-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1Himidazol-4-yl]methyl]-L-glutamine

To a solution of 1.70 g (5.6 mmol) of N-Boc-L-glutamic acid-α-tertbutyl ester (BACHEM) in 50 mL of methylene chloride under nitrogen is added 580 mg (2.8 mmol) of solid dicylcohexylcarbodiimide (DCC). The reaction is allowed to stir for 2 h and is filtered under nitrogen. The anhydride solution is then added to a solution of 1.01 g (2.4 mmol) of the 4-aminomethyl compound of step 2 in 75 mL of methylene chloride under nitrogen.

The reaction is stirred overnight, is concentrated to a volume of 25 mL, is cooled to 0°C, and is treated with 25 mL of TFA under nitrogen. The stirred reaction is allowed

concentrated in vacuo. The crude product is dissolved in 100 mL of acetonitrile/water (1:1) and the pH is adjusted to 8 with 1 M K₂CO₃. The solution is cooled to 0°C and 0.23 mL (2.4 mmol) of acetic anhydride and 2.4 mL (2.4 mmol) of 1 M K₂CO₃ is added every 30 min for 5 h; the pH is mainained at 9 and the reaction temperature is kept below

to warm to ambient temperature overnight and is

5°C. After the last addition, the reaction is allowed to warm to ambient temperature overnight. The pH is adjusted to 4 with 3 M HCl and the reaction is concentrated to 100 mL. Purification by reverse phase chromatography (Waters Delta-prep-3000) gives the pure product.

TABLE VI

$$R^1$$
 R^2
 CH_2
 R_5
 R_5
 R_6
 R_7
Ex:	#	R ¹	R ²	R ₅	A	В	E	P
149		Cl	Х	CO ₂ H	single bond	Н	Н	COCH 3
150		Cl	Х	СО2Н	single bond	Н	Н	COCH ₂ Cl
151		Cl	х	СО2Н	single bond	Н	Н	COC 4H9
152		Cl	Х	СО2Н	single bond	Н	СНЗ	COCH 3
153		Cl	Х	со2н	single bond	Н	С2Н5	COCH 3
154		Cl	Х	CN4H	single bond	Н	Н	COCH 3

Ex: #	R ¹	R ²	R ₅	A	В	E	P
155	Cl	X	CN4H	single bond	Н	Н	COCH ₂ Cl
156	Cl	х	CN4H	single bond	Н	Н	COC 4H9
157	Cl	X	CN4H	single bond	Н	СН3	COCH 3
158	Cl	x	CN4H	single bond	Н	С2Н5	COCH 3
159	Cl	х	со2н	single bond	Н	Н	Н
160	Cl	Х	со2н	single bond	Н	CH3	Н
161	Cl	х	со2н	single bond	Н	C ₂ H ₅	H
162	Cl	Х	CN4H	single bond	Н	Н	Н
163	Cl	Х	CN4H	single bond	Н	СНЗ	Н
164	Cl	Х	CN4H	single bond	Н	С2Н5	Н
165	Cl	X	СО2Н	-CH ₂ -	Н	Н	COCH 3
166	Cl	X	со2н	single bond	H	Н	COCH 2Cl

Ex: #	R ¹	R ²	R ₅	A	В	E	P
			~.				
167	Cl	Х	CO ₂ H	single bond	Н	Н	COC 4H9
168	Cl	Х	СО2Н	single bond	Н	СНЗ	COCH 3
169	Cl	Х	CO2H	single bond	Н	C ₂ H ₅	COCH 3
170	Cl	Х	CN4H	single bond	Н	Н	COCH ₂ Cl
171	Cl	Х	CN4H	single bond	Н	Н	COC 4H9
172	Cl	х	CN4H	single bond	Н	СН3	COCH 3
173	Cl	Х	CN4H	single bond	Н	С2Н5	COCH 3
.74	Cl	X	СО2Н	-CH ₂ -	Н	Н	Н
.75	Cl	х	CO ₂ H	single bond	Н	СНЗ	Н
76	Cl	Х	СО2Н	single bond	Н	C ₂ H ₅	Н
7 7	Cl	х	CN4H	-CH ₂ -	Н	Н	Н

Ex:	#	R ¹	R ²	R ₅	A .	В	E	P
178		Cl	X	CN4H	single bond	H	СНЗ	Н
179		Cl	х	CN4H	single bond	Н	C ₂ H ₅	Н
180		Cl	х	CN4H	-CH ₂ -	СН3	Н	Н
181		Cl	X	CN4H	-CH ₂ -	СНЗ	Н	COCH 3
182		Cl	х	СО2Н	-CH ₂ CH ₂ -	Н	Н	COCH 3
183		Cl	X	со2н	single bond	Н	Н	COCH ₂ Cl
184		Cl	х	CO ₂ H	single bond	Н	Н	COC 4H9
185		Cl	X	СО2Н	single bond	H	СН3	COCH 3
186		Cl	Х	со2н	single bond	Н	C ₂ H ₅	COCH 3
187		Cl	Х	CN4H	-CH 2CH2-	Н	Н	COCH 3
188		Cl	х	CN4H	single bond	Н	Н	COCH ₂ Cl

WO 92/02257 PCT/US91/05476

109

Ex: #	R ¹	R ²	R ₅	A	В	E	P
189	Cl	x	CN ₄ H	single bond	Н	Н	COC 4H9
190	Cl	x	CN4H	single bond	Н	СН3	COCH 3
191	Cl	x	CN4H	single bond	Н	C ₂ H ₅	COCH 3
192	Cl	х	CO ₂ H	-CH ₂ CH ₂ -	Н	Н	Н
193	Cl	x	CO ₂ H	single bond	Н	CH3	Н
194	Cl	х	CO ₂ H	single bond	Н	C ₂ H ₅	н
195	Cl	x	CN4H	-CH 2 CH2 -	Н	Н	Н
196	Cl	х	CN4H	single bond	Н	СН3	Н
197	Cl	х	CN4H	single bond	Н	C ₂ H ₅	Н
198	Cl	X	CO ₂ H	C3H6 (n)	Н	Н	COCH 3
199	Cl	х	CO ₂ H	single bond	Н	Н	COCH ₂ Cl

Ex: #	R1	R ²	R ₅	A	В	E	P
200	Cl	X	CO ₂ H	single bond	Н	Н	COC ₄ H ₉
201	Cl	Х	CO ₂ H	single bond	Н	CH3	COCH 3
202	Cl	Х	CO ₂ H	single bond	Н	C ₂ H ₅	COCH 3
203	Cl	Х	CN4H	C3H6 (n)	Н	Н	COCH 3
204	Cl	Х	CN4H	single bond	Н	Н	COCH ₂ Cl
205	Cl	х	CN4H	single bond	Н	Н	COC 4H9
206	Cl	х	CN4H	single bond	Н	СН3	COCH 3
207	Cl	Х	CN4H	single bond	Н	C ₂ H ₅	COCH 3
208	Cl	Х	со2н	C3H6 (n)	Н	Н	H
209	Cl	x	CO ₂ H	single bond	Н	CH3	Н
210	Cl	Х	CO ₂ H	single bond	Н	C ₂ H ₅	Н

Ex: ‡	# R ¹	R ²	R ₅	A	В	E	Р
211	Cl	х	CN4H	C3H6 (n)	Н	Н	Н
212	Cl	Х	CN4H	single bond	Н	СН3	Н
213	Cl	Х	CN4H	single bond	Н	C ₂ H ₅	Н
214	Cl	х	CO2H	C4H8 (n)	Н	Н	COCH 3
215	Cl	X	CO ₂ H	single bond	Н	Н	COCH ₂ Cl
216	Cl	Х	CO ₂ H	single bond	Н	Н	COC 4H9
217	Cl	Х	CO ₂ H	single bond	Н	СН3	COCH 3
218	Cl	Х	CO ₂ H	single bond	Н	C ₂ H ₅	COCH ₃
219	Cl	Х	CN4H	C4H8 (n)	Н	Н	COCH 3
220	Cl	Х	CN4H	single bond	Н	Н	COCH ₂ Cl
221	Cl	х	CN4H	single bond	Н	Н	COC 4H9

Ex: #	R ¹	R ²	R ₅	A	В	E	P
222	Cl	Х	CN4H	single bond	Н	CH3	COCH 3
223	Cl	х	CN4H	single bond	Н	C ₂ H ₅	COCH 3
224	Cl	х	CO ₂ H	C4H8 (n)	Н	Н	Н
225	Cl	х	CO ₂ H	single bond	Н	CH3	н
226	Cl	х	CO ₂ H	single bond	Н	C ₂ H ₅	Н
227	Cl	х	CN4H	C4H8 (n)	Н	Н	Н
228	Cl	X	CN4H	single bond	Н	СН3	Н
229	Cl	X	CN4H	single bond	Н	C ₂ H ₅	Н
230	Cl	X ·	CO ₂ H	→	Н	H	COCH 3
231	Cl	\mathbf{X}_{i}	CO ₂ H	single bond	Н	Н	COCH ₂ Cl
232	Cl	Х	CO ₂ H	single bond	Н	Н	COC 4H9

Ex: #	R ¹	R ²	R ₅	A	В	E	P
233	Cl	Х	CO ₂ H	single bond	Н	CH ₃	COCH 3
234	Cl	Х	CO ₂ H	single bond	Н	C ₂ H ₅	COCH 3
235	Cl	Х	CN4H	—	Н	Н	COCH 3
236	Cl	Х	CN4H	single bond	Н	Н	COCH ₂ Cl
237	Cl	х	CN4H	single bond	Н	Н	COC 4H9
238	Cl	Х	CN ₄ H	single bond	Н	CH ₃	COCH ₃
239	Cl	х	CN4H	single bond	Н	C ₂ H ₅	COCH ₃
240	Cl	Х	СО2Н	─	Н	Н	Н
241	Cl	Х	CO ₂ H	single bond	Н	CH3	Н
242	Cl	Х	СО2Н	single bond	Н	C ₂ H ₅	Н
243	Cl	х	CN4H	—	Н	Н	Н

Ex: #	R ¹	R ²	R ₅	A	В	E	P
244	Cl	Х	CN4H	single bond	Н	CH ₃	Н
245	Cl	x	CN4H	single bond	Н	C ₂ H ₅	н
246	Cl	Х	CO ₂ H	-CH ₂ -	Н	Н	COCH 3
247	Cl	Х	CO ₂ H	single bond	Н	Н	COCH ₂ Cl
248	Cl	Х	CO ₂ H	single bond	Н	H.	COC 4H9
249	Cl	Х	CO ₂ H	single bond	Н	CH ₃	COCH 3
250	Cl	Х	CO ₂ H	single bond	Н	C ₂ H ₅	COCH 3
251	Cl	Х	CN4H	-CH ₂	Н	Н	COCH 3
252	Cl	X	CN4H	single bond	Н	Н	COCH ₂ Cl
253	Cl	Х	CN ₄ H	single bond	Н	Н	COC ₄ H ₉
254	Cl	X	CN4H	single bond	Н	СН3	COCH 3

Ex: #	R ¹	R ²	R ₅	A	В	E	P
255	Cl	х	CN4H	single bond	Н	C ₂ H ₅	COCH 3
256	Cl	X	СО2Н	-CH ₂	Н	Н	Н
257	Cl	х	CO ₂ H	single bond	Н	СНЗ	Н
258	Cl	x	CO ₂ H	single bond	Н	C ₂ H ₅	Н
259	Cl	Х	CN4H	-CH ₂ -	Н	Н	Н
260	Cl	х	CN4H	single bond	Н	СНЗ	Н
261	Cl	Х	CN4H	single bond	Н	C ₂ H ₅	Н
262	Cl	Х	СО2Н	-CH ₂ -	Н	Н	COCH 3
263	Cl	Х	CO ₂ H	single bond	Н	Н	COCH ₂ Cl
264	Cl	Х	CO ₂ H	single bond	Н	Н	COC 4H9

Ex: #	R ¹	R ²	R ₅	A	В	E	P
			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				
265	Cl	x	CO ₂ H	single bond	Н	CH ₃	COCH 3
266	Cl	Х	CO ₂ H	single bond	Н	C ₂ H ₅	COCH 3
267	Cl	X	CN4H	-CH ₂ -	Н	Н	COCH 3
268	Cl	х	CN4H	single bond	Н	Н	COCH ₂ Cl
269	Cl	Х	CN4H	single bond	H	H	COC 4H9
270	Cl	Х	CN ₄ H	single bond	Н	CH ₃	COCH 3
271	Cl	Х	CN4H	single bond	Н	C ₂ H ₅	COCH 3
272	Cl	Х	CO ₂ H	-CH ₂ -	Н	Н	Н
273	Cl -	Х	CO ₂ H	single bond	Н	CH3	Н
274	C1	X	CO ₂ H	single bond	Н	C ₂ H ₅	Н
275	Cl	X	CN ₄ H	-CH ₂ -	Н	Н	Н

	_						
Ex: #	R ¹	_R 2	R ₅	A	В	E	P
276	Cl	Х	CN ₄ H	single bond	Н	СН3	Н
277	Cl	Х	CN4H	single bond	Н	C ₂ H ₅	Н
278	Cl	Х	CO ₂ H	-CH ₂ -CH ₂ -	Н	Н	COCH 3
279	Cl	Х	CO ₂ H	single bond	Н	Н	COCH ₂ Cl
280	Cl	х	CO ₂ H	single bond	Н	Н	COC 4H9
001	-1						
281	Cl	Х	CO ₂ H	single bond	Н	CH3	COCH 3
282	Cl	Х	CO ₂ H	single bond	Н	C ₂ H ₅	COCH 3
				/=			
283	Cl	Х	CN4H	-CH ₂ -CH ₂ -	Н	Н	COCH 3
284	Cl	X	CN4H	single bond	H	Н	COCH ₂ Cl
285	Cl	v	CNLI	oingle band		**	900 H
	CI	Х	CN4H	single bond	H	Н	COC 4H9
286	Cl	Х	CN ₄ H	single bond	Н	CH ₃	COCH 3

Ex: #	R ¹	R ²	R ₅	A	В	E	P
287	Cl	х	CN4H	single bond	Н	С ₂ Н ₅	COCH 3
288	Cl	x	CO2H	-CH ₂ -CH ₂ -	Н	Н	Н
289	Cl	Х	CO ₂ H	single bond	Н	CH ₃	Н
290	Cl	Х	CO ₂ H	single bond	Н	C ₂ H ₅	н
291	Cl	х	CN4H	-CH ₂ -CH ₂ -	Н	Н	Н
292	Cl	x	CN4H	single bond	Н	CH ₃	Н
293	Cl	X	CN4H	single bond	Н	C ₂ H ₅	н
294	Cl	х	CN4H	-CH ₂ CH ₂ -	Н	Н	COCH 3
295	Cl	Х	CO ₂ H	single bond	Н	Н	COCH ₂ Cl
296	Cl	Х	CO ₂ H	single bond	Н	Н	COC 4H9
297	Cl	Х	CO ₂ H	single bond	H	CH3	COCH 3

Ex:	¥ R ¹	R ²	R ₅	A	В	E	P
298	Cl	Х	CO ₂ H	single bond	Н	C ₂ H ₅	COCH 3
299	Cl	x	CN4H	-CH ₂ CH ₂ -	Н	Н	н
300	Cl	х	CN4H	single bond	Н	Н	COCH ₂ Cl
301	Cl	х	CN4H	single bond	H	COC 4H	19
302	Cl	х	CN4H	single bond	Н	CH ₃	COCH 3
303	Cl	х	CN4H	single bond	Н	C ₂ H ₅	COCH 3
304	Cl	Х	CN4H	-CH ₂ -CH ₂ -	- н	Н	COCH 3
305	Cl	Х	CO ₂ H	single bond	Н	СН3	Н
306	Cl	Х	СО2Н	single bond	Н	C ₂ H ₅	Н
307	Cl	Х	CN4H	-CH ₂ -CH ₂ -	Н	Н	Н

Ex: #	R ¹	R ²	R ₅	- A	В	E	P
308	Cl	х	CN4H	single bond	Н	CH ₃	Н
309	Cl	х	CN4H	single bond	Н	C ₂ H ₅	Н
310	Cl	X	CO ₂ H	\bowtie	Н	Н	COCH 3
311	Cl	x	СО2Н	single bond	Н	Н	COCH ₂ Cl
312	Cl	х	CO ₂ H	single bond	Н	Н	COC 4H9
313	Cl	Х	CO ₂ H	single bond	Н	СН3	COCH 3
314	Cl	X	CO ₂ H	single bond	Н	C ₂ H ₅	COCH 3
315	Cl	х	CN4H	\bowtie	H	Н	COCH 3
316	Cl	X	CN4H	single bond	Н	Н	COCH ₂ Cl
317	Cl	X	CN4H	single bond	Н	Н	COC 4H9
318	Cl	X	CN ₄ H	single bond	Н	СНЗ	COCH ₃

Ex:	# R ¹	_R 2	R ₅	A	В	E	P
319	Cl	х	CN4H	single bond	Н	C ₂ H ₅	COCH 3
320	Cl	х	CO ₂ H	\bowtie	Н	Н	Н
321	Cl	Х	CO ₂ H	single bond	Н	СНЗ	Н
322	Cl	Х	CO ₂ H	single bond	Н	C ₂ H ₅	Н
323	Cl	х	CN4H		Н	Н	Н
324	Cl	х	CN4H	single bond	Н	CH ₃	Н
325	Cl	Х	CN4H	single bond	Н	C ₂ H ₅	Н
326	Cl	Х	CO2H	-CH ₂	Н	Н	COCH 3
327	Cl	Х	CO ₂ H	single bond	Н	Н	COCH ₂ Cl
328	Cl	X	CO ₂ H	single bond	Н	Н	COC 4H9
329	Cl	X	CO ₂ H	single bond	Н	CH ₃	COCH ₃

Ex: #	R ¹	R ²	R ₅	A	В	E	P
330	Cl	х	CO ₂ H	single bond	Н	C ₂ H ₅	COCH 3
331	Cl	X	CN4H	-CH ₂	Н	H	COCH 3
332	Cl	х	CN4H	single bond	Н	Н	COCH ₂ Cl
333	Cl	x	CN4H	single bond	H	H	COC 4H9
334	Cl	Х	CN4H	single bond	Н	CH3	COCH 3
335	Cl	X.	CN4H	single bond	Н	C ₂ H ₅	COCH ₃
336	Cl	Х	СО2Н	-CH ₂	Н	Н	Н
337	Cl	х	CO ₂ H	single bond	Н	СН3	Н
338	Cl	Х	CO ₂ H	single bond	Н	C ₂ H ₅	н
339	Cl	Х	CN4H	-CH ₂	Н	Н	Н
340	Cl	Х	CN4H	single bond	н -	СН3	Н

Ex: #	R ¹	R ²	R ₅	A	В	E	Р
341	Cl	Х	CN ₄ H	single bond	Н	C ₂ H ₅	Н
342	Cl	Х	CO ₂ H	∠ CH ₂ -	Н	Н	COCH 3
343	Cl	Х	CO ₂ H	single bond	Н	Н	COCH ₂ Cl
344	Cl	Х	CO ₂ H	single bond	Н	Н	COC 4H9
345	Cl	Х	CO ₂ H	single bond	Н	СН3	COCH 3
346	Cl	Х	CO ₂ H	single bond	Н	C ₂ H ₅	COCH 3
347	Cl	х	CN4H	∠ CH ₂ -	Н	H	COCH 3
348	Cl	X	CN4H	single bond	H	Н	COCH ₂ Cl
349	Cl	x	CN4H	single bond	Н	Н	COC 4H9
350	Cl	Х	CN4H	single bond	Н	CH ₃	COCH 3
351	Cl	х	CN4H	single bond	Н	C ₂ H ₅	COCH 3

Ex: #	R ¹	R ²	R ₅	A	В	E	P
352	Cl	Х	СО2Н	∠ CH ₂ -	Н	Н	H
353	Cl	Х	CO ₂ H	single bond	H	CH3	Н
354	Cl	X	CO ₂ H	single bond	Н	C ₂ H ₅	Н
355	Cl	Х	CN4H	∠ CH ₂ -	Н	H .	Н
356	Cl	Х	CN4H	single bond	Н	CH3	Н
357	Cl _	x	CN4H	single bond	Н	C ₂ H ₅	Н
358	Cl	X	СО2Н	-CH ₂ -CH ₂ -	Н	Н	COCH 3
359	Cl	х	CO ₂ H	single bond	Н	Н	COCH ₂ Cl
360	Cl	х	CO ₂ H	single bond	Н	Н	COC 4H9
361	Cl	X	CO ₂ H	single bond	Н	CH ₃	COCH 3
362	Cl	Х	CO ₂ H	single bond	Н	C ₂ H ₅	COCH 3

Ex: #	R ¹	R ²	R ₅	A	В	E	P
		3-1-1-1-1					
363	Cl	Х	CN4H	-CH ₂ -CH ₂ -	- н	Н	COCH 3
364	Cl	х	CN4H	single bond	Н	Н	COCH ₂ Cl
365	Cl	Х	CN ₄ H	single bond	Н	Н	COC 4H9
366	Cl	х	CN4H	single bond	Н	СНЗ	COCH 3
367	Cl	Х	CN4H	single bond	Н	C ₂ H ₅	COCH 3
368	Cl	х	СО2H .	-СН ₂ -СН ₂ -	Н	Н	н
369	Cl	X	CO ₂ H	single bond	Н	СН3	Н
370	Cl	Х	CO ₂ H	single bond	Н	C ₂ H ₅	Н
371	Cl	X	CN4H	-CH ₂ -CH ₂ -	Н	Н	H
372	Cl	Х	CN ₄ H	single bond	Н	СНЗ	Н

Ex: #	R ¹	R ²	R ₅	A	В	E	Р
373	Cl	Х	CN4H	single bond	Н	C ₂ H ₅	Н
374	Cl	X	CN4H	-CH ₂ CH ₂	Н	Н	COCH 3
375	Cl	х	CO ₂ H	single bond	Н	Н	COCH ₂ Cl
376	Cl	х	CO ₂ H	single bond	Н	Н	COC 4H9
377	Cl	Х	CO ₂ H	single bond	Н	CH ₃	COCH 3
378	Cl	X	CO ₂ H	single bond	Н	C ₂ H ₅	COCH 3
379	Cl	X	CN4H	-CH ₂ CH ₂	H	Н	н
380	Cl	х	CN4H	single bond	Н	Н	COCH ₂ Cl
381	Cl	Х	CN4H	single bond	Н	Н	COC 4H9
382	Cl	Х	CN4H	single bond	H	СН3	COCH 3
383	Cl	Х	CN4H	single bond	Н	C ₂ H ₅	COCH 3

Ex: #	R ¹	R ²	R ₅	A	В	E	P
384	Cl	х	CN ₄ H	CH ₂ CH ₂ -	- н	Н	COCH 3
385	Cl	х	CO ₂ H	single bond	Н	СНЗ	Н
386	Cl	Х	CO ₂ H	single bond	Н	C ₂ H ₅	Н
387	Cl	х	CN4H	CH ₂ CH ₂ -	Н	Н	Н
388	Cl	Х	CN4H	single bond	Н	СН3	Н
389	Cl	х	CN4H	single bond	Н	C ₂ H ₅	н
390	Cl	Х	CN4H	✓ N-	*	Н	COCH 3
391	Cl	х	CO ₂ H	single bond	Н	H	COCH ₂ Cl
392	Cl	х	CO ₂ H	single bond	Н	Н	COC 4H9
393	Cl	х	CO ₂ H	single bond	Н	CH ₃	COCH 3
394	Cl	X	CO ₂ H	single bond	Н	C ₂ H ₅	COCH 3

Ex: #	R ¹	R ²	R ₅	A	В	E	P
395	Cl	X	CN4H	√N-	*	Н	Н
396	Cl	X	CN4H	single bond	Н	Н	COCH ₂ Cl
397	Cl	х	CN4H	single bond	Н	Н	COC 4H9
398	Cl	x	CN ₄ H	single bond	Н	СН3	COCH 3
399	Cl	X	CN4H	single bond	Н	C ₂ H ₅	COCH 3
400	Cl	X	CN4H	-CH ₂ N-	*	Н	COCH 3
401	Cl	Х	CO ₂ H	single bond	Н	СНЗ	Н
402	Cl	х	CO ₂ H	single bond	Н	C ₂ H ₅	Н
403	Cl	X	CN4H	-CH ₂ N-	*	Н	Н
404	Cl	X	CN4H	single bond	Н	CH3	Н

Ex:	# R ¹	R ²	R ₅	A	В	E	P
405	Cl	х	CN4H	single bond	Н	C ₂ H ₅	Н
406	Cl	х	CN4H	-CH ₂ CH ₂ N	- *	Н	COCH 3
407	Cl	Х	CO ₂ H	single bond	Н	Н	COCH ₂ Cl
408	Cl	Х	CO ₂ H	single bond	Н	Н	COC 4H9
409	Cl	Х	CO ₂ H	single bond	Н	CH3	COCH 3
410	Cl	Х	CO ₂ H	single bond	Н	C ₂ H ₅	COCH 3
411	Cl	Х	CN4H	-CH ₂ -CH ₂ -N	· *	Н	Н
412	Cl	х	CN4H	single bond	Н	Н	COCH ₂ Cl
413	Cl	Х	CN4H	single bond	Н	Н	COC 4H9
414	Cl	X	CN4H	single bond	Н	СН3	COCH 3
415	Cl	х	CN4H	single bond	Н	C ₂ H ₅	COCH 3

Ex:	#	R ¹	R ²	R ₅	A	В	Е	P
416		Cl	Х	CN4H	-CH ₂ -N N	*	H	COCH 3
417		Cl	Х	CO ₂ H	single bond	Н	CH3	Н
418		Cl	Х	CO ₂ H	single bond	Н	C ₂ H ₅	Н
419		Cl	X	CN4H	-CH ₂ -N	*	Н	Н
420		Cl	X	CN4H	single bond	·H	СНЗ	Н
421		Cl	X	CN4H	single bond	Н	C ₂ H ₅	Н
422		Cl .	X	CN4H _	·CH ₂ -CH ₂ -N	*	Н	COCH 3
423		Cl	Х .	CN4H	single bond	Н	H	COCH ₂ Cl
424		Cl	X	CN4H	single bond	H	Н	COC 4H9
425		Cl	X	CN4H		Н	CH3	COCH 3

Ex: #	R ¹	R	2 _{R5}	А	В	E	P
426	Cl	х	CN4H	single bond	Н	C ₂ H ₅	COCH 3
427	Cl	Х	CN4H	-CH ₂ CH ₂ -N	N *	Н	Н
428	Cl	Х	CN4H	single bond	Н	CH3	Н
429	Cl	Х	CN4H	single bond	Н	C ₂ H ₅	Н
430	х	Cl	СО2Н	single bond	Н	Н	COCH 3
431	х	Cl	CO ₂ H	single bond	Н	Н	COCH ₂ Cl
432	х	Cl	CO ₂ H	single bond	Н	Н	COC 4H9
433	Х	Cl	CO ₂ H	single bond	Н	СНЗ	COCH 3
434	X ·	Cl	СО 2Н	single bond	Н	C ₂ H ₅	COCH 3
135	х	Cl	CN 4H	single bond	Н	Н	COCH 3
136	x	Cl	CN 4H	single bond	Н	Н	COCH ₂ Cl

Ex: #	R ¹	R ²	R ₅	A	В	E	P
437	X	Cl	CN 4H	single bond	H	Н	COC 4H9
438	X	Cl	CN 4H	single bond	Н	СНЗ	COCH 3
439	X	Cl	CN 4H	single bond	Н	С2Н5	COCH 3
440	х	Cl	CO ₂ H	single bond	Н	Н	Н
441	Х	Cl	CO ₂ H	single bond	H	СНЗ	Н
442	Х	Cl	CO ₂ H	single bond	Н	С2Н5	Н
443	Х	Cl	CN 4H	single bond	Н	Н	Н
444	Х	Cl	CN 4H	single bond	H	CH3	Н
445	X	Cl	CN 4H	single bond	Н	C ₂ H ₅	Н
446	X	Cl	CO ₂ H	-CH ₂ -	Н	Н	COCH 3
447	Х	Cl	CO ₂ H	single bond	Н	Н	COCH ₂ Cl

Ex:	# R ¹	R	2 R ₅	A	В	E	P
448	Х	Cl	CO ₂ H	single bond	Н	Н	COC 4H9
449	Х	Cl	CO ₂ H	single bond	Н	СНЗ	COCH 3
450	Х	Cl	CO ₂ H	single bond	Н	С2Н5	COCH 3
451	Х	Cl	CN 4H	single bond	Н	Н	COCH ₂ Cl
452	Х	Cl	CN 4H	single bond	Н	Н	COC 4H9
453	х	Cl	CN 4H	single bond	Н	СНЗ	COCH 3
454	х	Cl	CN 4H	single bond	Н	С2Н5	COCH 3
455	Х	Cl	СО2Н	-CH 2-	Н	Н	Н
456	Х	Cl	СО 2Н	single bond	Н	СНЗ	Н
457	Х	Cl	СО2Н	single bond	Н	С2Н5	Н
458	Х	Cl	CN 4H	-CH ₂ -	Н	Н	Н

Ex: #	R ¹	R ²	R ₅	A	В	E	P
459	x	Cl	CN 4H	single bond	Н	CH3	Н
460	х	Cl	CN 4H	single bond	Н	С2Н5	Н
461	X	Cl	CN 4H	-CH ₂ -	СНЗ	Н	Н
462	х	Cl	CN 4H	-CH ₂ -	СНЗ	Н	COCH 3
463	Х	Cl	CO ₂ H	-CH ₂ CH ₂ -	Н	H	COCH 3
464	X	Cl	CO ₂ H	single bond	Н	H	COCH ₂ Cl
465	X	Cl	CO ₂ H	single bond	Н	Н	COC 4H9
466	х	Cl	CO ₂ H	single bond	Н	СН3	COCH 3
467	Х	Cl	CO 2H	single bond	H	C ₂ H ₅	COCH 3
468	X	Cl	CN 4H	-CH ₂ CH ₂ -	Н	Н	COCH 3
469	X	Cl	CN 4H	single bond	Н	Н	COCH ₂ Cl
470	X	Cl	CN 4H	single bond	Н	Н	COC 4H9

Ex: #	♯ R ¹	R	2 _{R5}	A	В	E	Р
471	х	Cl	CN 4H	single bond	Н	CH ₃	COCH 3
472	х	Cl	CN 4H	single bond	Н	C ₂ H ₅	COCH 3
473	Х	Cl	CO ₂ H	-CH ₂ CH ₂ -	Н	Н	Н
474	х	Cl	CO ₂ H	single bond	Н	CH ₃	Н
475	х	Cl	CO ₂ H	single bond	Н	C ₂ H ₅	Н
476	X	Cl	CN 4H	-CH 2CH2-	Н	Н	Н
477	Х	Cl	CN 4H	single bond	Н	CH ₃	Н
478	Х	Cl	CN 4H	single bond	Н	C ₂ H ₅	Н
479	Х	Cl	CO ₂ H	C3H6 (n)	Н	Н	COCH 3
480	х	Cl	CO ₂ H	single bond	Н	Н	COCH ₂ Cl
481	х	Cl	CO ₂ H	single bond	Н	Н	COC 4H9

Ex: #	R ¹	R ²	R ₅	A	В	E	P
							-
482	Х	Cl.	CO ₂ H	single bond	Н	СН3	COCH 3
483	Х	Cl	CO ₂ H	single bond	Н	C ₂ H ₅	COCH 3
484	X	Cl	CN 4H	C3H6 (n)	Н	Н	COCH 3
485	X .	Cl	CN 4H	single bond	H	Н	COCH ₂ Cl
486	Х	Cl	CN 4H	single bond	Н	Н	COC ₄ H ₉
487	X	C1	CN 4H	single bond	Н	СН3	COCH 3
488	х	Cl	CN 4H	single bond	Н	C ₂ H ₅	COCH 3
489	х	Cl	CO ₂ H	C3H6 (n)	Н	Н	Н
490	x	Cl	CO ₂ H	single bond	Н	СН3	Н
491	х	Cl	CO ₂ H	single bond	Н	C ₂ H ₅	Н
492	X	Cl	CN 4H	C3H6 (n)	Н	Н	Н

WO 92/02257 PCT/US91/05476

137

Ex: #	R1	R	2 _{R5}	A	В	E	P
						-	
493	X	Cl	CN 4H	single bond	Н	СНЗ	Н
494	Х	Cl	CN 4H	single bond	Н	C ₂ H ₅	H
495	х	Cl	СО 2Н	C4H8 (n)	Н	Н	сосн 3
496	х	Cl	CO ₂ H	single bond	Н	Н	COCH ₂ Cl
497	Х	Cl	CO ₂ H	single bond	Н	Н	COC 4H9
498	Х	Cl	CO ₂ H	single bond	Н	CH3	COCH 3
499	Х	Cl	CO ₂ H	single bond	Н	C ₂ H ₅	COCH 3
500	х	Cl	CN 4H	C4H8 (n)	Н	Н	COCH 3
501	х	Cl	CN 4H	single bond	Н	Н	COCH ₂ Cl
502	х	Cl	CN 4H	single bond	Н	Н	COC 4H9
503	х	Cl	CN 4H	single bond	Н	СН3	COCH 3

Ex: #	R ¹	R ²	R ₅	A	В	E	P
504	Х	Cl	CN 4H	single bond	Н	C ₂ H ₅	COCH 3
505	х	Cl	CO ₂ H	C4H8 (n)	Н	Н	Н
506	X	Cl	CO ₂ H	single bond	Н	CH ₃	Н
507	х	Cl	CO ₂ H	single bond	Н	C ₂ H ₅	H
508	Х	Cl	CN 4H	C4H8 (n)	Н	Н	H
509	х	Cl	CN 4H	single bond	Н	CH3	Н
510	Х	Cl	CN 4H	single bond	Н	C ₂ H ₅	H
511	х	Cl	CO ₂ H	←	Н	Н	COCH 3
512	X	el	CO ₂ H	single bond	Н	Н	COCH ₂ Cl
513	х .	Cl	CO ₂ H	single bond	Н	Н	COC 4H9
514	х	Cl	CO ₂ H	single bond	Н	CH ₃	COCH 3

Ex: #	R ¹	R	2 _{R5}	A	В	E	Р
515	Х	Cl	CO ₂ H	single bond	Н	C ₂ H ₅	COCH 3
516	х	Cl	CN 4H		Н	Н	СОСН 3
517	х	Cl	CN 4H	single bond	Н	Н	COCH ₂ Cl
518	Х	Cl	CN 4H	single bond	Н	Н	COC 4H9
519	x	Cl	CN 4H	single bond	Н	CH ₃	COCH 3
520	х	Cl	CN 4H	single bond	Н	C ₂ H ₅	COCH ₃
521	х	Cl	CO ₂ H		Н	Н	Н
522	Х	Cl	CO ₂ H	single bond	Н	СН3	Н
523	х	Cl	CO ₂ H	single bond	Н	C ₂ H ₅	Н
524	х	Cl	CN 4H		Н	Н	н

Ex: #	R ¹	R ²	R ₅	A	В	E	P
525	Х	Cl	CN 4H	single bond	Н	СН3	Н
526	X	Cl	CN 4H	single bond	Н	C ₂ H ₅	Н
527	X	Cl	CO ₂ H	-CH ₂	Н	Н	COCH 3
528	х	Cl	CO ₂ H	single bond	Н	Н	COCH ₂ Cl
529	x	Cl	CO ₂ H	single bond	Н	Н	COC 4H9
530	X	Cl	CO ₂ H	single bond	Н	CH3	COCH 3
531	X	Cl	СО 2Н	single bond	H	C ₂ H ₅	COCH 3
532	x	Cl	CN 4H	-CH ₂ -	Н	Н	COCH 3
533	х	Cl	CN 4H	single bond	Н	Н	COCH ₂ Cl
534	x	Cl	CN 4H	single bond	Н	Н	COC 4H9

Ex: #	R ¹	R	2 R ₅	A	В	E	P
535	х	Cl	CN 4H	single bond	Н	CH3	COCH 3
536	Х	Cl	CN 4H	single bond	Н	С ₂ Н ₅	COCH 3
537	х	Cl	CO ₂ H	-CH ₂ -	Н	Н	Н
538	Х	Cl	CO ₂ H	single bond	Н	СНЗ	Н
539	х	Cl	CO ₂ H	single bond	Н	C ₂ H ₅	Н
540	Х	Cl	CN 4H	-CH ₂ -	Н	Н	Н
541	Х	Cl	CN 4H	single bond	Н	СНЗ	Н
542	Х	Cl	CN 4H	single bond	Н	C ₂ H ₅	Н
543	X	Cl	СО2Н	-CH ₂ -	Н	н	COCH 3
544	Х	Cl	СО 2Н	single bond	Н	Н	COCH ₂ Cl

Ex: #	R ¹	R ²	R ₅	A	В	E	P
545	X	Cl	CO ₂ H	single bond	Н	Н	COC 4H9
546	Х	Cl	CO ₂ H	single bond	Н	CH3	COCH 3
547	x	Cl	CO ₂ H	single bond	Н	С ₂ Н ₅	COCH 3
548	х	Cl	CN 4H	-CH ₂ -	Н	Н	COCH 3
549	X -	Cl	CN 4H	single bond	Н	Н	COCH ₂ Cl
550	Х	Cl	CN 4H	single bond	Н	Н	COC ₄ H ₉
551	х	Cl	CN 4H	single bond	Н	CH3	COCH 3
552	х	Cl	CN 4H	single bond	Н	C ₂ H ₅	COCH 3
553	X	Cl	СО 2Н	-CH ₂ -	Н	Н	Н
554	Х	Cl	CO ₂ H	single bond	Н	СН3	Н

Ex: #	ŧ R ¹	R	2 _{R5}	A	В	E	Р
555	х	Cl	СО <u>2</u> Н	single bond	Н	C ₂ H ₅	Н
556	х	Cl	CN 4H	-CH ₂ -	Н	Н	Н
557	х	Cl	CN 4H	single bond	Н	CH ₃	Н
558	Х	Cl	CN 4H	single bond	Н	C ₂ H ₅	Н
559	х	Cl	CO ₂ H	-CH ₂ -CH ₂ -	Н	Н	COCH 3
560	х	Cl	CO ₂ H	single bond	Н	Н	COCH ₂ Cl
561	Х	Cl	CO ₂ H	single bond	Н	Н	COC 4H9
562	х	Cl	CO ₂ H	single bond	Н	CH ₃	COCH 3
563	X	Cl	CO ₂ H	single bond	Н	C ₂ H ₅	COCH 3

Ex: #	R ¹	R ²	R ₅	A	В	E	P
						-	
564	X	Cl	CN 4H	-CH ₂ -CH ₂ -	H	H	COCH 3
565	Х	Cl	CN ₄ H	single bond	H	Н	COCH ₂ Cl
566	Х	Cl	CN 4H	single bond	Н	Н	COC 4H9
567	х	Cl	CN 4H	single bond	Η	CH3	COCH 3
568	X	Cl	CN 4H	single bond	H ·	C ₂ H ₅	COCH 3
569	X	Cl	CO ₂ H	-CH ₂ -CH ₂ -	Н	Н	Н
570	х	Cl	CO ₂ H	single bond	H	CH3	Н
571	х	Cl	CO ₂ H	single bond	Н	C ₂ H ₅	Н
				au Cu			
572	Х	Cl	CN 4H	-CH ₂ -CH ₂ -	H	Н	H
573	Х	Cl	CN 4H	single bond	Н	CH ₃	Н

Ex: #	R1	R	2 _{R5}	A	В	E	P
574	х	Cl	CN 4H	single bond	Н	С ₂ Н ₅	Н
575	x	Cl	CN 4H	-CH ₂ CH ₂ -	Н	Н	COCH 3
576	Х	Cl	CO ₂ H	single bond	Н	Н	COCH ₂ Cl
577	х	Cl	CO ₂ H	single bond	Н	Н	COC ₄ H ₉
578	x	Cl	CO ₂ H	single bond	Н	CH ₃	COCH 3
579	Х	Cl	CO ₂ H	single bond	Н	C ₂ H ₅	COCH 3
580	x	Cl	CN 4H	-CH ₂ CH ₂ -	Н	Н	Н
581	Х	Cl	CN 4H	single bond	Н	Н	COCH ₂ Cl
582	х	Cl	CN 4H	single bond	Н	Н	COC 4H9
583	х	Cl	CN 4H	single bond	Н	СН3	COCH ₃

Ex: #	R ¹	R ²	R ₅	A	В	E	P
584	X	Cl	CN 4H	single bond	Н	C ₂ H ₅	COCH 3
585	Х	Cl.	CN4H -	-CH ₂ -CH ₂ -	Н	Н	COCH 3
586	X	Cl	CO ₂ H	single bond	Н	CH ₃	Н
587	X	Cl	CO ₂ H	single bond	Н	C ₂ H ₅	н
588	х	Cl	CN 4H	-CH ₂ -CH ₂ -	Н	Н	Н
589	Х	Cl	CN 4H	single bond	Н	CH ₃	Н
590	Х	Cl	CN 4H	single bond	Н	C ₂ H ₅	Н
591	X	Cl	СО 2Н		Н	H	COCH 3
592	X	Cl	CO ₂ H	single bond	Н	Н	COCH ₂ Cl
593	X	Cl	CO ₂ H	single bond	Н	Н	COC 4H9

Ex: #	R ¹	R	2 _{R5}	A	В	E	P
594	Х	Cl	CO ₂ H	single bond	Н	СН3	COCH 3
595	х	Cl	CO ₂ H	single bond	Н	C ₂ H ₅	COCH ₃
596	х	Cl	CN ₄H		Н	Н	COCH 3
597	Х	Cl	CN 4H	single bond	Н	Н	COCH ₂ Cl
598	х	Cl	CN 4H	single bond	Н	Н	COC 4H9
599	х	Cl	CN 4H	single bond	Н	CH ₃	COCH 3
600	X	Cl	CN 4H	single bond	Н	C ₂ H ₅	COCH 3
601	х	Cl	СО2Н	\bowtie	Н	Н	Н
602	х	Cl	CO ₂ H	single bond	Н	СН3	Н
603	х	Cl	CO ₂ H	single bond	Н	C ₂ H ₅	Н
604	х	Cl	CN 4H		Н	Н	Н

Ex: #	R ¹	R ²	R ₅	- A	В	E	P
				single bond	Н	CH3	Н
605	X	Cl	CN 4H	single bond	n	CII3	11
606	х	Cl	CN 4H	single bond	H	C ₂ H ₅	Н
607	х	Cl	CO2H	-CH ₂	Н	Н	COCH 3
608	X	Cl	CO ₂ H	single bond	Н	Н.	COCH ₂ Cl
609	x	Cl	CO ₂ H	single bond	Н	Н	COC 4H9
610	х	Cl	CO ₂ H	single bond	Н	CH3	COCH 3
611	X	Cl	CO ₂ H	single bond	Н	C ₂ H ₅	COCH 3
612	Х	Cl	CN 4H	-CH ₂	Н	Н	COCH 3
613	Х	C1	CN 4H	single bond	Н	H	COCH ₂ Cl
614	X	Cl	CN 4H	single bond	Н	Н	COC 4H9
615	Х	Cl	CN 4H	single bond	Н	CH3	COCH 3

Ex: #	R ¹	R ²	2 R ₅	A	В	E	Р
616	х	Cl	CN 4H	single bond	Н	С ₂ Н ₅	COCH 3
617	Х	Cl	СО 2Н	-CH ₂	Н	Н	Н
618	X	Cl	CO ₂ H	single bond	Н	CH3	Н
619	X	Cl	CO ₂ H	single bond	Н	C ₂ H ₅	Н
620	х	Cl	CN ₄H	-CH ₂	Н	Н	Н
621	X	Cl	CN 4H	single bond	Н	CH3	Н
622	Х	Cl	CN 4H	single bond	Н	C ₂ H ₅	Н
623	х	Cl	СО2Н	CH ₂ -	Н	Н	COCH 3
524	х	Cl	CO ₂ H	single bond	Н	Н	COCH ₂ Cl
525	Х	Cl	CO ₂ H	single bond	Н	Н	COC 4H9

Ex: #	R ¹	_R 2	R ₅	A	В	E	P
				-	···		
626	X .	Cl ·	CO ₂ H	single bond	Н	СНЗ	COCH 3
627	X	Cl	CO ₂ H	single bond	Н	C ₂ H ₅	COCH 3
628	Х	Cl	CN 4H	CH ₂ -	Н	Н	COCH 3
629	X	Cl	CN 4H	single bond	Н	Н	COCH ₂ Cl
630	X	Cl	CN 4H	single bond	Н	H	COC 4H9
631	Х	Cl	CN 4H	single bond	Н	CH3	COCH 3
632	х	Cl	CN 4H	single bond	Н	C ₂ H ₅	COCH ₃
633	X	Cl	СО2Н	∠CH ₂ -	Н -	H	Н
634	Х	Cl	CO ₂ H	single bond	Н	CH3	Н
635	X	Cl	CO ₂ H	single bond	Н	C ₂ H ₅	Н

Ex: #	R ¹	R	2 R ₅	A	В	E	P
636	x	Cl	CN 4H	CH ₂ -	Н	Н	н
637	х	Cl	CN 4H	single bond	Н	СН3	Н
638	х	Cl	CN 4H	single bond	Н	C ₂ H ₅	Н
639	Х	Cl	CO 2H -(CH ₂ -CH ₂ -	Н	Н	COCH 3
640	х	Cl	CO ₂ H	single bond	Н	Н	COCH ₂ Cl
641	Х	Cl	CO ₂ H	single bond	Н	Н	COC 4H9
642	Х	Cl	CO ₂ H	single bond	Н	СН3	COCH 3
643	Х	Cl	CO ₂ H	single bond	Н	C ₂ H ₅	COCH 3
644	х	Cl	CN 4H -C	H ₂ -CH ₂ -	Н	Н	COCH 3
645	Х	Cl	CN 4H	single bond	Н	Н	COCH ₂ Cl

Ex: #	R ¹	R ²	R ₅	A	В	E	P
646	Х	Cl	CN 4H	single bond	Н	Н	COC 4H9
647	X	Cl	CN 4H	single bond	Н	СНЗ	COCH ₃
648	Х	Cl	CN 4H	single bond	Н	C ₂ H ₅	COCH 3
649	х	Cl	CO ₂ H	-CH ₂ -CH ₂ -	Н	Н	Н
650	Х	Cl	CO ₂ H	single bond	Н	CH3	Н
651	X	Cl	CO ₂ H	single bond	Н	C ₂ H ₅	Н
652	X	Cl	CN 4H	-CH ₂ -	Н	Н	Н
653	х	Cl	CN 4H	single bond	Н	CH ₃	Н
654	Х	Cl	CN 4H	single bond	Ħ	C ₂ H ₅	Н
655	х	Cl	CN 4H	-CH ₂ CH ₂	Н	H	COCH 3
656	X	Cl	CO ₂ H	single bond	Н	Н	COCH ₂ Cl

Ex: #	R ¹	R	2 _{R5}	A	В	E	P
657	х	Cl	CO ₂ H	single bond	Н	Н	COC 4H9
658	Х	Cl	CO ₂ H	single bond	Н	CH ₃	COCH 3
659	X	Cl	CO ₂ H	single bond	Н	C ₂ H ₅	COCH 3
660	Х	Cl	CN 4H	-СН,СН,	Н	Н	Н
661	X	Cl	CN 4H	single bond	Н	Н	COCH ₂ Cl
662	Х	Cl	CN 4H	single bond	Н	Н	COC 4H9
663	Х	Cl	CN 4H	single bond	Н	СН3	COCH 3
664	Х	Cl	CN 4H	single bond	Н	C ₂ H ₅	COCH 3
665	х	Cl	CN 4H	CH ₂ CH ₂ -	Н	Н	COCH 3
666	Х	Cl	CO ₂ H	single bond	Н	СН3	Н

Ex: #	R ¹	R ²	R ₅	A	В	E	Р
667	х	Cl	CO ₂ H	single bond	Н	C ₂ H ₅	Н
668	Х	Cl	CN 4H	CH ₂ CH ₂ -	Н	Н	Н
669	х	Cl	CN 4H	single bond	Н	CH ₃	Н
670	х	Cl	CN 4H	single bond	Н	C ₂ H ₅	Н
671	X	Cl	CN 4H	√N-	*	Н	COCH 3
672	х	Cl	CO ₂ H	single bond	Н	Н	COCH ₂ Cl
673	Х	Cl	CO ₂ H	single bond	Н	Н	COC 4H9
674	х	Cl	CO ₂ H	single bond	Н	CH ₃	COCH 3
675	х	Cl	CO ₂ H	single bond	Н	C ₂ H ₅	COCH 3
676	х	Cl	CN 4H	N-	*	Н	н
677	Х	Cl	CN 4H	single bond	H	Н	COCH ₂ Cl

Ex: #	R ¹	R ²	2 R ₅	A	В	E	P
678	Х	Cl	CN 4H	single bond	Н	Н	COC 4H9
679	х	Cl	CN 4H	single bond	Н	СНЗ	COCH 3
680	х	Cl	CN 4H	single bond	Н	C ₂ H ₅	COCH 3
681	х	Cl	CN 4H	-CH ₂ N-	*	Н	COCH 3
682	Х	Cl	CO ₂ H	single bond	Н	CH ₃	Н
683	Х	Cl	CO ₂ H	single bond	Н	C ₂ H ₅	Н
684	X	Cl	CN 4H	-CH ₂ N-	*	Н	Н
685	X	Cl	CN 4H	single bond	Н	CH3	Н
686	Х	Cl	CN 4H	single bond	Н	C ₂ H ₅	Н
687	х	Cl	CN 4H -0	CH ₂ CH ₂ N-	*	Н	COCH 3

Ex: #	R ¹	R ²	R ₅	A	В	E	Р
688	х	Cl	CO ₂ H	single bond	Н	Н	COCH ₂ Cl
689	Х	Cl	CO ₂ H	single bond	Н	Н	COC ₄ H ₉
690	х	Cl	CO ₂ H	single bond	Н	CH ₃	COCH 3
691	х	Cl	CO ₂ H	single bond	Н	C ₂ H ₅	COCH 3
692	X	Cl	CN4H	-CH ₂ -CH ₂ N-	*	Н	н
693	х	Cl	CN 4H	single bond	Н	Н	COCH ₂ Cl
694	X	Cl	CN 4H	single bond	Н	Н	COC 4H9
695	Х	Cl	CN 4H	single bond	Н	СН3	COCH 3
696	х	Cl	CN 4H	single bond	Н	C ₂ H ₅	COCH 3
697	Х	Cl	CN 4H	-CH ₂ -N N	*	Н	COCH 3

Ex: #	R ¹	R.	2 R ₅	A	В	E	P
698	х	Cl	CO ₂ H	single bond	H	CH ₃	Н
699	x	Cl	CO ₂ H	single bond	Н	C ₂ H ₅	Н
700	х	Cl	CN 4H	-CH ₂ -N N	*	Н	Н
701	Х	Cl	CN 4H	single bond	Н	СН3	Н
702	х	Cl	CN 4H	single bond	Н	C ₂ H ₅	н
703	Х	Cl	CN4H -C	CH ₂ -CH ₂ -N	*	Н	COCH 3
704	х	Cl	CN 4H	single bond	Н	Н	COCH ₂ Cl
705	х	Cl	CN 4H	single bond	Н	Н	COC 4H9
706	X	Cl	CN 4H	single bond	H	СН3	COCH 3
707	х	Cl	CN 4H	single bond	Н	C ₂ H ₅	COCH 3

Ex: #	R ¹	R ²	R ₅	A	В	E	P
708	Х	Cl	CN 4H	-CH ₂ CH ₂ -N	*	Н	Н
709	Х	Cl	CN 4H	single bond	Н	СНЗ	Н
710	Х	Cl	CN 4H	single bond	H	C ₂ H ₅	H

*B is incorporated in A

Another class of highly preferred specific conjugates of the invention is provided by conjugates formed from a biphenylmethyl 1H-substituted imidazole AII antagonist compound having a terminal carboxyl group 5 attached to the imidazo nucleus. In this family of conjugates, the cleavable glutamyl residue is attached through a diamino linker moiety which connects the imidazo AII antagonist terminal carboxylic moiety through two amide bonds to the gamma carbon of the glutamyl residue 10 conjugates are shown as Examples 711-1526. General procedures for preparation of the conjugates of Examples #711-#1526 are described in Schemes VI-VII. Detailed procedures for preparation of representative conjugates are described in Examples #711 and #712. Procedures similar to 1 5 these aforementioned general and specific procedures may be used for preparation of the conjugates identified as Examples #711-#1526 shown in Table VII.

160

Example 711

N-acetyl-L-glutamic acid, 5-[2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazol-5-yl]acetylhydrazide

Step 1: Preparation of 2-butyl-5-cyanomethyl-4-chloro-1-[(2'-(1H-tetrazol-5-vl)biphenyl-4-methyl]imidazole.

10 Thionyl chloride (7.2 mL, 98 mmol) is slowly dripped into a solution of 8.45 g (20.0 mmol) of the compound of Example 78 in a minimum of chloroform. The mixture is stirred for 2 h at ambient temperature and the solvent is The chloride is dissolved in removed in vacuo. 15 dimethylsulfoxide (DMSO) and is added to a solution of 5.80 g (118 mmol) of sodium cyanide in 400 mL of DMSO. The solution is stirred overnight under nitrogen at ambient temperature; water is added and the aqueous layer is extracted with ethyl acetate. The extracts are combined, are dried (MgSO₄), and 20 are concentrated in vacuo to give the crude product. Purification by silica gel chromatography (Waters DeltaPrep-500A) provides the pure 5-cyanomethyl derivative.

Step 2: Preparation of 2-butyl-5-carboxymethyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-methyl]imidazole.

A solution of 6.5 g (15 mmol) of the 5-cyanomethyl derivative from step 1 in 150 mL of concentrated hydrochloric acid/acetic acid (1:1) is stirred at reflux overnight. The solvents are removed in vacuo to give the crude product. Purification by reverse phase chromatography (Waters Deltaprep-3000) provides the pure 5-acetic acid derivative.

10

Step 3: Preparation of 2-butyl-4-chloro-5methoxycarbonylmethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-methyl]imidazole.

A solution of 4.5 g (10 mmol) of the 5-acetic acid derivative from step 2 in 150 mL of absolute methanol is cooled to -10°C and is treated with 1.5 mL (20 mmol) of thionyl chloride under nitrogen. The reaction is allowed to warm to ambient temperature and is stirred at reflux overnight. The methanol is removed in vacuo and the crude product is dissolved in water. The pH is adjusted to pH 4 with 1N NaOH and the solution is extracted with ethyl acetate. The extracts are combined, are dried (MgSO₄), and are concentrated in vacuo to give the crude product. Purification by silica gel chromatography (Waters Prep-500A) provides the pure 5-methyl acetate derivative.

Step 4: Preparation of 2-butyl-4-chloro-5-hydrazinylcarbonyl-methyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-methyllimidazole.

30

Under nitrogen, 2.32 g (5.0 mmol) of the 5-methyl acetate derivative from step 3 is dissolved in 50 mL of methanol and is treated with 5mL (160 mmol) of anhydrous hydrazine. The reaction is allowed to stir at reflux

overnight; concentration in vacuo gives the crude material. Purification by silica gel chromatography (Waters Prep-500A) provides the pure 5-acetic acid hydrazide derivative.

5 Step 5: Preparation of N-acetyl-L-glutamic acid, 5-[2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1.1'-biphenyl]-4-yl]methyl]-1H-imidazol-5-yl]acetylhydrazide

To a solution of 1.70 g (5.6 mmol) of N-Boc-L-10 glutamic acid- α -tertbutyl ester (BACHEM) in 50 mL of methylene chloride under nitrogen is added 580 mg (2.8 mmol) of solid dicylcohexylcarbodiimide (DCC). The reaction is allowed to stir for 2 h and is filtered under nitrogen. The anhydride solution is then added to a solution of 1.01 g (2.4 mmol) of the hydrazide from step 4 in 75 mL of methylene chloride under 15 The reaction is stirred overnight, is concentrated to a volume of 25 mL, is cooled to 0°C, and is treated with 25 mL of TFA under nitrogen. The stirred reaction is allowed to warm to ambient temperature overnight and is concentrated \underline{in} vacuo. The crude product is dissolved in 100 mL of 20 acetonitrile/water (1:1) and the pH is adjusted to 8 with 1 M K_2CO_3 . The solution is cooled to 0°C and 0.23 mL (2.4 mmol) of acetic anhydride and 2.4 mL (2.4 mmol) of 1 M K₂CO₃ is added every 30 min for 5 h; the pH is mainained at 9 and the reaction temperature is kept below 5°C. After the last 25 addition, the reaction is allowed to warm to ambient temperature overnight. The pH is adjusted to 4 with 3 M HCl and the reaction is concentrated to 100 mL. Purification by reverse phase chromatography (Waters Deltaprep-3000) gives the 30 pure product.

Example 712

N-acetyl-L-glutamic acid, 5-[2-butyl-5-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazol-4-yl]acetylhydrazide

Step 1: Preparation of 2-butyl-4-cyanomethyl-5-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-methyl]imidazole.

10 Thionyl chloride (7.2 mL, 98 mmol) is slowly dripped into a solution of 8.45 g (20.0 mmol) of the compound of Example 79 in a minimum of chloroform. The mixture is stirred for 2 h at ambient temperature and the solvent is removed in vacuo. The chloride is dissolved in DMSO and is 15 added to a solution of 5.80 g (118 mmol) of sodium cyanide in 400 mL of DMSO. The solution is stirred overnight under nitrogen at ambient temperature; water is added and the aqueous layer is extracted with ethyl acetate. The extracts are combined, are dried (MgSO $_4$), and are concentrated <u>in vacuo</u> 20 to give the crude product. Purification by silica gel chromatography (Waters Prep-500A) provides the pure 4cyanomethyl derivative.

Step 2: Preparation of 2-butyl-4-carboxymethyl-5-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-methyllimidazole.

A solution of 6.5 g (15 mmol) of the 4-cyanomethyl derivative from step 1 in 150 mL of concentrated hydrochloric acid/acetic acid (1:1) is stirred at reflux overnight. The solvents are removed in vacuo to give the crude product.

Purification by reverse phase chromatography provides (Waters Deltaprep-3000) the pure 4-acetic acid derivative.

Step 3: Preparation of 2-butyl-5-chloro-4-methoxycarbonyl-methyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-methyl]imidazole.

A solution of 4.5 g (10 mmol) of the 4-acetic acid derivative from step 2 in 150 mL of absolute methanol is cooled to -10°C and is treated with 1.5 mL (20 mmol) of thionyl chloride under nitrogen. The reaction is allowd to warm to ambient temperature and is stirred at reflux overnight. The methanol is removed in vacuo and the crude product is dissolved in water. The pH is adjusted to pH 4 with 1N NaOH and the solution is extracted with ethyl acetate. The extracts are combined, are dried (MgSO₄), and are concentrated in vacuo to give the crude product. Purification by silica gel chromatography (Waters Prep-500A) provides the pure 4-methyl acetate derivative.

Step 4: Preparation of 2-butyl-5-chloro-4-hydrazinylcarbonyl-methyl-1-[(2'-(1H-tetrazole-5-yl)biphenyl-4-methyl]imidazole.

Under nitrogen, 2.32 g (5.0 mmol) of the 4-methyl acetate derivative from step 3 is dissolved in 50 mL of methanol and is treated with 5 mL (160 mmol) of anhydrous hydrazine. The reaction is allowed to stir at reflux

WO 92/02257 PCT/US91/05476

165

overnihgt; concentration <u>in vacuo</u> gives the crude material. Purification by silica gel chromatography (Waters Prep-500A) provides the pure 4-acetic acid hydrazide derivative.

5 Step 5: Preparation of N-acetyl-L-glutamic acid, 5-[2-butyl-5-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yllmethyll-1H-imidazol-4-yllacetylhydrazide

To a solution of 1.70 g (5.6 mmol) of N-Boc-Lglutamic acid- α -tertbutyl ester (BACHEM) in 50 mL of methylene 10 chloride under nitrogen is added 580 mg (2.8 mmol) of solid dicylcohexylcarbodiimide (DCC). The reaction is allowed to stir for 2 h and is filtered under nitrogen. The anhydride solution is then added to a solution of 1.01 g (2.4 mmol) of the hydrazide from step 4 in 75 mL of methylene chloride under 15 nitrogen. The reaction is stirred overnight, is concentrated to a volume of 25 mL, is cooled to 0°C , and is treated with 25 mL of TFA under nitrogen. The stirred reaction is allowed to warm to ambient temperature overnight and is concentrated in 20 vacuo. The crude product is dissolved in 100 mL of acetonitrile/water (1:1) and the pH is adjusted to 8 with 1 ${\tt M}$ K_2CO_3 . The solution is cooled to 0°C and 0.23 mL (2.4 mmol) of acetic anhydride and 2.4 mL (2.4 mmol) of 1 M K_2CO_3 is added every 30 min for 5 h; the pH is mainained at 9 and the 25 reaction temperature is kept below 5°C. After the last addition, the reaction is allowed to warm to ambient temperature overnight. The pH is adjusted to 4 with 3 M HCl and the reaction is concentrated to 100 mL. Purification by reverse phase chromatography (Waters Deltaprep-3000) gives the 30 pure product.

TABLE VII

Ex. #	‡ R ¹	R ²	A	L	В	E	Р
713	Cl	Х	single bond	-NH-	 Н	Н	сосн3
714	Cl	Х	single bond	-NH-	Н	Н	COCH 2Cl
715	Cl	х	single bond	-NH-	Н	Н	COC 4H9
716	Cl	Х	single bond	-NH-	Н	СНЗ	COCH 3
717	Cl	X	single bond	-NH-	Н	С ₂ Н ₅	COCH 3
718	Cl ·	X	single bond	-NH-	Н	Н	Н
719	Cl	Х	single bond	-NH-	H	СНЗ	H
720	Cl	Х	single bond	-NH-	Н	C ₂ H ₅	Н

Ex.	# R1	R ²	A	L	В	E	P
721	Cl	Х	single bond	-NHCH2CH2	- н	Н	СОСН 3
722	Cl	Х	single bond	-NHCH2CH2	- Н	Н	COCH 2Cl
723	Cl	х	single bond	-NHCH2CH2-	- Н	Н	COC 4H9
724	Cl	Х	single bond	-NHCH2CH2-	- Н	СНЗ	СОСНЗ
725	Cl	Х	single bond	-NHCH2CH2-	Н	С2Н5	COCH3
726	Cl	х	single bond	-NHCH2CH2-	Н	Н	Н
727	Cl	Х	single bond	-NHCH2CH2-	Н	СНЗ	Н
728	Cl	Х	single bond	-NHCH2CH2-	Н	C ₂ H ₅	H
729	Cl	Х	single bond	-N_N-	*	Н	COCH3
730	Cl	Х	single bond	-N_N-	Н	H	COCH2C1

Ex. #	R1	R ²	A	L	в Е	P	
731	Cl	X	single bond	-NN-	н н	COC 4H9	
732	Cl	Х	single bond	-NN-	н СНЗ	COCH3	
733	Cl	X	single bond	-N_N-	н С2Н5	COCH3	
734	Cl	х	single bond	-N_N-	* Н	Н	
735	Cl	X	single bond	-NN-	н сн ₃	Н	
736	Cl	Х	single bond	-N_N-	н С2Н5	Н	
737	Cl	Х	CH ₂	-NH-	н н	COCH 2Cl	-
738	Cl	X	CH ₂	-NH-	н н	COC 4H9	

Ex.	# R1	R ²	A	L	В	E	P
739	Cl	х	CH ₂	-NH-	Н	СН3	сосн3
740	Cl	х	CH ₂	-NH-	Н	С ₂ Н ₅	COCH ₃
741	Cl	X	CH ₂	-NH-	H	Н	Н
742	Cl	Х	CH ₂	-NH-	Н	СНЗ	Н
743	Cl	х	CH ₂	-NH-	Н	С ₂ Н ₅	Н
744	Cl	Х	CH ₂	-NHCH2CH2-	Н	Н	сосн3
745	Cl	X	CH ₂	-NHCH2CH2-	Н	Н	COCH ₂ Cl
746	Cl	Х	CH ₂	-NHCH2CH2-	Н	Н	COC 4H9
747	Cl	Х	CH ₂	-NHCH2CH2-	Н	СНЗ	COCH3
748	Cl	Х	CH2	-NHCH2CH2-	Н	С ₂ Н ₅	сосн3
749	Cl	X	CH ₂	-NHCH2CH2-	н г	H	Н

Ex. #	ŧ R ¹	R ²	A	L	в Е	P
750	Cl	X	CH ₂	-NHCH2CH2-	н снз	Н
751	Cl		CH ₂	-NHCH2CH2-	н С2Н5	Н
752	Cl	х	CH ₂	-N_N-	* H	COCH3
753	Cl	х	CH ₂	-N_N-	н н	COCH2Cl
754	Cl	X	CH ₂	-N_N-	н н	COC 4H9
755	Cl	х	CH ₂	-NN-	н СН3	COCH3
756	Cl	X	CH ₂	-NN-	н С ₂ н ₅	COCH3
757	Cl	Х	CH ₂	-N_N-	* H	Н

Ex.	# R ¹	R ²	A	L	В	E	P
758	Cl	x	CH ₂	-NN-	F	H CH3	Н
759	Cl	Х	CH ₂	-N_N-	Н	С ₂ Н ₅	Н
760	Cl	Х	CH ₂ CH ₂	-NH-	Н	Н	COCH3
761	Cl	х	CH ₂ CH ₂	- NH-	Н	Н	COCH2C1
762	Cl	Х	CH ₂ CH ₂	-NH-	Н	Н	COC 4H9
763	Cl	Х	CH ₂ CH ₂	-NH-	Н	СНЗ	COCH3
764	Cl	Х	CH ₂ CH ₂	-NH-	Н	С2Н5	COCH3
765	Cl	Х	CH ₂ CH ₂	-NH-	Н	Н	Н
766	Cl	х	CH ₂ CH ₂	-NH-	Н	СНЗ	Н
767	Cl	Х	CH ₂ CH ₂	-NH-	Н	С ₂ Н ₅	Н
768	Cl	X	CH ₂ CH ₂	-NHCH2CH2-	Н	- H	COCH3

Ex.	# R1	R ²	A	L	В	E	Р
769	Cl	X	CH ₂ CH ₂	-NHCH2CH2-	Н	Н	COCH ₂ Cl
770	Cl	X	CH ₂ CH ₂	-NHCH2CH2-	Н	Н	COC 4H9
771	Cl	Х	CH ₂ CH ₂	-NHCH2CH2-	H	СНЗ	COCH3
772	Cl	X	CH ₂ CH ₂	-NHCH2CH2-	Н	C ₂ H ₅	COCH ₃
773	Cl	X	CH ₂ CH ₂	-NHCH2CH2-	Н	Н	Н
774	Cl	X	CH ₂ CH ₂	-NHCH2CH2-	Н	СНЗ	Н
775	Cl	X	CH ₂ CH ₂	-NHCH2CH2-	Н	С ₂ Н ₅	Н
776	Cl	X	CH ₂ CH ₂	-N_N-	*	H .	COCH3
· 777	Cl	х	CH ₂ CH ₂	-N_N-	Н	Н	COCH2Cl
778	Cl	X	CH ₂ CH ₂	-NN-	Н	Н	COC 4H9

Ex.	# R ¹	R ²	A	L	в Е	P
779	Cl	Х	CH ₂ CH ₂	-NN-	н СН3	COCH3
780	Cl	Х	CH ₂ CH ₂	-NN-	н С ₂ н ₅	сосн3
781	Cl	X	CH ₂ CH ₂	-NN-	* H	Н
782	Cl	х	CH ₂ CH ₂	-N_N-	н снз	Н
783	Cl	X	CH ₂ CH ₂	-N_N-	н С ₂ н ₅	Н
784	Cl	Х	C3H6 (n)	-NH-	н н	COCH3
785	Cl	Х	C3H6 (n)	-NH-	н н	COCH2C1
786	Cl	Х	C3H6 (n)	-NH-	н н	COC 4H9

Ex. #	# R1	R ²	A	L	В	Е	P
787	Cl	х	C3H6 (n)	-NH-	Н	CH3	соснз
788	Cl	Х	C3H6 (n)	-NH-	Н	С2Н5	COCH ₃
789	Cl	Х	C3H6 (n)	-NH-	Ħ	Н	Н
790	Cl	X	C3H6 (n)	-NH-	Н	CH ₃	Н
791	Cl	X	C 3H6 (n)	-NH-	Н	С2Н5	Н
792	Cl	Х	C3H6 (n)	-NHCH2CH2-	Н	Н	COCH3
793	Cl	Х	C3H6 (n)	-NHCH2CH2-	H	Н	COCH ₂ Cl
794	Cl	Х	C3H6 (n)	-инсн2сн2-	Н	Н	COC 4H9
795	Cl	Х	C3H6 (n)	-NHCH2CH2-	Н	СНЗ	СОСН3
796	Cl	Х	C 3H6 (n)	-NHCH2CH2-	Н	C ₂ H ₅	сосн3
797	Cl	х	C3H6 (n)	-NHCH2CH2-	Н	H	Н

Ex	k. # R1	R ²	A	L	В	E	P
79	8 Cl	X	C3H6 (n)	-NHCH2CH2-	- н	СНЗ	Н
799	9 Cl	х	C 3H6 (n)	-NHCH2CH2-	- н	С2Н5	Н
800) C1	х	C3H6 (n)	-NN-	*	Н	СОСН3
801	. Cl	Х	C3H6 (n)	-NN-	Н	Н	COCH2C1
802	Cl	х	C3H6 (n)	-NN-	Н	H	COC 4H9
803	Cl	X	C 3H6 (n)	-NN-	Н (СНЗ	COCH3
804	Cl	х	C3H6 (n)	-NN-	Н (С ₂ н ₅	COCH3
805	Cl	Х	С 3Н6 (п)	-NN-	* F	Ŧ	Н

Ex. #	ŧ R1	R ²	A	L	в Е	P
806	Cl	х	C3H6 (n)	-NN-	н снз	H
807	Cl	Х	C3H6 (n)	-NN-	н С ₂ н ₅	H
808	Cl	X.	C4H8 (n)	- NH-	н н	сосн3
809	Cl	х	C4H8 (n)	-NH-	н н	COCH2Cl
810	Cl	Х	C4H8 (n)	-NH-	н н	COC 4H9
811	Cl	X	C4H8 (n)	-NH-	н СН3	COCH3
812	Cl	X	C4H8 (n)	-NH-	н С ₂ н ₅	COCH ₃
813	Cl	X ·	C4H8 (n)	-NH-	н н	Н
814	Cl -	X	C4H8 (n)	-NH-	н СН3	Н
815	Cl	х	C4H8 (n)		н С2Н5	Н
816	Cl	х	C4H8 (n)	-NHCH2CH2-	н н	COCH3

Ex.	# R ¹	R ²	A	L	В	E	P
817	Cl	Х	C4H8 (n)	-NHCH2CH2-	Н	Н	COCH2Cl
818	Cl	Х	C4H8 (n)	-NHCH2CH2-	Н	Н	COC 4H9
819	Cl	х	C4H8 (n)	-NHCH2CH2-	Н	СН3	COCH3
820	Cl	Х	C4H8 (n)	-NHCH2CH2-	Н	С ₂ Н ₅	сосн3
821	Cl	Х	C 4H8 (n)	-NHCH2CH2-	Н	Н	Н
822	Cl	Х	C4H8 (n)	-NHCH2CH2-	Н	CH ₃	Н
823	Cl	Х	C4H8 (n)	-NHCH2CH2-	Н	C ₂ H ₅	H
824	Cl	X	C4H8 (n)	-N_N-	*	н	COCH3
825	Cl	X	C4H8 (n)	-NN-	H 1	Н	COCH2Cl

Ex. #	# R ¹	R ²	A	L	в Е	P
826	Cl	х	C4H8 (n)	-N_N-	н н	COC 4H9
827	Cl	х	C4H8 (n)	-N N-	н снз	COCH 3
828	Cl	х	C4H8 (n)	-N N-	н С ₂ н ₅	COCH ₃
829	Cl	X	C4H8 (n)	-NN-	* H	H
830	Cl	х	C4H8 (n)	-N N-	н снз	Н
831	Cl	X	C4H8 (n)	-N_N-	н С ₂ н ₅	Н
832	Cl	Х	-	-NH-	н н	COCH3

Ex.	# R1	R ²	A	L	в Е	P	
833	Cl	х	─	-NH-	н н	COCH2Cl	•
834	Cl	Х	_	-NH-	н н	COC 4H9	
835	Cl	х	─	-NH-	н Снз	COCH 3	
836	Cl	Х		-NH-	н С ₂ н ₅	сосн3	
837	Cl	х	_	-NH-	н н	Н	
838	Cl	Х	-	-NH-	н сн ₃	Н	
839	Cl	Х	-	-NH-	н С ₂ н ₅	Н	

Ex. #	R1	R ²	A	L	В	E	Р
840	Cl	Х	——————————————————————————————————————	-NHCH2CH2-	Н	Н	COCH3
841	Cl	X		-NHCH2CH2-	Н	Н	COCH2Cl
842	Cl	х		-NHCH2CH2-	Н	Н	COC 4H9
843	Cl	X	~ <u></u>	-NHCH2CH2-	Н	СН3	COCH 3
844	Cl	X	─	-NHCH2CH2-	Н	С ₂ Н ₅	COCH3
845	Cl	Х	~ <u></u>	-NHCH2CH2-	Н	Н	н
846	Cl	Х		-NHCH2CH2-	Н	СНЗ	Н

Ex.	# R1	R ²	A	L	в Е	P
847	Cl	Х		-NHCH2CH2-	· н С ₂ н ₅	Н
848	Cl	X	—	-NN-	* H	сосн3
849	Cl	х	~ <u></u>	-N_N-	н н	COCH ₂ Cl
850	Cl	х	~ <u></u>	-N_N-	н н	COC 4H9
851	Cl	х		-NN-	н СНЗ	COCH 3
852	Cl	Х	—	-NN-	н С ₂ н ₅	COCH ₃
853	Cl	х	—	-NN-	* Н	Н

Ex. #	† R ¹	R ²	A	L	в Е	P
854	Cl	X	←	-NN-	н СН3	Н
855	Cl	Х	—	-N_N-	н С2Н5	Н
856	Cl	х	-CH _Z	-NH-	н н	COCH3
857	Cl	х	$-CH_{\overline{Z}}$	-NH-	н н	COCH ₂ Cl
858	Cl	Х	-CH ₂	-NH-	н н	COC 4H9
859	Cl	X	-CH ₂	- NH-	н СН3	COCH 3
. 860	Cl	х	-CH2	-NH-	н С2Н5	COCH3
861	Cl	х	-CH ₂	-NH-	н н	Н

Ex. # R¹ R² A L B E P Cl $X - CH_2$ 862 -NH- н СН3 н 863 -NH- H C₂H₅ H Cl Cl 864 -NHCH2CH2- H H COCH3 Cl X 865 -NHCH2CH2- H H COCH2Cl 866 Cl - -NHCH2CH2- H H COC4H9 - -NHCH2CH2- H CH3 COCH3 867 Cl X Cl $X - CH_2$ 868

- -NHCH $_2$ CH $_2$ - H C $_2$ H $_5$ COCH $_3$

Ex	ĸ. #	R ¹	R ²	A	L	В	E	P
86	9	Cl	Х	-CH ₂	-NHCH2CH2-	Н	Н	Н
87	0	Cl	Х	-CH ₂	-NHCH2CH2-	Н	CH ₃	Н
87	1	Cl	х	-CH ₂	-NHCH2CH2-	Н	С ₂ н ₅	H
87	2	Cl	X	-CH ₂ -	-N N-	*	Н	COCH3
87	3	Cl	X	-CH ₂	-N N-	H	Н	COCH ₂ Cl
87	4	Cl	X	-СН2	-N_N-	Н	Н	COC 4H9
. 87	5	Cl	Х	-CH ₂	-N_N-	Н	СН3	COCH 3

Ex.	# R1	R ²	A	L	в Е	P
876	Cl	Х	-CH ₂ ————————————————————————————————————	-N_N-	н С ₂ Н5	COCH3
877	Cl	Х	-CH ₂	-N_N-	* H	Н
878	Cl	x	-CH ₂	-NN-	н сн ₃	Н
879	Cl	Х	-CH ₂	-NN-	н С ₂ н ₅	Н
880	Cl	Х	—СH ₂ CH ₂ —	>− -NH-	н н	COCH3
881	Cl	Х	—CH ₂ CH ₂ —	>− -NH-	н н	COCH2Cl
882	Cl	Х	—СH ₂ CH ₂ —	≻ −NH	н н	COC 4H9
883	Cl	Х	—СH ₂ CH ₂ —	— −NH−	н снз	COCH 3

Ex. # R ¹	R ²	A	L	ВЕ	P	

884 Cl X
$$-\text{CH}_2\text{CH}_2$$
 -NH- H C₂H₅ COCH₃

885 Cl X
$$-CH_2CH_2$$
 -NH- H H

887 Cl X —
$$CH_2CH_2$$
 — NH — H C_2H_5 H

Ex.# R1	R ²	Α	L E	3 E	P
888 Cl	Х	—СH ₂ CH ₂ —	— −NHCH2CH2− F	ł H	СОСН3
889 Cl	х	—СН ₂ СН ₂ —	NHCH2CH2- H	I Н	COCH ₂ Cl
890 Cl	X	—СН ₂ СН ₂ —	- -NHCH2CH2- Н	Н	COC 4H9
891 Cl	х	-CH ₂ CH ₂	NHCH ₂ CH ₂ - н	СНЗ	COCH 3
892 Cl	Х	—CH ₂ CH ₂ ————————————————————————————————————	-NHCH2CH2- H	С ₂ н ₅	COCH ₃
893 Cl	х	—CH ₂ CH ₂ —	-NHCH2CH2- H	Н	Н
894 Cl	х	—CH ₂ CH ₂ ————————————————————————————————————	-NHCH ₂ CH ₂ - H	СНЗ	Н
895 Cl	X	—CH ₂ CH ₂ —	-NHCH ₂ CH ₂ - H	С ₂ Н ₅	Н

Ex.# R ¹	R ²	A	L	В	E	P
896 Cl	x	—CH ₂ CH ₂ —	-N N-	*	Н	COCH 3
897 Cl	х	-CH ₂ CH ₂	-N N-	Н	н	COCH ₂ Cl
898 Cl	Х	—CH ₂ CH ₂ ————————————————————————————————————	-N_N-	Н	H	COC 4H9
899 Cl	х	—CH ₂ CH ₂ ————————————————————————————————————	-N_N-	Н	CH3	COCH 3
900 Cl	x	—CH ₂ CH ₂ —	-NN-	H	С ₂ Н ₅	COCH 3
901 Cl	Х	—CH ₂ CH ₂ —	-N N-	*	H	Н
902 Cl	Х	-CH ₂ CH ₂	-NN-	Н	CH ₃	Н
903 Cl	Х	—СH ₂ CH ₂ —	-NN-	Н	С ₂ Н ₅ _	Н

Ex.# R ¹	R ²	A	L	в Е	Р
904 Cl	х	-{CH ₂ -	- NH-	н н	COCH3
905 Cl	х	-CH ₂ -	-NH-	н н	COCH2Cl
906 Cl	Х	-CH ₂ -	-NH-	н н	COC 4H9
907 Cl	х	-CH ₂ -	-NH-	н снз	сосн3
908 Cl	X	-CH ₂ -	-NH-	н С2Н5	COCH3
909 Cl	Х	-CH ₂ -	-NH-	н н	Н
910 Cl	Х	-CH ₂ -	-NH-	н снз	Н
911 Cl	Х	-CH ₂ -	-NH-	н С2Н5	Н

Ex.# R ¹	R ²	A	L	В	Е	Р
912 Cl	х	- ⟨ _}CH ₂ -	-NHCH2CH2-	Н	Н	COCH3
913 Cl	Х	-CH ₂ -	-NHCH2CH2-	Н	Н	COCH2Cl
914 Cl	X	-CH ₂ -	-NHCH2CH2-	Н	Н	COC 4H9
915 Cl	Х	-CH ₂ -	-NHCH2CH2-	Н	CH3	сосн3
916 Cl	X	-CH ₂ -	-NHCH2CH2-	Н	С2Н5	COCH ₃
917 Cl	Х	-CH ₂ -	-NHCH2CH2-	Н	Н	Н
918 Cl	X	-CH ₂ -	-NHCH2CH2-	Н	CH ₃	Н
919 Cl	X	-CH ₂ -	-NHCH2CH2-	Н	С ₂ Н ₅	Ħ

Ex.# R1	R ²	A	L	в Е	P
920 Cl	х	-{CH ₂	-NN-	* Н	COCH3
921 Cl	Х	-CH2-	-NN-	н н	COCH2Cl
922 Cl	Х	- € CH ₂ -	-NN-	н н	COC 4H9
923 Cl	x	-CH ₂ -	-NN-	н СНЗ	COCH3
924 Cl	Х	-CH ₂ -	-N_N-	н С ₂ Н5	COCH ₃
925 Cl	Х	-CH2-	-NN-	* H	Н
926 Cl	X	-CH2-	-NN-	н снз	Н

Ex.# R1	R ²	A	L	В	E	P
927 Cl		-CH ₂ -				
928 Cl	X	-CH2-CH2-	-NH-	Н	Н	COCH3
929 Cl	Х	-CH2-CH2-	-NH-	Н	Н	COCH2Cl
930 Cl	х	-CH2-CH2-	-NH-	Н	Н	COC 4H9
931 Cl	х	-CH2-CH2-	NH-	Н	СНЗ	COCH3
932 Cl	Х	-CH2-CH2-	NH-	Н	С ₂ Н ₅	COCH3
933 Cl	Х	-CH ₂ -CH ₂ -	NH-	Н	Н	Н
934 Cl	Х	-CH2-CH2-	-NH-	Н	CH ₃	Н

Ex.# R ¹	R ² A	L	В	E	P
935 Cl	х —СН	₂ —CH ₂ — -NH-	Н	С ₂ Н ₅	Н
936 Cl	х ————сн	₂ —CH ₂ — -NHCH ₂ CH ₂ -	Н	Н	СОСН3
937 Cl	х ————СН;	₂ —CH ₂ — -NHCH ₂ CH ₂ -	Н	Н	COCH ₂ Cl
938 Cl	х ————————————————————————————————————	2 −CH 2− −NHCH2CH2−	Н	Н	COC 4H9
939 Cl	х ————————————————————————————————————	-CH ₂ NHCH ₂ CH ₂ -	Н	CH3	COCH 3
940 Cl	х —СН2	-CH ₂ NHCH ₂ CH ₂ -	Н	С ₂ Н ₅	COCH3
941 Cl	х —СН2	-CH ₂ NHCH ₂ CH ₂ -	Н	Н	Н
942 C1	х —СН2-	-CH ₂ NHCH ₂ CH ₂ -	Н	CH ₃	Н

Ex.# R ¹	R ²	A	L	В	E	P
		CH ₂ CH ₂	NHCH2CH2-	Н	C ₂ H ₅	Н
944 Cl	× -{		-NN-	*	Н	COCH3
945 Cl	х —	CH ₂ -CH ₂ -	-N N-	Н	Н	COCH2Cl
946 Cl	x –		-N_N-	Н	Н	COC 4H9
947 Cl	x –		-N_N-	Н	СН3	COCH3
948 Cl	x –	CH ₂ -CH ₂ -	-NN-	Н	С ₂ Н ₅	COCH ₃
949 Cl	х —	CH2-CH2-	-N N-	*	Н	Н
950 Cl	x	CH ₂ -CH ₂ -	-NN-	Н	СН3	Н

Ex.# R ¹	R	2 A	L	в Е	P
951 Cl	х	-CH ₂ -CH ₂ -	-N_N-	н С ₂ н ₅	Н
952 Cl	X	-CH ₂ -CH ₂ -	-NH-	н н	СОСН3
953 Cl	х	-CH ₂ -CH ₂ -	-NH -	н н	COCH ₂ Cl
954 Cl	х	-CH ₂ -CH ₂ -	-NH-	н н	COC 4H9
955 Cl	х	-CH ₂ -CH ₂ -	- NH-	н Снз	СОСН3
956 Cl	х	-CH ₂ -CH ₂ -	-NH-	н С ₂ Н5	COCH3
957 Cl	х	-CH ₂ -CH ₂ -	-NH-	нн	Н
958 Cl	х	-CH ₂ -CH ₂ -	-NH-	н снз	Н

Ex.# R	1 R ²	A	L	в Е	P
959 Cl	х	-CH ₂ -CH ₂ -	-NH-	н С ₂ Н ₅	Н
960 Cl	х	-CH ₂ -CH ₂ -	-NHCH2CH2-	н н	COCH 3
961 Cl	Х	-CH ₂ -CH ₂ -	-NHCH2CH2-	н н	COCH 2Cl
962 Cl	х	-CH ₂ -CH ₂ -	-NHCH2CH2-	н н	COC 4H9
963 Cl	х	-CH ₂ -CH ₂ -	-NHCH2CH2-	н СН3	COCH 3
964 Cl	х	-CH ₂ -CH ₂ -	-NHCH2CH2-	н С2Н5	COCH 3
965 Cl	Х	-CH ₂ -CH ₂ -	-NHCH 2CH2-	н н	Н
966 Cl	X	-CH ₂ -CH ₂ -	-NHCH2CH2-	H CH3	Н

Ex.# R ¹	R ² A	L	в Е	<u>P</u>
967 Cl	х -CH ₂ -С	H ₂ NHCH ₂ CH ₂ -	н С ₂ н ₅	Н
968 Cl	х -СН ₂ -СН	2NN-	* Н	сосн3
969 Cl	х -СН ₂ -СН ₂	2N N-	н н	COCH ₂ Cl
970 Cl	х -CH ₂ -СН ₂	2N_N-	н н	COC 4H9
971 Cl	х -CH ₂ СН ₂	NN-	н СНЗ	сосн3
972 Cl	х -CH ₂ -СН ₂	N N-	н С2Н5	сосн3
973 Cl	х -CH ₂ -СН ₂ -	N N-	* H	Н

Ex.# R ¹	R ²	A	L	в Е	P
974 Cl	х -С	CH ₂ -CH ₂ -	-N N-	н снз	Н
975 Cl	х -С	CH ₂ -CH ₂ -	-NN-	н С ₂ Н5	H
976 Cl	x		-NH-	н н	COCH3
977 Cl	х		-NH-	н н	COCH ₂ Cl
978 Cl	х	\bowtie	-NH-	н н	COC 4H9
979 Cl	х	\bowtie	-NH-	н СН3	COCH3
980 Cl	x		-NH-	н С ₂ н ₅	COCH ₃
981 Cl	Х	\bowtie	-NH-	н н	Н
982 Cl	x	\bowtie	-NH-	н снз	Н

Ex.# R ¹	R ²	A	L	в Е	P
983 Cl	х		-NH-	н С ₂ Н5	Н
984 Cl	x		-NHCH2CH2-	н н	СОСН3
985 Cl	х		-NHCH2CH2-	н н	COCH ₂ Cl
986 Cl	х		-NHCH2CH2-	н н	COC 4H9
987 Cl	x		-NHCH2CH2-	н СН3	сосн3
988 Cl	x		-NHCH2CH2-	н С2Н5	соснз
989 Cl	х	\bowtie	-NHCH2CH2-	н н	Н
990 Cl	х	\bowtie	-NHCH2CH2-	н снз	Н

Ex.# R ¹	R ²	A	L	в Е	Р
991 Cl	Х	\bowtie	-NHCH2CH2-	н С2Н5	Н
992 Cl	х		-NN-	* Н	COCH 3
993 Cl	Х		-NN-	н н	COCH ₂ Cl
994 Cl	Х		-N N-	н н	COC 4H9
995 Cl	х	\bowtie	-N N-	н снз	COCH3
996 Cl	x		-N N-	н С ₂ Н5	COCH3
997 Cl	х		-NN-	* Н	Н
998 Cl	х		-NN-	н Снз	H

Ex.# R ¹	l R ²	A	L	в Е	P	
999 Cl	Х	\bowtie	-NN-	н С ₂ н ₅	Н	
1000	Cl		X	-CH ₂	→ -NH-	
1001	Cl		х	-CH ₂	✓ -NH-	
1002 Cl	х -с	CH ₂	-NH-	н н	COC 4H9	
1003 Cl	х -с	CH ₂	-NH-	н СНЗ	COCH3	
1004 Cl	x -c	H ₂	-NH-	н С ₂ Н ₅	COCH3	
1005 Cl	x -c	H ₂	- NH-	н н	н	
1006 Cl	X -CF	Hz	-NH-	н снз	H	

Ex.# R ¹	R ²	A	L	В	E	P
1007 Cl	X	-CH ₂	-NH-	Н	С ₂ Н ₅	Н
1008 Cl	X	-CH ₂	-NHCH2CH2-	Н	Н	COCH3
1009 Cl	Х	-CH ₂	-NHCH2CH2-	Н	Н	COCH2Cl
1010 Cl	х	-CH ₂	-NHCH2CH2-	Н	Н	COC 4H9
1011 Cl	х	-CH ₂	-NHCH2CH2-	H	СН3	COCH3
1012 C1	X	-CH ₂	-NHCH2CH2-	Н	С2Н5	сосн3
1013 Cl	Х	-CH ₂	-NHCH2CH2-	Н	Н	Н
1014 Cl	Х	-CH ₂	-NHCH2CH2-	Н	СНЗ	Н

Ex.# R ¹	l R	2 A	L	в Е	P
1015 Cl	х	-CH ₂	-NHCH2CH2	?- н С ₂ н ₅	Н
1016 Cl	Х	-CH ₂	-N N-	* Н	сосн3
1017 Cl	Х	-CH ₂	-N_N-	н н	COCH ₂ Cl
1018 Cl	Х	-CH ₂	-N_N-	н н	COC 4H9
1019 Cl	Х	-CH ₂	-NN-	н СН3	COCH3
1020 Cl	x	-CH ₂	-NN-	н С2Н5	сосн3
1021 Cl	Х	-CH of	-NN-	* H	Н
1022 Cl	х	-CH ₂	-NN-	н сн ₃	Н

Ex.# R ¹	R ² A	L	в Е	Р
1023 Cl	X -CH ₂	-NN-	н С2Н5	Н
1024 Cl	X -CH ₂ CH ₂	-NH-	н н	COCH3
1025 Cl	X -CH ₂ CH ₂	-NH-	н н	COCH ₂ Cl
1026 Cl	X -CH ₂ CH ₂	- NH-	н н	COC 4H9
1027 Cl	X -CH ₂ CH ₂	- NH-	н СН3	COCH3
1028 Cl	X -CH ₂ CH ₂	-NH-	н С ₂ Н5	COCH3
1029 Cl	X -CH ₂ CH ₂	−NH −	н н	Н
1030 Cl	X -CH ₂ CH ₂	-NH-	н снз	Н

Ex.# R1	R ²	A	L	в Е	Р
1031 Cl	Х	-CH ₂ CH ₂	- -NH-	н С2Н5	Н
1032 Cl	х	-CH ₂ CH ₂	- -NHCH2CH2-	н н	СОСНЗ
1033 Cl	х	-CH ₂ CH ₂	-NHCH2CH2-	н н	COCH ₂ Cl
1034 Cl	x	-CH ₂ CH ₂	-NHCH2CH2-	н н	COC 4H9
1035 Cl	Х	-CH ₂ CH ₂	-NHCH2CH2-	н снз	COCH3
1036 Cl	x	-CH ₂ CH ₂	-NHCH2CH2-	н С2Н5	сосн3
1037 Cl	х	-CH ₂ CH ₂	-NHCH2CH2-	н н	Н
1038 Cl	Х	-CH ₂ CH ₂	-NHCH2CH2-	н снз	Н
1039 Cl	X	-CH ₂ CH ₂	-NHCH2CH2-	н С ₂ н ₅	Н

Ex.# R ¹	R ²	A	L	в Е	P
1040 Cl	х	-CH ₂ CH ₂	-N_N-	* Н	COCH3
1041 Cl	Х	-CH ₂ CH ₂	-NN-	н н	COCH2Cl
1042 Cl	Х	-CH ₂ CH ₂	-N_N-	н н	COC 4H9
1043 Cl	Х	-CH ₂ CH ₂	-NN-	н СНЗ	COCH 3
1044 Cl	х	-CH ₂ CH ₂	-NN-	н С ₂ н ₅	COCH3
1045 Cl	Х	-CH ₂ CH ₂	-NN-	* H	Н
1046 Cl	х	-CH ₂ CH ₂	-NN-	н СН3	Н
1047 Cl	х	-CH ₂ CH ₂	-NN-	н С ₂ Н5	Н

Ex.# R1	R ²	A	L	в е	P
1048 Cl	Х	∠ CH₂-	-NH-	н н	COCH3
1049 Cl	х	CH ₂ -	-NH-	н н	COCH2C1
1050 Cl	Х	CH ₂ -	-NH-	н н	COC 4H9
1051 Cl	x	CH ₂ -	-NH-	н снз	COCH 3
1052 Cl	X	CH ₂ -	-NH-	н С2Н5	сосн3
1053 Cl	Х	CH ₂ -	-NH-	н н	Н
1054 Cl	x L	CH ₂ -	-NH-	н снз	Н
1055 Cl	x _	✓ CH ₂ -	-NH-	н С ₂ н ₅	Н

Ex.# R ¹	R ² A	L 1	в Е	P
1056 Cl	хСH ₂ -	-NHCH2CH2-	н н	COCH3
1057 Cl.	xCH ₂ -	-NH-	н н	COCH ₂ Cl
1058 Cl	XCH ₂ -	-NH-	н н	COC 4H9
1059 Cl	XCH ₂ -	- NH-	н СНЗ	COCH 3
1060 Cl	XCH ₂ -	-NH-	н С ₂ Н ₅	COCH ₃
1061 Cl	X CH ₂ -	-NHCH2CH2-	н н	Н
1062 Cl	XCH ₂ -	-NHCH2CH2-	н снз	Н
1063 Cl	XCH ₂ -	-NHCH2CH2-	н С ₂ н ₅	Н
1064 Cl	XCH ₂ -	-NN-	* Н	COCH3

Ex.# R ¹	R ² A	L	в е	P
1065 Cl	X CH	2 ⁻ -N N-	н н	COCH2C1
1066 Cl	XCH ₂	-N_N-	н н	COC 4H9
1067 Cl	X CH ₂	NN-	н снз	COCH 3
1068 Cl	XCH ₂ -	-NN-	С ₂ Н5	COC:
1069 Cl	X CH ₂ -	-N_N-	* H	Н
1070 Cl	XCH ₂ -	-NN-	н СН3	Н
1071 Cl	XCH ₂ -	-NN-	н С ₂ Н5	Н
1072 Cl	X CH ₂ Ci	H ₂ - <u>-</u> NH-	н н	COCH3

Ex.# R ¹	R ² A	L	в Е	P
1073 Cl	X	H ₂ - _{–NH} –	н н	COCH ₂ Cl
1074 Cl	X CH ₂ C	H ₂ - _{–NH} –	н н	COC 4H9
1075 Cl	X CH ₂ C	H ₂ NH-	н СН3	COCH 3
1076 Cl	X CH ₂ CI	H ₂ - _{-NH} -	н С ₂ Н ₅	сосн3
1077 Cl	X CH ₂ CH	H ₂ - _{NH} -	н н	Н
1078 Cl	X CH ₂ CI	H ₂ - _{-NH} -	н снз	Н
1079 Cl	X CH ₂ CH	H ₂ - –NH–	н С2Н5	Н
1080 Cl	X CH ₂ Cl	H ₂ NHCH2CH2-	н н	COCH 3
1081 Cl	X CH ₂ CH	H ₂ NHCH2CH2-	н н	COCH ₂ Cl

Ex.# R ¹	R ²	A	L	в Е	P
1082 Cl	× 4	CH₂CH₂·	- NHCH2CH2-	н н	COC 4H9
1083 Cl	× _	CH ₂ CH ₂ -	-NHCH2CH2-	н снз	COCH 3
1084 Cl	× ∠	CH ₂ CH ₂ -	-NHCH2CH2-	н С ₂ Н5	COCH3
1085 Cl	× ∠	CH ₂ CH ₂ -	-NHCH2CH2-	н н	Н
1086 Cl	× _L	CH ₂ CH ₂ -	-NHCH2 CH2 -	н снз	Н
1087 Cl	× L	CH ₂ CH ₂ -	-NHCH2CH2-	н С ₂ н ₅	Н
1088 Cl	× L	CH ₂ CH ₂ -	-NN-	* H	COCH3
1089 Cl	× ∠	CH ₂ CH ₂ -	.NN-	н н	COCH ₂ Cl

Ex.# R ¹	R ²	A	L	в Е	P
		CH ₂ CH ₂ -			
1091 Cl	×	CH ₂ CH ₂ -	-N N-	н СН3	COCH 3
1092 Cl	× _	CH ₂ CH ₂ -	-N N-	н С ₂ Н5	COCH3
1093 Cl	x	CH ₂ CH ₂ -	-N N-	* Н	Н
1094 Cl	× L	CH ₂ CH ₂ -	-N N-	н снз	H
1095 Cl	× _L	CH ₂ CH ₂ -	-NN-	н С ₂ н ₅	Н
1096 Cl	X -CH	CH ₂ -	NH	н н	COCH3
1097 C1	X -CH	CH ₂ -	-NH-	н н	COCH2Cl

Ex.# R ¹	R ²	A	L	в Е	P
1098 Cl	X -CH _ź	CH ₂	2 ⁻ -NH-	н н	COC 4H9
1099 Cl	^Х -СН ₂	CH ₂	 -NH-	н Снз	COCH 3
1100 Cl	Х -СН ₂ -	CH ₂	- -NH-	н С ₂ н ₅	COCH3
1101 Cl	X -CH₂¯	CH ₂ -	-NH-	н н	Н
1102 Cl	X -CH₂~	CH ₂ -	-NH-	н снз	Н
1103 Cl	Х -СН ₂	CH₂-	-NH-	н С ₂ н ₅	Н
1104 Cl	X -CH ₂ -4	CH ₂ -	NHCH2CH?-	н н	СОСН3
1105 Cl	X -CH ₂	CH ₂	NHCH2CH2-	н н	COCH ₂ Cl

Ex.# R ¹	R ² A	L	в Е	Р
1106 Cl	X -CH ₂	CH ₂ - -NHCH ₂ CH ₂ -	н н	COC 4H9
1107 Cl	X -CH ₂	CH ₂ - -NHCH2CH2-	н СН3	COCH 3
1108 Cl	X -CH ₂	CH ₂ - -NHCH ₂ CH ₂ -	н С2Н5	сосн3
1109 Cl	X -CH ₂	CH ₂ - -NHCH2CH2-	н н	Н
1110 Cl	X -CH ₂	CH ₂ - -NHCH2CH2-	н снз	Н
1111 Cl	X -CH ₂	CH ₂ - -NHCH ₂ CH ₂ -	н С ₂ н ₅	Н
1112 Cl	X -CH ₂	CH ₂ N N-	* H	сосн3
1113 Cl	X -CH ₂	CH ₂ NN-	н н	COCH ₂ Cl

Ex.# R ¹ R	2 A	L	ВЕ	P
114 Cl X	-CH ₂ CH ₂ ·	NN-	н н	COC 4H9
1115 Cl X	-CH ₂ -CH ₂ -	-NN-	н Снз	COCH 3
1116 Cl X	-CH ₂ -	-NN-	н С ₂ Н5	COCH ₃
1117 Cl X	CH ₂ -CH ₂ -	-NN-	* н	н
1118 Cl X -C	CH ₂ -	N-N-	н снз	Н
1119 Cl X -C	H ₂ CH ₂ -	N_N-	н С ₂ Н ₅	H
1120 X Cl	single bond		н н	COCH 3
1121 X Cl	single bond	-NH-	н н	COCH ₂ Cl
1122 X Cl	single bond	-NH-	н н	COC 4H9

Ex.#	R1	R ²	A	L	В	E	P
							
1123	Х	Cl	single bond	-NH-	Н	CH3	COCH 3
1124	Х	Cl	single bond	-NH-	Н	С ₂ Н ₅	COCH 3
1125	Х	Cl	single bond	-NH-	Н	Н	Н
1126	Х	Cl	single bond	-NH-	Н	CH ₃	Н
1127	х	Cl	single bond	-NH-	Н	С ₂ Н ₅	Н
1128	X	Cl	single bond	-NHCH2CH2-	Н	Н	COCH 3
1129	х	Cl	single bond	-NHCH2CH2-	Н	Н	COCH2Cl
1130	Х	Cl	single bond	-NHCH2CH2-	H	Н	COC 4H9
1131	X	Cl	single bond	-NHCH2CH2-	Н	CH3	COCH3
1132	Х	Cl	single bond	-NHCH2CH2-	Н	С ₂ Н ₅	COCH ₃
1133	х	Cl	single bond	-NHCH2CH2-	Н	Н	Н
1134	Х	Cl	single bond	-NHCH2CH2-	Н	CH ₃	Н

Ex.	# R	1 R ²	A	L	в е	P
1105	,	01				
1133) х	CI	single bond	-NHCH2CH	2- н С ₂ н ₅	H
1136	X	Cl	single bond	-NN-	* Н	COCH3
1137	Х	Cl	single bond	-NN-	н н	COCH2Cl
1138	х	Cl	single bond	-NN-	н н	COC 4H9
1139	х	Cl	single bond	-NN-	н СН3	COCH3
1140	х	Cl	single bond	-NN-	н С2Н5	COCH ₃
1141	X	Cl	single bond	-NN-	* H	Н

Ex.#	R1	R ²	A	L	В	E	P
1142	Х	Cl	single bond	-NN-	Н	СНЗ	Н
1143	Х	Cl	single bond	-N_N-	Н	С ₂ Н ₅	Н
1144	Х	Cl	CH ₂	-NH-	Н	Н	COCH ₂ Cl
1145	х	Cl	CH ₂	-NH-	Н	Н	COC 4H9
1146	х	Cl	CH ₂	-NH-	Н	СНЗ	COCH3
1147	Х	Cl	CH ₂	-NH-	Н	С ₂ Н ₅	COCH ₃
1148	х	Cl	CH ₂	-NH-	Н	Н	Н
1149	х	Cl	CH ₂	-NH-	Н	CH3	Н
1150	Х	Cl	CH ₂	-NH-	Н	С ₂ Н ₅	Н
1151	Х	Cl	CH ₂	-NHCH ₂ CH ₂ -	Н	Н	СОСНЗ
1152	x	Cl	CH ₂	-NHCH2CH2-	Н	Н	COCH2Cl

Ex.# R ¹ R ²	A	L B E	P
1153 X Cl	CH ₂	-NHCH2CH2- H H	COC 4H9
1154 X Cl	CH ₂	-NHCH2CH2- H CH3	COCH3
1155 X Cl	CH ₂	-NHCH2CH2- н С2H5	COCH3
1156 X Cl	CH ₂	-NHCH2CH2- Н Н	Н
1157 X Cl	CH ₂	-NHCH ₂ CH ₂ - H CH ₃	Н
1158 X Cl	CH ₂	-NHCH ₂ CH ₂ - н С ₂ H ₅	Н
1159 X Cl	CH ₂	-N	COCH3
1160 X Cl	CH ₂	-NN- н н	COCH2C1
1161 X Cl	CH 2	-NN- н н	COC 4H9

Ex.#	R ¹	R ²	A	L	в Е	P
1162	х	Cl	CH2	-NN-	н СНЗ	COCH3
1163	х	Cl	CH ₂	-NN-	н С ₂ н ₅	COCH ₃
1164	х	Cl	CH2	-NN-	* Н	Н
1165	х	CI	CH ₂	-N_N-	H CH3	Н
1166	Х	Cl	CH ₂	-N_N-	н С2Н5	Н
1167	x	Cl	CH ₂ CH ₂	-NH-	н н	COCH3
1168	X	Cl	CH ₂ CH ₂	-NH-	н н	COCH ₂ Cl
1169	X	Cl	CH ₂ CH ₂	-NH-	н н	COC 4H9
1170	х	Cl	CH ₂ CH ₂	-NH-	н снз	COCH3

T	<i>u</i> •	1 52					
Ex.	# F	R ¹ R ²	A	L	В	E	P
1171	L X	Cl	CH ₂ CH ₂	-NH-	Н	С2Н5	сосн3
1172	2 X	Cl	CH ₂ CH ₂	-NH-	Н	Н	Н
1173	х	Cl	CH ₂ CH ₂	-NH-	Н	CH ₃	Н
1174	Х	Cl	CH ₂ CH ₂	-NH-	Н	С ₂ Н ₅	Н
1175	X	Cl	CH ₂ CH ₂	-NHCH2CH2-	Н	Н	COCH3
1176	х	Cl	CH ₂ CH ₂	-NHCH2CH2-	Н	Н	COCH ₂ Cl
1177	х	Cl	CH ₂ CH ₂	-NHCH2CH2-	H	Н	COC 4H9
1178	Х	Cl	CH ₂ CH ₂	-NHCH2CH2-	Н	CH 3	COCH 3
1179	X	Cl	CH ₂ CH ₂	-NHCH2CH2-	Н	С ₂ Н ₅	COCH 3
1180	x	Cl	CH ₂ CH ₂	-NHCH2CH2-	Н	Н	Н
1181	x	Cl	CH ₂ CH ₂	-NHCH2CH2-	Н	CH ₃	Н
1182	x	Cl	CH ₂ CH ₂	-NHCH2CH2-	Н	С ₂ Н ₅	Н

Ex.#	R1	R ²	A	L	В	E	P
1183	х	Cl	CH ₂ CH ₂	-N N-	*	Н	COCH 3
1184	Х	Cl	CH ₂ CH ₂	-N_N-	Н	Н	COCH ₂ Cl
1185	х	Cl	CH 2CH2	-NN-	Н	Н	COC 4H9
1186	Х	Cl	CH ₂ CH ₂	-NN-	Н	CH 3	COCH 3
1187	x	Cl	CH ₂ CH ₂	-NN-	Н	C ₂ H ₅	COCH 3
1188	Х	Cl	CH ₂ CH ₂	-NN-	*	Н	Н
1189	X	Cl	CH ₂ CH ₂	-N_N-	H	CH ₃	Н
1190	х	Cl	CH ₂ CH ₂	-NN-	Н	С ₂ Н ₅	Н

WO 92/02257 PCT/US91/05476

223

Ex	. #	R ¹ R	2 A	L	В Е	P
119	91 3	K Cl	С 3Н6 (:	n) -NH-		
119	2 x	Cl	СЗН6 (г	n) -NH-	н н	COCH ₂ Cl
119	3 x	Cl	С3Н6 (г	n) —NH—	н н	COC 4H9
1194	4 X	Cl	C3H6 (n) –NH-	н СНЗ	COCH 3
1195	5 X	Cl	C3H6 (n)) -NH-	н С ₂ н ₅	COCH 3
1196	x	Cl	Сзн6 (n)	-NH-	н н	Н
1197	Х	Cl	C3H6 (n)	-NH-	н снз	Н
1198	Х	Cl	C3H6 (n)	-, IH-	н С2Н5	Н
1199	Х	Cl	C3H6 (n)	-NHCH 2CH2-	н н	COCH 3
1200	Х	Cl	C3H6 (n)	-NHCH2CH2-	н н	COCH ₂ Cl
1201	X	Cl	C3H6 (n)	-NHCH ₂ CH ₂ -	н н	COC 4H9
1202	х	Cl	C3H6 (n)	-NHCH2CH2-	н снз	COCH 3

Ex.#	R ¹	R ²	A	L	В	E	P
1203	х	Cl	C3H6 (n)	-NHCH2CH2-	Н	С ₂ Н ₅	COCH 3
1204	х	Cl	C3H6 (n)	-NHCH2CH2-	Ħ	Н	Н
1205	Х	Cl	C3H6 (n)	-NHCH2CH2-	Н	CH ₃	Н
1206	х	Cl	C3H6 (n)	-NHCH2CH2-	Н	С ₂ Н ₅	Н
1207	Х	Cl	C3H6 (n)	-NN-	*	Н	COCH 3
1208	Х	Cl	C3H6 (n)	-NN-	Н	Н	COCH ₂ Cl
1209	х	Cl	C3H6 (n)	-N_N-	Н	Н	COC 4H9
1210	х	Cl	C3H6 (n)	-N_N-	Н	CH 3	COCH 3
1211	Х	Cl	C3H6 (n)	-NN-	Н	С ₂ Н ₅	COCH 3

Ex.#	R ¹ R	2 A	L		в е	P
1212 >	K Cl	C3H6 (n)	-NN-	*	Н	Н
1213 x	C1	С3H6 (n)	-NN-	Н	CH ₃	Н
1214 X	Cl	C3H6 (n)	-N	Н	С ₂ н ₅	Н
1215 X	Cl	C4H8 (n)	-NH-	Н	Н	COCH 3
1216 X	Cl	C4H8 (n)	-NH-	Н	Н	CJCH ₂ Cl
1217 X	Cl	C4H8 (n)	-NH-	Н	Н	COC 4H9
1218 x	Cl	C4H8 (n)	-NH-	Н	CH 3	COCH 3
1219 CX	Cl	C4H8 (n)	-NH-	Н	C ₂ H ₅	COCH 3
1220 X	Cl	C4H8 (n)	-NH-	Н	Н	Н
1221 X	Cl	C4H8 (n)	- NH-	Н	CH ₃	Н

Ex.#	R ¹	R ²	A	L	В	E	Р
1222	х	Cl	C4H8 (n)	-NH-	Н	С ₂ Н ₅	Н
1223	Х	Cl	C4H8 (n)	-NHCH 2CH2-	Н	Н	COCH 3
1224	Х	Cl	C4H8 (n)	-NHCH ₂ CH ₂ -	Н	H	COCH ₂ Cl
1225	Х	Cl	C4H8 (n)	-NHCH ₂ CH ₂ -	Н	Н	COC 4H9
1226	х	Cl	C4H8 (n)	-NHCH ₂ CH ₂ -	Н	CH 3	COCH 3
1227	х	Cl	C4H8 (n)	-NHCH2CH2-	Н	С ₂ Н ₅	COCH 3
1228	х	Cl	C4H8 (n)	-NHCH2CH2-	Н	Н	Н
1229	Х	Cl	C4H8 (n)	-NHCH 2CH2-	Н	CH ₃	Н
1230	х	Cl	C4H8 (n)	-NHCH2CH2-	Н	С2Н5	Н
1231	х	Cl	C4H8 (n)	-NN-	*	Н	COCH 3
1232	х	Cl	C4H8 (n)	-NN-	Н	Н	COCH ₂ Cl

Ex.	# R	R1 R	2 A	L	в Е	P
1233	х	Cl	C4H8 (n)	-NN-	н н	COC 4H9
1234	х	Cl	C4H8 (n)	-NN-	н снз	сосн 3
1235	Х	Cl	C4H8 (n)	-NN-	н С2Н5	COCH 3
1236	Х	Cl	C4H8 (n)	-NN-	* н	Н
1237	х	Cl	C4H8 (n)	-NN-	H CH3	Н
1238	х	Cl	C4H8 (n)	-NN-	н С2Н5	Н
1239	х	Cl	-N_N-	- NH-	н н	COCH 3
1240 :	X	Cl		-NH-	н н	COCH ₂ Cl

Ex.#	R ¹	R ²	A	L	В	Е	P
1241	X	Cl	→	- NH-	Н	Н	COC 4H9
1242	Х	Cl		-NH-	Н	CH3	COCH 3
1243	x	Cl	─	-NH-	Н	С ₂ Н ₅	COCH 3
1244	Х	Cl	─	-NH-	Н	Н	Н
1245	х	Cl	—	- NH-	Н	CH ₃	Н
1246	X	Cl	—	-NH-	Н	С ₂ Н ₅	Н
1247	Х	Cl	─	-NHCH2CH2-	H	Н	COCH 3

Ex.# R ¹ R ²	A	L B E	P
1248 X C1	~ <u></u>	-NHCH2CH2- Н Н	COCH ₂ Cl
1249 X Cl	-	-NHCH2CH2- Н Н	COC 4H9
1250 X Cl	→	-NHCH ₂ CH ₂ - H CH ₃	COCH 3
1251 X Cl	←	-NHCH2CH2- Н С2H5	COCH 3
1252 X Cl	~ <u></u>	-NHCH ₂ CH ₂ - н н	н
1253 X Cl		-NHCH2CH2- H CH3	Н
1254 X Cl	-	-NHCH2CH2- н С2H5	Н
1255 X Cl	—	-NN- * H	COCH 3

Ex.#	R ¹ R ²	A	L	В Е	P
1256	X Cl	—	-NN-	Н Н	COCH 2Cl
1257 >	K Cl	—	-N_N-	н н	COC 4H9
1258 X	Cl	√	-NN-	н снз	COCH 3
1259 x	C1		-N_N-	н С2Н5	COCH 3
1260 X	Cl	—	-NN-	* Н	Н
1261 X	Cl		-NN-	н СН3	Н
1262 X	Cl		-N_N-	н С2Н5	Н

Ex.# R ¹ R	2 A	L	в Е	P
1263 X Cl	-CH ₂	-NH-	н н	COCH 3
1264 X Cl	-CH ₂	- NH-	н н	COCH ₂ Cl
1265 X Cl	-CH ₂	-NH-	н н	COC 4H9
1266 X Cl	-CH ₂	- NH-	н СНЗ	COCH 3
1267 X Cl	-CH ₂	-NH-	н С ₂ н ₅	COCH ₃
1268 X Cl	-CH ₂	-NH-	н н	Н
1269 X C1	-CH ₂	-NH-	н Сн3	Н
270 X Cl	-CH ₂	-NH-	н с ₂ н ₅	Н

Ex.#	R ¹	R	2 A	L	В	E	P
1271	х	Cl	-CH₂	-NHCH2CH2-	• н	Н	COCH 3
1272	х	Cl	-CH ₂	NHCH2CH2-	Н	Н	COCH ₂ Cl
1273	х	Cl	-CH ₂	NHCH2CH2-	Н	Н	COC 4H9
1274	Х	Cl	-CH _Z	NHCH2CH2-	Н	CH3	COCH 3
1275	х	Cl	-CH ₂ -	-NHCH2CH2-	Н	С2Н5	COCH 3
1276	Х	Cl ·	-CH ₂ -	-NHCH2CH2-	Н	Н	Н
1277	Х	Cl .	-CH ₂	-NHCH2CH2-	Н	CH ₃	Н
1278	Х	Cl -	-CH ₂	-NHCH2CH2-	Н	С ₂ Н ₅	Н

Ex.# R	1 R ²	A	L	в е	P
1279 X	Cl —CH _Z		-NN-	* Н	COCH 3
1280 X	Cl —CH ₂	~ <u></u>	-N_N-	н н	COCH ₂ Cl
1281 X	Cl —CH ₂ —	-	-N_N-	н н	COC 4H9
1282 X	Cl — CH ₂ —	─	-NN-	н снз	COCH 3
1283 X	Cl —CH ₂ —	<u></u>	-NN-	н С ₂ н ₅	COCH 3
1284 X	Cl -CH ₂	◯	-N_N-	* Н	Н
1285 X	Cl —CH ₂ —	⟨ >	-NN-	н СН _З	Н
1286 x	Cl − CH _z − ⟨	<u> </u>	N-N-	н С ₂ н ₅	Н

Ex.#	R ¹ R	2 A	L	В	E	P
1287 >	K Cl -	-CH ₂ CH ₂	- - NH-	Н	Н	COCH 3
1288 X	Cl -	-CH ₂ CH ₂ -	- - NH-	Н	Н	COCH ₂ Cl
1289 X	Cl —	-CH ₂ CH ₂ -	-NH-	Н	Н	COC 4H9
1290 X	Cl	—СH ₂ CH ₂ —	NH-	Н	СН3	COCH 3
1291 X	Cl	-CH ₂ CH ₂	NH-	Н	С ₂ Н ₅	COCH 3
1292 X	Cl	—СН ₂ СН ₂ —	NH-	Н	Н	Н
1293 X	Cl	—СH ₂ CH ₂ —	NH	Н	СНЗ	Н
1294 X	Cl	—CH ₂ CH ₂ —	NH-	H	С ₂ Н ₅	Н

Ex.# I	R ¹ R	2 A	L	в е	P
1295 X	Cl	-CH ₂ CH ₂ -	-NHCH2CH2-	н н	COCH 3
1296 X	Cl	—CH ₂ CH ₂ —	-NHCH2CH2-	н н	COCH 2Cl
1297 X	Cl	—CH ₂ CH ₂ —	-NHCH2CH2-	н н	COC 4H9
1298 X	Cl	—CH ₂ CH ₂ —	-NHCH2CH2- F	и снз	COCH 3
1299 X	Cl	—СН ₂ СН ₂ —	-NHCH2 СН2 – Н	С2Н5	COCH 3
1300 X	Cl	—CH ₂ CH ₂ ————————————————————————————————————	NHCH2CH2- H	Н	Н
1301 X	Cl	-CH ₂ CH ₂ -	NHCH2CH2- H	CH3	Н
1302 X	Cl	—CH ₂ CH ₂ ————————————————————————————————————	NHCH2CH2- H	С ₂ Н ₅	Н

Ex.# R ¹	R ²	A	L	В	E	P
1303 X	Cl	—CH₂CH₂—	NN-	*	Н	COCH 3
1304 X	Cl	—CH ₂ CH ₂ —	NN-	Н	Н	COCH ₂ Cl
1305 X	Cl	—СН ₂ СН ₂ —	NN-	Н	Н	COC 4H9
1306 X	Cl	—СН ₂ СН ₂ —	NN-	Н	СНЗ	COCH 3
1307 X	Cl	−CH ₂ CH ₂ −	NN-	Н	С ₂ Н ₅	COCH 3
1308 X	Cl	−CH ₂ CH ₂	NN-	*	Н	Н
1309 X	Cl	—СH ₂ CH ₂ ————————————————————————————————————	NN-	Н	СНЗ	Н
1310 X	Cl	—CH ₂ CH ₂ —	NN-	Н	С ₂ Н ₅	Н

Ex.#]	R1	R ² A	L	В	E	P
1311 X	Cl	-CH2-	-NH-	н	Н	COCH 3
1312 X	Cl	- ⟨ _}-CH ₂ -	-NH-	Н	Н	COCH ₂ Cl
1313 X	Cl	- √ CH₂-	- NH-	Н	Н	COC 4H9
1314 X	Cl	-CH ₂ -	- NH-	Н	СНЗ	COCH 3
1315 X	Cl	-CH2-	-NH-	Н	С ₂ Н ₅	COCH 3
1316 X	Cl	-CH2-	-NH-	Н	Н	Н
1317 X	Cl	-CH ₂ -	-NH-	Н	CH ₃	Н
1318 X	Cl	-√_>-CH ₂	-NH-	Н	С ₂ Н ₅	Н

Ex.# R ¹	R ²	A	L	В	E	P
1319 X	Cl	-CH ₂ -	-NHCH2CH2-	Н	Н	COCH 3
1320 X	Cl	-CH ₂ -	-NHCH2CH2-	Н	Н	COCH ₂ Cl
1321 X	Cl	-CH2-	-NHCH 2CH2-	Н	Н	COC 4H9
1322 X	Cl	-CH2-	-NHCH2CH2-	Н	СН3	COCH 3
1323 X	Cl	-CH2-	-NHCH 2CH2-	Н	С2Н5	COCH 3
1324 X	Cl	-CH2-	-NHCH 2CH2-	Н	Н	Н
1325 X	Cl	-CH ₂ -	-NHCH 2CH2-	Н	СНЗ	Н
1326 X	Cl	-CH2-	-NHCH 2CH2-	Н	С ₂ Н ₅	Н

Ex.# R ¹	R ² A	L	в е	P
1327 X C1	— СН2—	-NN-	* Н	COCH 3
1328 X Cl	-CH2-	-NN-	н н	COCH ₂ Cl
1329 X Cl	-CH2-	-NN-	н н	COC 4H9
1330 X Cl	-√_CH ₂ -	-NN-	н СН3	COCH 3
1331 X Cl	-CH2-	-NN-	н С2Н5	COCH 3
1332 X Cl	CH₂-	-NN-	* Н	Н
1333 X Cl	-CH2-	-NN-	н сн ₃	Н
1334 X Cl	-CH2-	-NN-	н С ₂ Н ₅	Н

Ex.# R ¹	l R ²	A	L	В	E	P
1335 X	Cl	-CH2-CH2-	-NH-	Н	Н	COCH 3
1336 X	Cl	-CH ₂ -CH ₂ -	-NH-	Н	Н	COCH ₂ Cl
1337 X	Cl	-CH ₂ -CH ₂ -	-NH-	Н	Н	COC 4H9
1338 X	Cl	-CH2-CH2-	-NH-	Н	СН3	COCH 3
1339 X	Cl	-CH ₂ -CH ₂ -	- NH-	Н	С ₂ Н ₅	COCH 3
1340 X	Cl	CH ₂ CH ₂	-NH-	Н	Н	Н
1341 X	Cl	CH ₂ CH ₂	-NH-	H	СНЗ	Н
1342 X	Cl	——————————————————————————————————————	-NH-	Н	С ₂ Н ₅	Н

Ex.#]	R ¹ R	2 A	L	В	E P	
1343 X	Cl	-CH ₂	-СН ₂ NНСН ₂ СН ₂	н н	COCH 3	
1344 X	Cl	-CH ₂ -	-CH ₂ NHCH2CH2-	н н	COCH ₂ Cl	
1345 X	Cl	-()-CH ₂ -	-CH ₂ —-NHCH2CH2-	н н	COC 4H9	
1346 X	Cl	-{CH ₂	CH ₂ —-NHCH ₂ CH ₂ -	н СНЗ	COCH 3	
1347 X	Cl	-CH ₂ -C	CH ₂ NHCH2CH2-	н С2Н	5 COCH 3	
1348 X	Cl	-CH ₂ -C	CH ₂ —-NHCH2CH2- I	H H	Н	
1349 X	Cl	—(H ₂ NHCH2CH2- F	! CH₃	Н	
1350 X	Cl	-CH ₂ -C	Н ₂ —-NHCH2CH2- Н	C ₂ H ₅	; н	

Ex.# R	1 R ²	A	L	В	E	P
1351 X	C1	-CH ₂ -CH	H ₂ -N N-	*	Н	COCH 3
1352 X	Cl	-CH2-CH	H ₂ NN-	Н	Н	COCH ₂ Cl
1353 X	Cl	-CH2-CH	l ₂ -N N-	Н	Н	COC 4H9
1354 X	Cl	-CH ₂ -CH	-N_N-	Н	СНЗ	COCH 3
1355 X	Cl	-CH ₂ -CH	2 -N N-	Н	С ₂ Н ₅	COCH 3
1356 X	Cl	—CH₂—CH₂	2 -N N-	*	Н	Н
1357 x	Cl	——————————————————————————————————————	2N_N-	Н		Н
1358 X	Cl	— СН2 — СН2	-N_N-	Н	С ₂ Н ₅	Н

Ex.#	R ¹	R ² A	L	E	ВЕ	P
1359 x	: Cl	-CH ₂ -CH ₂ -	- NH-	Н	Н	COCH 3
1360 X	Cl	-CH ₂ -CH ₂ -	NH-	Н	Н	COCH ₂ Cl
1361 X	Cl	-CH ₂ -CH ₂ -	-NH-	Н	Н	COC 4H9
1362 X	Cl	-CH ₂ -CH ₂ -	-NH-	H	СНЗ	COCH 3
1363 X	Cl	-CH ₂ -CH ₂ -	-NH-	Н	С2Н5	COCH 3
1364 X	Cl	-CH ₂ -CH ₂ -	-NH-	Н	Н	Н
1365 x	Cl	-CH ₂ -CH ₂ -	-NH-	Н	СНЗ	Н
1366 X	Cl	-CH ₂ -CH ₂ -	-NH-	Н	С ₂ Н ₅	Н

Ex.# R ¹	l R ²	A	L	В	E	P
1367 X	Cl	-CH ₂ -CH ₂ -	-NHCH2CH2-	Н	Н	COCH 3
1368 X	Cl	-CH ₂ -CH ₂ -	-NHCH2CH2-	Н	Н	COCH ₂ Cl
1369 X	Cl	-CH ₂ -CH ₂ -	-NHCH2CH2-	Н	Н	COC 4H9
1370 X	Cl	-CH ₂ -CH ₂ -	-NHCH2CH2-	Н	СНЗ	COCH 3
1371 X	Cl	-CH ₂ -CH ₂ -	-NHCH2CH2-	Н	С ₂ Н ₅	COCH 3
1372 X	Cl	-CH ₂ -CH ₂ -	-NHCH2CH2-	Н	Н	Н
1373 X	Cl	-CH ₂ -CH ₂ -	-NHCH2CH2-	Н	СНЗ	Н
1374 X	Cl	-CH ₂ -CH ₂ -	-NHCH ₂ CH ₂ -	Н	С ₂ Н5	Н

Ex.# R ¹	R ² A L	в Е	P
1375 X Cl	-CH ₂ -CH ₂ N N-	* Н	COCH 3
1376 X Cl	-CH ₂ -CH ₂ N N-	н н	COCH ₂ Cl
1377 X Cl	-CH ₂ -CH ₂ N N-	н н	COC 4H9
1378 X Cl	-CH ₂ -CH ₂ NNN-	н СН3	COCH 3
1379 X Cl	-CH ₂ -CH ₂ N N-	н С ₂ Н5	COCH 3
1380 X Cl	-CH ₂ -CH ₂ N N-	* Н	Н
1381 X Cl	-CH ₂ -CH ₂ N N-	н сн ₃	Н
1382 X Cl	-CH ₂ -CH ₂ N N-	н С2Н5	Н

Ex.# R	1 R ²	A	L	В	E	P
1383 X	Cl		-NH-	Н	Н	COCH 3
1384 X	Cl	\bowtie	-NH-	Н	Н	COCH ₂ Cl
1385 X	Cl	\bowtie	-NH-	Н	Н	COC 4H9
1386 X	Cl ·	\bowtie	-NH-	H	СН3	COCH 3
1387 X	Cl	\bowtie	-NH-	Н	С ₂ Н ₅	COCH 3
1388 X	Cl	\bowtie	-NH-	Н	Н	н
1389 X	Cl	\bowtie	-NH-	Н	CH ₃	н
1390 X	Cl	\bowtie	- NH-	Н	С ₂ Н ₅	н
1391 X	Cl	\bowtie	-NHCH2CH2-	- H	Н	COCH 3

Ex.# I	R ¹ R ²	A	L B	E	P
1392 X	Cl		-NHCH2CH2- H	H.	COCH 2Cl
1393 X	Cl		-NHCH2CH2- H	Н	COC 4H9
1394 X	Cl	\bowtie	-NHCH2CH2- H	СНЗ	COCH 3
1395 X	Cl		-NHCH ₂ CH ₂ - H	С ₂ Н ₅	COCH 3
1396 X	Cl		-NHCH2CH2- H	Н	Н
1397 X	Cl	\bowtie	-NHCH ₂ CH ₂ - H	СНЗ	Н
1398 X	Cl	\bowtie	-NHCH ₂ CH ₂ - H	С ₂ Н ₅	Н
1399 X	Cl		-NN- *	Н	COCH 3
1400 X	Cl		-NН	Н	COCH ₂ Cl

Ex.# R ¹	R ²	A	L.	В	E	Р
1401 X	Cl		-N_N-	н	Н	COC 4H9
1402 X	Cl		-N_N-	Н	СНЗ	COCH 3
1403 X	Cl		-NN-	Н	С2Н5	COCH 3
1404 X	Cl	\bowtie	-NN-	*	Н	Н
1405 X	Cl		-N_N-	Н	СНЗ	Н
1406 X	Cl	\bowtie	-NN-	H	С ₂ Н ₅	Н
1407 X	Cl	-CH ₂	-NH-	Н	Н	COCH 3
1408 X	Cl	-CH ₂ -CT	NH	Н	Н	COCH 2Cl

Ex.# R ¹ R ²	A	L	F	B E	P
1409 X Cl		-NH-	ъ	IJ	COC 4H9
1410 X Cl	-CH ₂				
1411 X C1	-CH ₂	-NH-			
1412 X Cl	-CH ₂	- NH-			
1412 X C1	-CH ₂	−NH−			
	-CH ₂	- NH-		J	H
1414 X Cl	-CH ₂			С ₂ Н ₅	Н
1415 X Cl	-CH ₂ -N				
1416 X Cl	-CH ₂	HCH2CH2-	Н	Н	COCH ₂ Cl

Ex.# R	1 R ²	A	L	В	E	P
1417 X	Cl	-CH ₂	- -NHCH2CH2-	Н	Н	COC 4H9
1418 X	Cl	-CH ₂	- -NHCH2CH2-	Н	СНЗ	COCH 3
1419 X	Cl	-CH ₂	- -NHCH2CH2-	Н	C ₂ H ₅	COCH 3
1420 X	Cl	-CH ₂	- -NHCH2CH2-	Н	Н	Н
1421 X	Cl	-CH ₂	-NHCH2CH2-	Н	СНЗ	Н
1422 X	Cl	-CH ₂	-NHCH2CH2-	Н	С2Н5	Н
1423 X	Cl	-CH ₂	-NN-	*	Н	COCH 3
1424 X	Cl	-CH ₂	-NN-	Н	Н	COCH ₂ Cl

Ex.# I	R1 R2	A	L	В	E	P
1425 X	Cl	-CH ₂	-N N	- Н	Н	COC 4H9
1426 X	Cl	-CH ₂	-NN-	Н	СНЗ	COCH 3
1427 X	Cl	-CH ₂	-N_N-	Н	С ₂ Н ₅	COCH 3
1428 X	Cl	-CH ₂	-NN-	*	Н	Н
1429 X	Cl	-CH ₂	-NN-	Н	СН3	Н
1430 X	Cl	-CH ₂	-NN-	Н	С ₂ н ₅	Н
1431 X	Cl -CH ₂ (CH ₂	-NH-	Н	Н	СОСН 3
1432 X	Cl -CH ₂ C	CH ₂	- NH-	Н	Н	COCH ₂ Cl

Ex.# R	1	R ² A	L	В	E	Р
1433 X	Cl	-CH ₂ CH ₂	7 −NH−	H	Н	COC 4H9
1434 X	Cl	-CH ₂ CH ₂	7 −NΗ−	Н	СН3	COCH 3
1435 X	Cl	-CH ₂ CH ₂	-NH-	Н	С ₂ Н ₅	COCH 3
1436 X	Cl	-CH ₂ CH ₂	-NH-	Н	Н	Н
1437 X	Cl	-CH ₂ CH ₂	-NH-	Н	CH ₃	Н
1438 X	Cl	-CH ₂ CH ₂	-NH-	Н	С2Н5	Н
1439 X	Cl	-CH ₂ CH ₂	- -NHCH 2CH2-	Н	Н	COCH 3

Ex.# R	1	R ²	A	L	В	E	P	
1440 X	Cl	-CH ₂ (CH ₂	-NHCH 2CH2-	Н	Н	COCH ₂ Cl	
1441 X	Cl	-0	CH ₂ CH ₂	√ -NHCH 2CH2-	Н	Н	COC 4H9	
1442 X	Cl	- C	H ₂ CH ₂	√ -NHCH 2CH2-	Н	СНЗ	COCH 3	
1443 X	Cl	-C	H ₂ CH ₂	T -NHCH2CH2-	Н	С ₂ Н ₅	COCH 3	
1444 X	Cl	-C	H ₂ CH ₂	T -NHCH2CH2-	Н	Н	Н	
1445 X	Cl	-Cł	H ₂ CH ₂	√ -NHCH2CH2-	H	СН3	Н	
1446 X	Cl	-Cł	H ₂ CH ₂	T-NHCH2CH2-	Н	С ₂ Н ₅	Н	

Ex.# R ¹	R ²	A	L	В	E	P
1447 X	Cl	-CH ₂ CH ₂	-N_N-	*	Н	COCH 3
1448 X	Cl	-CH ₂ CH ₂	-N_N-	Н	Н	COCH ₂ Cl
1449 X	Cl	-CH ₂ CH ₂	-N_N-	Н	Н	COC 4H9
1450 X	Cl	-CH ₂ CH ₂	-N_N-	Н	СН3	COCH 3
₁₄₅₁ X	Cl	-CH ₂ CH ₂	-N_N-	Н	C ₂ H ₅	COCH 3
1452 X	Cl	-CH ₂ CH ₂	-NN-	*	Н	Н
1453 X	Cl	-CH ₂ CH ₂	-N_N-	Н	CH3	Н

Ex.# R^1 R^2 A L B E P

Ex.# R ¹	R ²	A	L	В	E	P
						
1461 X	Cl	∠ CH ₂ -	-NH-	Н	СНЗ	H
1462 X	Cl	CH ₂ -	-NH-	Н	C ₂ H ₅	H
1463 X	Cl	CH ₂ -	-NHCH 2CH2-	Н	Н	COCH 3
1464 X	Cl	∠ CH ₂ -	-NH-	Н	Н	COCH ₂ Cl
1465 X	Cl	CH ₂ -	-NH-	Н	Н	COC 4H9
1466 X	Cl	CH ₂ -	-NH-	Н	СНЗ	COCH 3
1467 X	Cl	CH ₂ -	-NH-	Н	С ₂ Н ₅	COCH 3
1468 X	Cl	CH ₂ -	-NHCH2CH2-	Н	H	Н

Ex.# R	1 R2	A	L	В	E	P
1469 X	Cl	∠ CH ₂ -	-NHCH2CH2-	- н	СН3	Н
1470 X	Cl	CH ₂ -	-NHCH2CH2-	- н	С ₂ Н ₅	Н
1471 X	Cl	∠ CH ₂ -	-NN-	*	Н	COCH 3
1472 X	Cl	∠ CH ₂ -	-NN-	н	Н	COCH 2Cl
1473 X	Cl	∠ CH ₂ -	-NN-	Н	Н	CCC 4H9
1474 X	Cl	CH ₂ -	-NN-	Н	СНЗ	COCH 3
1475 X	Cl	CH ₂ -	-NN-	Н	С ₂ Н ₅	COCH 3

Ex.# R ¹	R ²	A	L	В	E	P
						
1476 X	Cl	CH ₂ -	-NN-	*	Н	Н
1477 X	Cl	∠ CH ₂ -	-N_N-	Н	СНЗ	н
1478 X	Cl	CH ₂ -	-N_N-	Н	С ₂ Н ₅	Н
1479 X	Cl	CH ₂ CH	¹ 2- –NH-	Н	H	COCH 3
1480 X	C1	CH ₂ CH	H ₂ - –NH-	Н	Н	COCH ₂ Cl
1481 X	Cl	CH ₂ CH	H ₂ - –NH-	Н	Н	COC 4H9

Ex.# F	₂ 1	R ²	A		L	В	E	P
1482 X	Cl	-4	\sim	H ₂ C⊟ ₂ -	-NH-	Н	СНЗ	COCH 3
1483 X	Cl	-4	✓ cr	H ₂ CH ₂ -	-NH-	Н	С ₂ н ₅	сосн 3
1484 X	Cl		CF CF	H ₂ CH ₂ -	- NH-	Н	Н	Н
1485 X	Cl	4	₩ CH	Ⅎ₂CH₂-	-NH-	Н	СН3	Н
1486 X	Cl	4	 C⊦	l ₂ CH ₂ -	- NH-	Н	С ₂ н ₅	Н
1487 X	Cl	L	CH ₂	.СН ₂ - _{—]}	NHCH2CH2-	Н	Н	COCH 3
1488 X	Cl	\angle	√CH ₂ C	H ₂ - _{–NF}	HCH2CH2-	Н	Н	COCH2Cl
1489 X	Cl		J CH₂CI	H ₂ NHC	CH2CH2-	Н	Н	COC 4H9
1 4 90 X	Cl	\triangle	J CH₂CI	H ₂ - _{—NH}	CH2CH2-	Н	СН3	COCH 3

Ex.# R ¹	R ²	A	L	В	E	P
1491 X	cı 🔎	J CH₂C	CH ₂ NHCH ₂ CH ₂ -	Н	С ₂ Н ₅	COCH 3
1492 X	cı 🔎	J CH₂C	CH ₂ NHCH ₂ CH ₂ -	Н	Н	н .
1493 X	C1	✓ CH₂C	CH ₂ NHCH2CH2-	Н	CH ₃	Н
1494 X	Cl 🖍	J CH₂CH	^{Н₂₋NHCH2CH2-}	Н	С2Н5	Н
1495 X	cı 🔎	J CH₂C⊦	H ₂ N N-	*	Н	COCH 3
1496 X	cı 🗲	J CH₂CF	H ₂ N N-	Н	Н	COCH2Cl
1497 X	C1 _	J CH₂CF	H ₂ N N-	Н	Н	COC 4H9
1498 X	Cl	J CH₂Ci	H ₂ N N-	H.	СН3	COCH 3
1499 X	Cl _	CH ₂ CI	H ₂ N N-	Н	С ₂ Н ₅	COCH3

Ex.# R ¹	R ²	A	L	В	E	P

1503 X Cl
$$-CH_2$$
 $-NH-$ H H COCH 3

1507 X C1
$$-CH_2$$
 $-NH-$ H C_2H_5 COCH 3

Ex.# R ¹	R.	2 A	L	В	E	P
1508 X	Cl	-CH ₂	H ₂ - -NH-	Н	Н	Н
1509 X	Cl	-CH ₂	:H ₂ - -NH-	Н	СНЗ	H
1510 X	Cl	-CH ₂	:H ₂ - -NH-	Н	С ₂ Н ₅	Н
1511 X	Cl	-CH ₂	CH ₂ - -nhCh2Ch2	– н	Н	COCH 3
1512 X	Cl	-CH ₂	CH ₂ - -nhCh2CH2	<u>-</u> н	Н	COCH ₂ Cl
1513 X	Cl	-CH ₂	CH₂- -NHCH2C	СН2- Н	Н	COC 4H9
1514 X	Cl	-CH ₂	CH ₂ - -NHCH ₂ CH ₂	2- H	СНЗ	COCH 3
1515 X	Cl	-CH ₂	CH ₂ - -NHCH2CH2	2- H	С ₂ Н ₅	COCH 3

Ex.# R ¹		_R 2	A	L	В	E	P
1516 X	Cl	-CH ₂ -	CH ₂ ·	-NHCH2CH2-	Н	Н	Н
1517 X	Cl	-CH ₂	CH ₂ -	-NHCH2CH2-	Н	СНЗ	Н
1518 X (Cl	-CH ₂	₩ CH ₂ -	-NHCH ₂ CH ₂ -	Н	С ₂ н ₅	Н
1519 X (Cl	-CH ₂	₩ CH ₂ -	-N_N-	*	Н	COCH 3
1520 X (Cl	-CH ₂ -C	₩ CH ₂ -	-NN-	Н	Н	COCH ₂ Cl
1521 X C	21	-CH ₂	CH ₂ ·	-N N-	Н	Н	COC 4H9
1522 X C	:1	-CH ₂	CH ₂ -	-N_N-	Н	СНЗ	COCH 3
L523 X C.	1	-CH ₂	CH ₂ -	-N_N-	Н	С ₂ Н ₅	COCH 3

Ex.# R ¹	•	R ²	A	L	В	E	P
1524 X	C1	-CH ₂ -	CH.	2 ⁻ -N N-	*	Н	Н
1525 X	Cl	-CH ₂ -	CH ₂	2 ⁻ -N N-	Н	СНЗ	H
1526 X	Cl	-CH ₂ -	CH ₂	2" -NN-	Н	С ₂ Н ₅	н

265

BIOLOGICAL EVALUATION

Compounds of Examples 1-80 are suitable angiotension II antagonists for use as the first component of conjugates of the invention. The AII receptor binding activity of many of the Example #1-#80 compounds, for example, is described in EP #253,310 published 20 January 1988. The compound of Example #5 was further evaluated in three biological assays (Assays "A", "B" and "C") for AII antagonist and blood pressure lowering properties. In two other assays, blood-pressure lowering effects of the conjugate of Example #81 were evaluated (Assays "D" and "E").

15 Assay A: Angiotensin II Binding Activity

Compound of Example #5 was tested for ability to bind to the smooth muscle angiotensin II receptor using a rat uterine membrane preparation. Angiotensin II (AII) was purchased from Peninsula Labs. 125 I-angiotensin II 20 (specific activity of 2200 Ci/mmol) was purchased from Du Pont-New England Nuclear. Other chemicals were obtained from Sigma Chemical Co. This assay was carried out according to the method of Douglas et al [Endocrinology, 25 106, 120-124 (1980)]. Rat uterine membranes were prepared from fresh tissue. All procedures were carried out at 4°C. Uteri were stripped of fat and homogenized in phosphatebuffered saline at pH 7.4 containing 5 mM EDTA. The homogenate was centrifuged at $1500 \times g$ for 20 min., and the 30 supernatant was recentrifuged at 100,000 x g for 60 min. The pellet was resuspended in buffer consisting of 2 mM EDTA and 50 mM Tris-HCl (pH 7.5) to a final protein concentration of 4 mg/ml. Assay tubes were charged with 0.25 ml of a solution containing 5 mM MgCl₂, 2 mM EDTA, 35 0.5% bovine serum albumin, 50 mM Tris-HCl, pH 7.5 and $125_{\mathrm{I}-}$ AII (approximately 10^5 cpm) in the absence or in the presence of unlabelled ligand. The reaction was initiated by the addition of membrane protein and the mixture was

15

incubated at 25°C for 60 min. The incubation was terminated with ice-cold 50 mM Tris-HCl (pH 7.5) and the mixture was filtered to separate membrane-bound labelled peptide from the free ligand. The incubation tube and filter were washed with ice-cold buffer. Filters were assayed for radioactivity in a Micromedic gamma counter. Nonspecific binding was defined as binding in the presence of 10 μM of unlabelled AII. Specific binding was calculated as total binding minus nonspecific binding. The receptor binding affinity of an AII antagonist compound was indicated by the concentration (IC50) of the tested AII antagonist which gives 50% displacement of the total specifically bound $125_{\,\text{I-AII}}$ from the high affinity AII receptor. Binding data were analyzed by a nonlinear least-squares curve fitting program. Results are reported in Table VIII.

Assay B: In Vitro Vascular Smooth Muscle-Response for AII

Compound of Example #5 was tested for AII antagonist activity in rabbit aortic rings. Male New 20 Zealand white rabbits (2-2.5 kg) were sacrificed using an overdose of pentobarbital and exsanguinated via the carotid arteries. The thoracic aorta was removed, cleaned of adherent fat and connective tissue and then cut into 3-mm ring segments. The endothelium was removed from the rings 25 by gently sliding a rolled-up piece of filter paper into the vessel lumen. The rings were then mounted in a waterjacketed tissue bath, maintained at 37°C, between moveable and fixed ends of a stainless steel wire with the moveable end attached to an FT03 Grass transducer coupled to a Model 30 7D Grass Polygraph for recording isometric force responses. The bath was filled with 20 ml of oxygenated (95% oxygen/5% carbon dioxide) Krebs solution of the following composition (nM): 130 NaCl, 15 NaHCO3, 15 KCl, 1.2 NaH2PO4, 1.2 MgSO4, 2.5 $CaCl_2$, and 11.4 glucose. The preparations were 35 equilibrated for one hour before approximately one gram of passive tension was placed on the rings. Angiotensin II concentration-response curves were then recorded (3 \times 10 $^{-10}$

267

to 1 \times 10⁻⁵ M). Each concentration of AII was allowed to elicit its maximal contraction, and then AII was washed out repeatedly for 30 minutes before rechallenging with a higher concentration of AII. Aorta rings were exposed to the test antagonist at 10^{-5} M for 5 minutes before challenging with AII. Adjacent segments of the same aorta ring were used for all concentration-response curves in the presence or absence of the test antagonist. effectiveness of the test compound was expressed in terms 10 of pA_2 values and were calculated according to H.O. Schild [Br. J. Pharmacol. Chemother., 2,189-206 (1947)]. value is the concentration of the test antagonist compound which increases the EC50 value for AII by a factor of two. The test compound was evaluated in aorta rings from three 15 rabbits. Results are reported in Table VIII.

PCT/US91/05476 WO 92/02257

268

TABLE VIII

In Vitro Angiotensin II Activity of Compounds of Formula I

	Test Compound	¹ Assay A IC ₅₀ (nM)	² Assay B PA ₂
10	Ex. #5	216 ± 45	7.13 ± 0.16

15

25

30

5

¹Assay A: <u>In Vitro</u> angiotensin II Binding Activity 2_{Assay B: In Vitro Vascular Smooth Muscle Response}

Assay C: In Vivo Intraduodenal and Intravenous Pressor 20 Assay Response for AII Antagonists

The <u>in vivo</u> AII receptor antagonist activity of Example #5 compound was examined in ganglion-blocked male Sprague-Dawley rats (Harlan Sprague-Dawley, Inc.), weighing 300-400 g, anesthetized with 100 mg/kg i.p. Inactin. Catheters (PE-50) were implanted in a femoral artery and vein to measure mean arterial pressure and to administer compounds, respectively. A tracheal catheter maintained airway patency. For intravenous experiments, autonomic neurotransmission was blocked by teatment with mecamylamine (3 mg/kg i.v.) and atropine (400 μ g/kg i.v.). AII (30 ng/kg i.v., $20-25 \mu l$ volume) was administered four times at 10 minute intervals to establish a reproducible control pressor response. 35 Example #5 compound was then administered at 1, 3 and 10 mg/kg in separate groups of rats as an intravenous bolus (0.2 ml volume) before rechallenging with AII

269

(30 ng/kg, 20-25 μ l volume) for the following 2 hours. For intraduodenal experiments, rats were anesthetized as above, but ganglion blockade was not performed. AII was administered at 100 ng/kg i.v. (20-25 μ l volume), and 5 was administered at 10, 30 and 100 mg/kg in separate groups of rats as an intraduodenal bolus (0.2 ml volume). Angiotensin II injections were then given 5, 10, 20, 30, 45, 60, 75, 90, and 120 minutes after administration of the test compound and response of 10 arterial pressure was monitored. The response to AII was calculated as percent of the control response and then the percent inhibition was calculated as 100 minus the percent control response. Duration of action of a test compound was defined as the time from peak percent 15 inhibition to 50% of peak. The test compound was tested in two rats and the values for the two rats were averaged. Results are reported in Tables IX and X as percent of the control of AII pressor response, where "control" is defined as AII pressor response before the 20 AII antagonist test compound is administered.

270

TABLE IX

In Vivo Intravenous Angiotensin II

Activity of Example #5 Compound
(% Control of AII Pressor Response)

	Dose (mg/k						Tim	e (mi	<u>n)</u>	F		
		1_	5_	10	20	30	40	50	60	75	90	120
10	1	80	85	92	90	88	86	86	89	93	95	100
	n=4	<u>+</u> 3	<u>+</u> 4	<u>+</u> 4	<u>±</u> 6	<u>+</u> 5	<u>+</u> 5	<u>+</u> 6	<u>+</u> 5	<u>+</u> 3	±5	<u>+</u> 0
15	3	39	55	63	68	74	75	75	81	88	92	98
	n=4	<u>+</u> 5	<u>+</u> 7	<u>+</u> 8	<u>+</u> 6	<u>+</u> 7	<u>+</u> 5	<u>+</u> 3	<u>+</u> 7	<u>+</u> 7	±5	<u>+</u> 1
	10	4	16	23	31	40	47	51	60	71	80	96
	n=6	<u>+</u> 2	<u>+</u> 2	<u>+</u> 2	<u>+</u> 2	±3	<u>+</u> 4	<u>+</u> 4	<u>+</u> 6	±7	±8	<u>±</u> 6

20

271

TABLE X

In Vivo Intraduodenal Angiotensin II Activity of Example #5 Compound

5 (% Control of AII Pressor Response)

	Dose mg/kg	1	5	10	<u>Time</u> 20	e (min 30	<u> </u>	50	60	7 <u>5</u>
10	10	100	94	99	85	91	91	95	93	95
	n=3	<u>±</u> 0	<u>+</u> 4	<u>+</u> 1	<u>+</u> 11	±9	<u>+</u> 9	<u>+</u> 5	<u>+</u> 7	<u>+</u> 5
15	30	48	48	44	28	34	42	41	53	74
	n=4	<u>+</u> 4	<u>+</u> 7	<u>+</u> 11	<u>+</u> 5	<u>+</u> 4	<u>+</u> 6	<u>+</u> 0	<u>+</u> 2	<u>+</u> 7
	100	28	19	15	14	9	5	13	10	13
	n=4	<u>+</u> 3	<u>+</u> 4	±3	<u>+</u> 8	<u>+</u> 5	<u>+</u> 2	±6	<u>+</u> 4	<u>+</u> 5

Assay D: In Vivo Effects of Chronic Infusion of Conjugate of the Invention

A conjugate of the invention as synthesized in Example 81 was evaluated biologically by an in vivo 5 assay to determine the ability of the conjugate to selectively inhibit renal action and thereby control blood pressure. This in vivo experiment was conducted to characterize the effects of the Example 81 conjugate on spontaneously hypertensive rats (SHR) by acute 10 administration i.v. and by chronic administration i.v. The Example 81 compound or saline vehicle was infused continuously for four days in SHR. Mean arterial pressure was measured (Gould Chart Recorder, model 3800; Statham P23Db pressure transducer) via an indwelling 15 femoral artery catheter between 10:00 A. M. and 2:00 P. M. each day. The Example 81 conjugate (10 mg/hr) or saline was infused via a jugular vein catheter with a Harvard infusion pump. After administration of the Example 81 conjugate, there was observed a lowered mean 20 arterial pressure as compared to the saline vehicle control as reported in Table XI and also in Fig. 1. A test was conducted to determine whether the Example 81 conjugate would antagonize non-renal, vascular 25 angiotensin II receptors. In this test AII was administered by bolus injection (100 ng/kg) to the SHR rats (described above) on the control day and on days 1, 2 and 3 during conjugate infusion. No evidence for systemic angiotensin II receptor antagonism was observed, given the similar pressor responses to 30 injections of angiotensin II on the control day and days 1, 2 and 3 of infusion of the Example 81 conjugate as shown in Table XII and also in Figure 2.

273

TABLE XI

Effect of Ex. #81 Conjugate on Mean
Arterial Pressure: Chronic Administration

5

Time (days): Control 1 2 3 MAP (mm Hg) 163 148 135 140

10

TABLE XII

15 Effect of Ex. #81 Conjugate on

AII Pressor Response

Time (days): Control 1 2 3 MAP (mm Hg) 44 45 65 60

Assay "E": In Vivo Effects of Acute Infusion of Conjugate of the Invention

In this assay, a comparison was made between an angiotensin II antagonist compound (Ex. #5) and a glutamyl 5 conjugate (Ex. #81) of the Ex. #5 AII antagonist compound to determine the renal selectivity of the conjugate. Male Sprague-Dawley rats (300-350 g body weight) had catheters implanted into the femoral artery and vein under chloral hydrate anesthesia (400 mg/kg, i.p.). After 2 to 4 days of 10 recovery, on the experimental day, a urinary bladder catheter was implanted under methohexital anesthesia (50 mg/kg, i.p.). Rats were placed in a restraint device to allow for urine collection and mean arterial pressure measurements. After 1-2 hours of recovery, in conscious 15 rats, an isotonic saline infusion (50 μl/min) was started and continued for the duration of the experiment. one hour equilibration to the saline infusion, a 20 minute control urine and mean arterial pressure collection were obtained. Then angiotensin II was infused at 20 ng/min for 20 25 minutes. After 5 minutes of angiotensin II infusion, a 20 minute experimental collection was made. Finally, 5 minutes after the end of angiotensin II infusion, a 20 minute recovery collection was obtained. In separate groups of rats, vehicle (0.3 ml isotonic saline, i.v. 25 bolus), Example #5 angiotensin II antagonist compound (100 mg/kg, i.v. bolus), or Example #81 conjugate (100 mg/kg, i.v. bolus) was administered 1-2 minutes prior to onset of angiotensin II infusion. Infusion of angiotensin II increased mean arterial pressure and 30 decreased urinary sodium excretion. The Example #5 AII antagonist compound prevented both responses to angiotensin The Example #81 conjugate had no effect on the mean arterial pressure response but prevented the antinatriuretic response to angiotensin II. Angiotensin II 35 infusion following administration of Example #81 conjugate actually increased urinary sodium excretion, probably due to a pressure natriuresis. Results are shown in Tables

275

XIII and XIV and also in Figs. 3 and 4. Data are presented as means \pm SE. Repeated measures analysis of variance was used for main effects and interactions and Tukey's HSD test was used for pairwise comparisons among means. Statistical significance was defined as p<0.05.

276

TABLE XIII

Effect of Ex. #81 Conjugate on Urinary Sodium Excretion (µEq/min/100 g BW)

5		Control	AII	Recovery
	Vehicle Ex. #5	1.9 ± 0.8 2.4 ± 0.5	$0.8 \pm 0.3*$ 2.5 ± 1.1	1.7 ± 0.5 2.6 ± 0.7
10	Ex. #81	1.3 ± 0.3	4.1 <u>+</u> 1.3*	1.8 ± 0.4

15 TABLE XIV

Effect of Ex. #81 Conjugate on Mean Arterial Pressure (mm Hg): Acute Administration

20				
		Control	AII	Recovery
	Vehicle (n=6)	121 ± 3	155 ± 3*	123 ± 4
	Ex. $#5$ (n=6)	123 ± 5	125 ± 7	124 <u>+</u> 7
25	Ex. #81 (n=6)	117 <u>+</u> 3	151 <u>+</u> 4*	121 <u>+</u> 4

Also embraced within this invention is a class of pharmaceutical compositions comprising one or more conjugates which comprises a first component selected from angiotensin II antagonist compounds of Formula I linked to a second component provided by an enzyme-cleavable moiety. 5 Such pharmaceutical compositions further comprise one or more non-toxic, pharmaceutically acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as "carrier" materials) and, if desired, other active 10 ingredients. The conjugates of the present invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. Therapeutically effective doses of a conjugate of the 15 present invention required to prevent or arrest the progress of the medical condition are readily ascertained by one of ordinary skill in the art. The conjugates and composition may, for example, be administered intravascularly, intraperitoneally, subcutaneously, intra-20 muscularly or topically.

For oral administration, the pharmaceurical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the conjugate. Examples of such dosage units are tablets or capsules. These may with advantage contain an amount of conjugate from about 1 to 250 mg, preferably from about 25 to 150 mg. A suitable daily dose for a mammal may vary widely depending on the condition of the patient and other factors. However, a dose of from about 0.1 to 3000 mg/kg body weight, particularly from about 1 to 100 mg/kg body weight, may be appropriate.

The conjugate may also be administered by injection as a composition wherein, for example, saline, dextrose or water may be used as a suitable carrier. A suitable daily dose is from about 0.1 to 100 mg/kg body weight injected per day in multiple doses depending on the disease being treated. A preferred daily dose would be from about 1 to 30 mg/kg body weight. Conjugates indicated for prophylactic therapy will preferably be administered in a daily dose generally in a range from about 0.1 mg to about 100 mg per kilogram of body weight per day. A more 10 preferred dosage will be a range from about 1 mg to about 100 mg per kilogram of body weight. Most preferred is a dosage in a range from about 1 to about 50 mg per kilogram of body weight per day. A suitable dose can be administered, in multiple sub-doses per day. These sub-15 doses may be administered in unit dosage forms. Typically, a dose or sub-dose may contain from about 1 mg to about 100 mg of active compound per unit dosage form. A more preferred dosage will contain from about 2 mg to about 50 mg of active compound per unit dosage form. Most preferred 20 is a dosage form containing from about 3 mg to about 25 mg of active compound per unit dose.

The dosage regimen for treating a disease

25 condition with the conjugates and/or compositions of this invention is selected in accordance with a variety of factors, including the type, age, weight, sex and medical condition of the patient, the severity of the disease, the route of administration, and the particular conjugate

30 employed, and thus may vary widely.

For therapeutic purposes, the conjugates of this invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered per os, the conjugate may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium

and calcium salts of phosphoric and sulfur. acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets 5 may contain a controlled-release formulation as may be provided in a dispersion of conjugate in hydroxypropylmethyl cellulose. Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These 10 solutions and suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The conjugates may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, 15 cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.

Although this invention has been described with respect to specific embodiments, the details of these embodiments are not to be construed as limitations. Various equivalents, changes and modifications may be made without departing from the spirit and scope of this invention, and it is understood that such equivalent embodiments are part of this invention.

10

WHAT IS CLAIMED IS:

- 1. A conjugate comprising a residue of an angiotensin II antagonist compound, said conjugate being renal selective.
- 2. Conjugate of Claim 1 comprising a first residue and a second residue, said first and second residues connected together by a cleavable bond, wherein said first residue is provided by an angiotensin II antagonist compound, and wherein said second residue is capable of being cleaved from said first residue selectivity in the kidney.
- 3. Conjugate of Claim 2 wherein said first and second residues are provided by precursor compounds wherein the precursor compound of one of said first and second residues has a reactable carboxylic acid moiety and the precursor of the other of said first and second residues has a reactable amino moiety or a moiety convertible to a reactable amino moiety, whereby a cleavable bond may be formed between said carboxylic acid moiety and said amino moiety.
- 25 4. Conjugate of Claim 3 wherein said angiotensin II antagonist compound providing said first residue is selected from biphenylmethyl 1H-substituted-1,3-imidazole compounds.

5. Conjugate of Claim 4 wherein said angiotensin II antagonist compound is selected from a class of compounds defined by Formula I:

5 $R^{1} \xrightarrow{R^{2}} CH_{2} \xrightarrow{R^{3}} R^{4} \xrightarrow{R^{5}} R^{6}$ $R^{1} \xrightarrow{R^{2}} CH_{2} \xrightarrow{R^{3}} R^{4} \xrightarrow{R^{5}} R^{6}$ $R^{1} \xrightarrow{R^{2}} CH_{2} \xrightarrow{R^{3}} R^{4} \xrightarrow{R^{5}} R^{6}$ $R^{1} \xrightarrow{R^{5}} R^{6} \xrightarrow{R^{5}} R^{6}$ $R^{2} \xrightarrow{R^{5}} R^{6} \xrightarrow{R^{5}} R^{6}$ $R^{3} \xrightarrow{R^{5}} R^{6} \xrightarrow{R^{5}} R^{6}$ $R^{5} \xrightarrow{R^{5}} R^{6} \xrightarrow{R^{5}} R^{6}$

wherein m is a number selected from one to four, inclusive;

- wherein each of R⁰ through R¹¹ is independently selected from hydrido, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, formyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkenyl,
- cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl, mercaptothiocarbonyl, mercaptoalkyl, alkoxycarbonyloxy,
- alkylthio, cycloalkylthio, alkylthiocarbonyl, alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio, alkylthiothiocarbonyl, alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy,
- arylthiocarbonylthio, arylthiothiocarbonyl, arylthiothiocarbonylthio, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy, aralkylthiocarbonylthio, alkylthiocarbonyl, aralkylthiocarbonylthio, mercapto, alkylsulfinyl,
- 30 alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl,

20

25

30

arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl— and cyclohetero—containing groups has one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R⁰ through R¹¹ may be further independently selected from amino and amido radicals of the formula

wherein X is oxygen atom or sulfur atom;

wherein each n is a number independently selected from zero to six, inclusive;

wherein each of R¹² through R²⁴ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R¹² and R¹³ taken together, R¹⁴ and R¹⁵ taken together, R¹⁶ and R¹⁷ taken together may each form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical and which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein R¹² and R¹³ taken together, R¹⁴ and R¹⁵ taken together, R¹⁹ and R²⁰ taken together and R²¹ and R²¹ taken together may each form an aromatic heterocyclic

283

group having five ring members including the nitrogen atom of said amino or amido radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms;

and wherein each of \mathbb{R}^3 through \mathbb{R}^{11} may be further independently selected from hydrido and haloalkyl, and from acidic moieties of the formula

10

15

20

25

30


35

5

 $-Y_nA$

wherein n is a number selected from zero through three, inclusive, and wherein A is an acidic group selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms;


and wherein any of the foregoing R¹ through R²⁴, Y and A groups having a substitutable position may be substituted with one or more groups selected from hydroxy, alkyl, alkenyl, alkynyl, aralkyl, hydroxyalkyl, trifluoromethyl, difluoroalkyl, oxo, alkoxy, aryloxy, aralkoxy, aralkylthio, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aroyl, cycloalkenyl, cyano, cyanoamino, nitro, alkylcarbonyloxy, alkoxycarbonyloxy, alkylcarbonyl, alkoxycarbonyl, carboxyl, mercapto, mercaptocarbonyl, alkylthio, arylthio, arylthio, alkylthiocarbonyl, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfinyl, arylsulfinyl, arylsulfinyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and amino and amido radicals of the formula



wherein X is selected from oxygen atom and sulfur atom; wherein R²⁵ is selected from hydrido, alkyl, cycloalkyl, cycloalkyl, aralkyl, aryl, DR³⁰ and



wherein D is selected from oxygen atom and sulfur atom and R³⁰ is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R²⁵, R²⁶, R²⁷, R²⁸, R²⁹, R³¹ and R³² is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl, arylsulfonyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein each of R²⁶, R²⁷, R²⁸, R²⁹, R³¹ and R³² is further independently selected from amino and amido radicals of the formula



wherein X is oxygen atom or sulfur atom;

20

wherein each of R³³, R³⁴, R³⁵, R³⁶, R³⁷ and R³⁸ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein R²⁶ and R²⁷ taken together and R²⁸ and R²⁹ taken together may each form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical,

15

which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein R²⁶ and R²⁷ taken together and R³¹ and R³² taken together may each form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino or amido radical and which aromatic heterocyclic group may further contain one or mor letero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms;

with the proviso that at least one of said R^1 through R^{24} , Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

6. Conjugate of Claim 5 wherein m is one; wherein each of R⁰ through R¹¹ is independently selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aryloxyalkyl, alkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl,

mercaptothiocarbonyl, mercaptoalkyl, alkoxycarbonyloxy,

- mercaptothiocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, alkylthiocarbonyl, alkylcarbonylthio, alkylthiocarbonyloxy, alkylthio-carbonylthio, alkylthiothiocarbonyl, alkylthiothio-carbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio,
- 35 arylthiocarbonyloxy, arylthiocarbonylthio, arylthiothiocarbonyl, arylthiothiocarbonylthio, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio,

aralkylthiocarbonyloxy, aralkylthiocarbonylthio, aralkylthiocarbonyl, aralkylthiocarbonylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, 5 cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of ${\rm R}^{\,0}$ through ${\rm R}^{\,11}$ may be further independently selected from amino and amido radicals of the formula

15

10

wherein X is selected from oxygen atom or sulfur atom;

wherein each n is a number independently selected from zero 20 to six, inclusive;

wherein each of ${\bf R}^{12}$ through ${\bf R}^{24}$ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl;

and wherein each of \mathbb{R}^3 through \mathbb{R}^{11} may be further independently selected from hydrido and haloalkyl, and from acidic moieties of the formula

30

20

wherein n is a number selected from zero through three, inclusive; wherein A is an acidic group selected from acids containing one or more atoms selected from oxygen, sulfur, phosphorus and nitrogen atoms, and wherein said acidic group is selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms;

and wherein any of the foregoing R¹ through R²⁴, Y and A groups having a substitutable position may be substituted with one or more groups selected from alkyl, alkenyl, aralkyl, hydroxyalkyl, trifluoromethyl, difluoroalkyl, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, mercaptocarbonyl, alkylthio, alkylthiocarbonyl, and amino and amido radicals of the formula

$$X$$
 \parallel
 $-C-R^{25}$, $-N$
 R^{26}
 R^{27}
and $-NC-R^{28}$
 R^{29}

wherein X is selected from oxygen atom and sulfur atom; 25 wherein R^{25} is selected from hydrido, alkyl, cycloalkyl, cycloalkyl, aralkyl, aryl, and DR 30 and

$$-N < R^{31}$$

wherein D is selected from oxygen atom and sulfur atom, and R³⁰ is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R²⁶, R²⁷, R²⁸, R²⁹, R³¹ and R³² is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl,

cycloalkylalkyl, alkoxyalkyl, alkanoyl, alkoxycarbonyl, carboxyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein each of R^{26} , R^{27} , R^{28} , R^{29} , R^{31} and R^{32} is further independently selected from amino and amido radicals of the formula

$$-\mathrm{N} \underset{\mathrm{R}^{34}}{\overset{\mathrm{R}^{33}}{\stackrel{\mathrm{X}}{\longrightarrow}}} \underset{-\mathrm{CN}}{\overset{\mathrm{X}}{\overset{\mathrm{R}^{35}}{\longrightarrow}}} \underset{\mathrm{R}^{36}}{\overset{\mathrm{X}}{\overset{\mathrm{X}}{\longrightarrow}}} \underset{\mathrm{R}^{38}}{\overset{\mathrm{X}}{\overset{\mathrm{X}}{\longrightarrow}}}$$

wherein X is selected from oxygen atom or sulfur atom;

10

20

5

wherein each of R²⁶ through R³¹ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, haloalkylsulfinyl,

15 haloalkylsulfonyl, aralkyl and aryl;

with the proviso that at least one of said R¹ through R²⁴, Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

7. Conjugate of Claim 6 wherein m is one; wherein each of R⁰ through R¹¹ is independently selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aryloxyalkyl, alkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, mercaptocarbonyl, alkoxycarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, alkylthio, cycloalkylthio, arylthio, aralkylthio,

aralkylthiocarbonylthio, mercapto, alkylsulfinyl,

alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R⁰ through R¹¹ may be further independently selected from amino and amido radicals of the formula

wherein X is selected from oxygen taom or sulfur atom;

wherein each n is a number independently selected from zero to six, inclusive;

wherein each of R¹² through R²⁴ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl;

and wherein each of \mathbb{R}^3 through \mathbb{R}^{11} may be an acidic moiety further independently selected from hydrido and haloalkyl, and from acidic moieties of the formula

$$-Y_nA$$

30 wherein n is a number selected from zero through three, inclusive;

wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from

5

10

wherein each W is independently selected from oxygen atom, sulfur atom and NR 43 ; wherein each of R³⁹, R⁴⁰, R⁴¹, R⁴² and R⁴³ is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, cycloalkylalkyl, aryl and aralkyl; wherein each of R³⁹, R⁴⁰, R⁴¹ and R⁴² may be further independently selected from amino radicals of the formula

$$-N$$
 R^{44}
 R^{45}

15

20

25

30

wherein each of \mathbf{R}^{44} and \mathbf{R}^{45} is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein ${\rm R}^{44}$ and ${\rm R}^{45}$ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein \mathbf{R}^{44} and \mathbf{R}^{45} taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; wherein each of ${\rm R}^{\,40}$ and ${\rm R}^{\,41}$ may be further independently selected from hydroxy, alkoxy, alkylthio, aryloxy, arylthio, aralkylthio and aralkoxy; and the amide, ester and salt derivatives of said acidic groups;

wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members,


5 which heterocyclic ring contains at least one hetero atom selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R³ through R¹¹ or may be attached at any two adjacent positions selected from R³ through R¹¹ so as to form a fused-ring system with one of the phenyl rings of the biphenyl moiety of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups;

15

wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl;

and wherein any of the foregoing R¹ through R²⁴, Y and A groups having a substitutable position may be substituted by one or more groups selected from alkyl, difluoroalkyl, alkenyl, aralkyl, hydroxyalkyl, trifluoromethyl, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl,

25 alkoxycarbonyl, carboxyl, mercaptocarbonyl, alkylthio, alkylthiocarbonyl, and amino and amido radicals of the formula



30

wherein X is selected from oxygen atom and sulfur atom; wherein R^{25} is selected from hydrido, alkyl, cycloalkyl, cycloalkyl, aralkyl, aryl and DR 30 and

WO 92/02257 PCT/US91/05476

292



wherein D is selected from oxygen atom and sulfur atom, wherein R³⁰ is selected from hydrido, alkyl, cycloalkyl, cycloalkyl, aralkyl and aryl;

wherein each of R²⁶, R²⁷, R²⁸, R²⁹, R³¹ and R³² is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkanoyl, alkoxycarbonyl, carboxyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl;

with the proviso that at least one of said R¹ through R²⁴,

Y and A substituents contains a terminal primary or

secondary amino moiety or a moiety convertible to a primary
or secondary amino moiety;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

20

25

30

35

10

8. Conjugate of Claim 7 wherein m is one; wherein each of R⁰, R¹ and R² is independently selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, mercaptocarbonyl, mercaptoalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl, mercaptoalkyl, aralkylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfinyl, arylsulfinyl, aralkylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl

and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl— and cycloheteroalkyl—containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R⁰ through R¹¹ may be further independently selected from amino and amido radicals of the formula

10

wherein X is selected from oxygen atom and sulfur atom;

wherein each n is a number independently selected from zero to six, inclusive;

15

wherein each of R^{12} through R^{24} is independently selected from hydride. alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl;

20

25

30

wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, hoo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, alkylthio, aralkylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfinyl, arylsulfonyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms;

and wherein each of ${\bf R}^3$ through ${\bf R}^{11}$ may be an acidic moiety further independently selected from acidic moieties of the formula

$$-Y_nA$$

5

wherein n is a number selected from zero through three, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from

10

15

wherein each W is independently selected from oxygen atom, sulfur atom and NR 43 ; wherein each of R 39 , R 42 and R 43 is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, cycloalkyl, aryl and aralkyl; wherein each of R 39 and R 42 may be further independently selected from amino radical of the formula

20

25

30

35

wherein each of R^{44} and R^{45} is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R^{44} and R^{45} taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms, and which heterocyclic group may be saturated or partially unsaturated; wherein R^{44} and R^{45} taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen

WO 92/02257 PCT/US91/05476

295

and sulfur atoms; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, w ich ring contains at least one 5 hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from \mathbb{R}^3 through \mathbb{R}^{11} or may be attached at any two 10 adjacent positions selected from \mathbb{R}^3 through \mathbb{R}^{11} so as to form a fused-ring system with one of the phenyl rings of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups;

wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl;

15

35

wherein each of R¹ through R²⁴, Y and A independently may be substituted at any substitutable position with one or more groups selected from alkyl, cycloalkyl, cycloalkylalkyl, hydroxy, oxo, trifluoromethyl, difluoroalkyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy;

with the proviso that at least one of said R¹ through R²⁴,
Y and A substituents contains a terminal primary or
secondary amino moiety or a moiety convertible to a primary
or secondary amino moiety;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

9. Conjugate of Claim 8 wherein m is one; wherein each of R^0 , R^1 and R^2 is independently selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl,

cycloalkylalkyl, alkoxy, aralkyl, aryl, benzoyl, phenoxy, phenoxyalkyl, phenalkyloxy, phenylthio, phenalkylthio, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, 5 alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and 10 cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of ${\bf R}^0$ through ${\bf R}^{11}$ may be further independently selected from amino and amido 15 radicals of the formula

20

wherein X is selected from oxygen atom and sulfur atom;

wherein each n is a number independently selected from zero to six, inclusive;

25

wherein each of R^{12} through R^{24} is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl;

30 wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenalkyl,

15

30

35

297

phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio, mercapto and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms;

and wherein each of \mathbb{R}^3 through \mathbb{R}^{11} may be an acidic moiety further independently selected from acidic moieties of the formula

 $-Y_{n}$

wherein n is a number selected from zero through two, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from

wherein each W is independently selected from oxygen atom, sulfur atom and NR⁴³; wherein each of R³⁹, R⁴² and R⁴³ is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, phenyl and benzyl; wherein each of R³⁹ and R⁴² may be further independently selected from amino radical of the formula

 $-N < R^{44}$ 25

wherein each of R^{44} and R^{45} is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, alkoxyalkyl, benzyl and phenyl; and the amide, ester and salt derivatives of said acidic groups;

wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from

WO 92/02257 PCT/US91/05476

oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from \mathbb{R}^3 through \mathbb{R}^{11} or may be attached at any two adjacent positions selected from \mathbb{R}^3 through \mathbb{R}^{11} so as to form a fused-ring system with one of the phenyl rings of the biphenyl moiety of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups;

10

wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, phenyl, phenalkyl and aralkyl;

wherein each of R¹ through R²⁴, Y and A and independently may be substituted at any substitutable position with one or more groups selected from alkyl, cycloalkyl, cycloalkylalkyl, hydroxy, oxo, trifluoromethyl, difluoroalkyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy;

with the proviso that at least one of said R¹ through R²⁴, Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

30

35

25

10. Conjugate of Claim 9 wherein m is one; wherein R⁰ is selected from alkyl, alkenyl, phenyl, alkylthio, cycloalkyl, cycloalkylalkyl and cycloalkylthio; wherein each of R¹ and R² is independently selected from alkyl, aminoalkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, benzoyl, phenoxy, phenoxyalkyl, phenalkyloxy, phenylthio, phenalkylthio, aralkoxy, alkoxyalkyl, acetyl,

20

25

alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, mercaptoalkyl, mercaptocarbonyl, alkoxycarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, phthalimido, phthalimidoalkyl, imidazoalkyl, tetrazole, tetrazolealkyl, alkylthio, cycloalkylthio, and amino and amido radicals of the formula

wherein X is selected from oxygen atom and sulfur atom;

wherein each n is a number independently selected from zero to six, inclusive;

wherein each of R^{12} through R^{24} is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl;

wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenalkyl, phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, acetyl, alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio and mercapto;

and wherein each of R^3 through R^{11} may be an acidic moiety further independently selected from acidic moieties consisting of CO_2H , CO_2CH_3 , SH, CH_2SH , C_2H_4SH , PO_3H_2 , $NHSO_2CF_3$, $NHSO_2C_6F_5$, SO_3H , $CONHNH_2$, $CONHNHSO_2CF_3$, $CONHOCH_3$, $CONHOCC_2H_5$, $CONHCF_3$, OH, CH_2OH , C_2H_4CH , OPO_3H_2 , OSO_3H ,

wherein each of R⁴⁶, R⁴⁷ and R⁴⁸ is independently selected from H, Cl, CN, NO₂, CF₃, C₂F₅, C₃F₇, CHF₂, CH₂F, CO₂CH₃, CO₂C₂H₅, SO₂CH₃, SO₂CF₃ and SO₂C₆F₅; wherein Z is selected from O, S, NR⁴⁹ and CH₂; wherein R⁴⁹ is selected from hydrido, CH₃ and CH₂C₆H₅; and wherein said acidic moiety may be a heterocyclic acidic group attached at any two adjacent positions of R³ through R¹¹ so as to form a fused ring system so as to include one of the phenyl rings of the biphenyl moiety of Formula I, said biphenyl fused ring system selected from

and the esters, amides and salts of said acidic moieties;

- with the proviso that at least one of said R¹ through R²⁴ substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;
- or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
 - 11. Conjugate of Claim 10 wherein m is one; wherein R^0 is selected from $C_4H_9\,(n)$, $CH_3CH_2CH=CH$, $C_3H_7\,(N)$,

CH₂CO₂H, CH (CH₃)CO₂H, NO₂, Cl,
$$\stackrel{N-N}{\downarrow}_{H}$$
,

-CH₂OCOCH₂CH₂
$$\longrightarrow$$
 , -CO₂CH₃, -CONH₂, -CONHCH₃, CON(CH₃)₂,

-CH2NHCO2CH2(CH3)2, -CH2NHCO2C4H9, CH2NHCO2-adamantyl,

5 -CH2NHCO2-(1-napthyl), -CH2NHCONHCH3, -CH2NHCONHC2H5,


-CH2NHCONHC3H7, -CH2NHCONHC4H9, -CH2NHCONHCH(CH3)2,

-CH2NHCONH(1-napthyl), -CH2NHCONH(1-adamantyl), CO2H,

-CH₂-N

-CH₂CH₂CH₂F, -CH₂ONO₂, , -CH₂SH, -CH₂O-O,

12. Cl, NO₂, CF₃, CH₂OH, Br, F, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl, 1,1-dimethoxypropyl, 1,1-dimethoxybutyl, 1,1-dimethoxypentyl, hydroxyalkyl, halo, difluoromethyl, 1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl and 1,1-difluoropentyl; wherein each of R³ through ¹¹ is hydrido, with the proviso that at least one of R⁵, R⁶, R⁸ and R⁹ is an acidic group selected from CO₂H,



SH, PO₃H₂, SO₃H, CONHNH₂, CONHNHSO₂CF₃, OH,

25 wherein each of R^{46} and R^{47} is independently selected from C1, CN, NO₂, CF₃, CO₂CH₃ and SO₂CF₃;

with the proviso that at least one of said R^1 through R^{11} substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

12. Conjugate of Claim 11 wherein m is one; wherein R⁰ is selected from C₄H₉(n), CH₃CH₂CH=CH, C₃H₇(N), SC₃H₇, C₂H₅, C₅H₁₁(n), C₆H₁₃(n), SC₄H₉, CH₂S, CH₃CH=CH and CH₃CH₂CH=CH-; wherein R¹ is selected from amino, aminomethyl, aminoethyl,

aminopropyl, CH₂OH, CH₂OCOCH₃, CH₂Cl, Cl, CH₂OCH₃, CH₂OCH (CH₃)₂, I, CHO, CH₂CO₂H, CH (CH₃)₂CO₂H, -CO₂CH₃, -CONH₂, -CONHCH₃, CON (CH₃)₂,

-CH₂-NHCO₂C₂H₅, -CH₂NHCO₂ -CH₂NHCO₂CH₃, -CH₂NHCO₂C₃H₇,

-CH 2NHCO 2CH2 (CH 3) 2, -CH2NHCO 2C 4H 9, CH 2NHCO 2-adamantyl, - 20 CH2NHCO 2-(1-napthyl), -CH2NHCONHCH3, -CH2NHCONHC 2H5, - CH2NHCONHC 3H7, -CH2NHCONHC 4H9, -CH2NHCONHCH (CH3) 2, - CH2NHCONH (1-napthyl), -CH2NHCONH (1-adamantyl), CO2H,

-CH₂CH₂-CO
$$-$$
N \bigcirc O, -CH₂CH₂CH₂CO₂H,

-CH₂CH₂F, -CH₂OCONHCH₃, -CH₂CH₂CH₂F, -CH₂SH and -CH₂O-O;

wherein R² is selected from H, Cl, NO₂, CF₃, CH₂OH, Br, F,

I, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl,
isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl,
phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, 1oxoethyl, 1- xopropyl, 1-oxobutyl, 1-oxopentyl, 1,1
dimethoxypropyl, 1,1-dimethoxybutyl, 1 1-dimethoxypontyl

dimethoxypropyl, 1,1-dimethoxybutyl, 1,1-dimethoxypentyl, hydroxyalkyl, halo, difluoromethyl, 1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl and 1,1-difluoropentyl; wherein each of R³ through ¹¹ is hydrido, with the proviso that at least one of R⁵, R⁶, R⁸ and R⁹ is an acidic group

SUBSTITUTE SHEET

5

20

25

selected from CO₂H, SH, PO₃H₂, SO₃H, CONHNH₂, CONHNHSO₂CF₃, OH,

wherein each of R^{46} and R^{47} is independently selected from Cl, CN, NO₂, CF₃, CO₂CH₃ and SO₂CF₃;

with the proviso that at least one of said R¹ through R¹¹
substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

13. Conjugate of Claim 11 wherein m is one; wherein R⁰ is selected from C₄H₉(n), CH₃CH₂CH=CH, C₃H₇(N), C₂H₅, C₂H₅, C₅H₁₁(n), C₆H₁₃(n),

 $SC_{3}H_{7}$, $C_{2}H_{5}$, $C_{5}H_{11}(n)$, $C_{6}H_{13}(n)$,

SC₄H₉, CH₂S, CH₃CH=CH and CH₃CH₂CH=CH-; wherein R¹ is selected from H, Cl, NO₂, CF₃, CH₂OH, Br, F, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl, 1,1-dimethoxypropyl, 1,1-dimethoxybutyl, 1,1-dimethoxypentyl, hydroxyalkyl, halo, difluoromethyl, 1,1-difluoroethyl, 1,1-

difluoropropyl, 1,1-difluorobutyl and 1,1-difluoropentyl; wherein R² is selected from amino, aminomethyl, aminoethyl, aminopropyl, CH₂OH, CH₂OCOCH₃, CH₂Cl, Cl, CH₂OCH₃, CH₂OCH (CH₃)₂, I, CHO, CH₂CO₂H, CH(CH₃)CO₂H, ,-CO₂CH₃, -CONH₂, -CONHCH₃, CON(CH₃)₂,

25

305

-CH₂NHCO₂CH₂(CH₃)₂, -CH₂NHCO₂C₄H₉, CH₂NHCO₂-adamantyl,

-CH $_2$ NHCO $_2$ -(1-napthyl), -CH $_2$ NHCONHCH $_3$, -CH $_2$ NHCONHC $_2$ H $_5$,

-CH₂NHCONHC₃H₇, -CH₂NHCONHC₄H₉, -CH₂NHCONHCH(CH₃)₂,

5 -CH₂NHCONH(1-napthyl), -CH₂NHCONH(1-adamantyl), CO₂H,

 $CH_2CH_2CH_2F$, $-CH_2SH$ and $-CH_2O$

wherein each of R^3 through 11 is hydrido, with the proviso that at least one of R^5 , R^6 , R^8 and R^9 is an acidic group selected from CO_2H , SH, PO_3H_2 , SO_3H , $CONHNH_2$, $CONHNHSO_2CF_3$, OH,

wherein each of R^{46} and R^{47} is independently selected from Cl, CN, NO₂, CF₃, CO₂CH₃ and SO₂CF₃;

with the proviso that at least one of said R¹ through R¹¹ substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

14. Conjugate of Claim 3 wherein said second residue forms a kidney-enzyme-cleavable amide bond with the residue of said angiotensin II antagonist compound.

30 15. Conjugate of Claim 14 wherein said second residue is provided by a compound of Formula II:

wherein each of R⁵⁰ and R⁵¹ may be independently selected from hydrido, alkylcarbonyl, alkoxycarbonyl, alkoxyalkyl, hydroxyalkyl and haloalkyl; and wherein G is selected from hydroxyl, halo, mercapto, -OR⁵², -SR⁵³ and NR⁵⁴ with each of R⁵², R⁵³ and R⁵⁴ independently selected from hydrido and alkyl; with the proviso that said Formula II compound is selected such that formation of the cleavable amide bond occurs at carbonyl moiety attached at the gamma-position carbon of said Formula II compound.

16. Conjugate of Claim 15 wherein each G substituent is hydroxy.

15

- 17. Conjugate of Claim 16 wherein each G substituent is hydroxy; wherein ${\bf R}^{50}$ is hydrido; and wherein ${\bf R}^{51}$ is selected from
- 20 -CR⁵⁵ wherein R⁵⁵ is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, neopentyl, n-hexyl and chloromethyl.
- 18. Conjugate of Claim 17 wherein said second 25 residue is

$$\begin{array}{cccc} \text{O} & \text{COOH} \\ \parallel & \parallel \\ -\text{CCH}_2\text{CH}_2\text{CHNHCCH}_3 \\ \gamma & \beta & \alpha & \parallel \\ \text{O} \end{array}$$

19. Conjugate of Claim 18 wherein said first 30 residue is an angiotensin II antagonist compound containing

a terminal primary or secondary amino moiety selected from amino and linear or branched aminoalkyl moieties containing linear or branched alkyl groups selected from aminomethyl, aminoethyl, aminopropyl, aminoisopropyl, aminobutyl, aminosecbutyl, aminoisobutyl, aminotertbutyl, aminopentyl, aminoisopentyl and aminoneopentyl.

- 20. Conjugate of Claim 3 wherein said first residue is an angiotensin II antagonist compound containing a moiety convertible to a primary or secondary amino terminal moiety.
- 21. Conjugate of Claim 20 wherein said moiety convertible to an amino terminal moiety is a carboxylic acid group reactable with an amino moiety of a diaminoterminated linker group to provide a terminal amino moiety which may then be further reacted with a carboxylic acid moiety of a compound providing said second residue sc as to form a hydrolyzable amide bond.

20

10

15

22. Conjugate of Claim 21 wherein said iamino-terminated linker group is a divalent radical of Formula III:

25

$$-\frac{\stackrel{?}{\downarrow}^{200}}{N} \frac{\stackrel{R^{201}}{\downarrow}}{N} -$$
 (III)

wherein each of R²⁰⁰ and R²⁰¹ may be independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, hydroxyalkyl, aralkyl, aryl, haloalkyl, amino, monoalkylamino, dialkylamino, cyanoamino, carboxyalkyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl and arylsulfonyl; and wherein n is zero or a number selected from three through seven, inclusive.

- 23. Conjugate of Claim 24 wherein each of \mathbb{R}^{200} and \mathbb{R}^{201} is hydrido.
- 24. Conjugate of Claim 21 wherein said diamino-5 terminated linker group is a divalent radical of Formula IV:




10 wherein each of Q and T is one or more groups independently selected from

$$\begin{bmatrix}
R^{202} \\
C
\end{bmatrix}$$
and
$$\begin{bmatrix}
R^{204} & R^{205} \\
C
\end{bmatrix}$$

$$C = C$$

- wherein each of R²⁰² through R²⁰⁵ is independently selected from hydrido, hydroxy, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, alkoxy, aralkoxy, aryloxy, alkoxyalkyl, haloalkyl, hydroxyalkyl, halo, cyano, amino, monoalkylamino, dialkylamino, carboxy, carboxyalkyl, alkanoyl, alkenyl, cycloalkenyl and alkynyl.
 - 25. Conjugate of Claim 24 wherein said diaminoterminated linker group is a divalent radical of Formula V:

WO 92/02257 PCT/US91/05476



wherein each of R²⁰² and R²⁰³ is independently selected from hydrido, hydroxy, alkyl, phenalkyl, phenyl, alkoxy, benzyloxy, phenoxy, alkoxyalkyl, hydroxyalkyl, halo, amino, monoalkylamino, dialkylamino, carboxy, carboxyalkyl and alkanoyl; and wherein each of p and q is a number independently selected from one through six, inclusive; with the proviso that when each of R²⁰² and R²⁰³ is selected from halo, hydroxy, amino, monoalkylamino and dialkylamino, then the carbon to which R²⁰² or R²⁰³ is attached in Formula V is not adjacent to a nitrogen atom of Formula V.

26. Conjugate of Claim 25 wherein each of R²⁰² and R²⁰³ is independently selected from hydrido, hydroxy, alkyl, alkoxy, amino, monoalkylamino, carboxy, carboxyalkyl and alkanoyl; and wherein each of p and q is a number independently selected from two through four, inclusive.

20

25

27. Conjugate of Claim 26 wherein each of R^{202} and R^{203} is independently selected from hydrido, amino, monoalkylamino and carboxyl; and wherein each of p and q is independently selected from the numbers two and three.

 $\,$ 28. Conjugate of Claim 27 wherein each of R 202 and R 203 is hydrido; and wherein each of p and q is two.

29. Conjugate of Claim 21 wherein said diaminoterminated linker group is a divalent radical of Formula VI:

$$\begin{array}{c|c}
R^{214} & R^{216} \\
-N & C \\
R^{217} \\
\end{array}$$

$$\begin{array}{c}
R^{215} \\
N \\
\end{array}$$
(VI)

5

10

wherein each of R²¹⁴ through R²¹⁷ is independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, aralkyl, aryl, haloalkyl, amino, monoalkylamino, dialkylamino, cyanoamino, carboxyalkyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl and arylsulfonyl; and wherein p is a number selected from one through six inclusive.

30. Conjugate of Claim 29 wherein each of R²¹⁴ and R²¹⁵ is hydrido; wherein each of R²¹⁶ and R²¹⁷ is independently selected from hydrido, alkyl, phenalkyl, phenyl, alkoxyalkyl, hydroxyalkyl, haloalkyl and carboxyalkyl; and wherein p is two or three.

20

31. Conjugate of Claim 30 wherein each of R^{214} and R^{215} is hydrido; wherein each of R^{216} and R^{217} is independently selected from hydrido and alkyl; and wherein p is two.

25

- 32. Conjugate of Claim 31 wherein each of R^{214} , R^{215} , R^{216} and R^{217} is hydrido; and wherein p is two.
- 33. Conjugate of Claim 12 wherein said
 30 angiotensin II antagonist compound is 4'-[2-butyl-5-chloro-4-(hydroxymethyl)-1H-imidazol-1-ylmethyl][1,1'-biphenyl]-2-carboxylic acid.
- 34. Conjugate of Claim 33 which is N-acetyl-L-35 glutamic acid, 5-[[4'-[2-butyl-5-chloro-4-(hydroxymethyl)-

1H-imidazol-1-ylmethyl][1,1'-biphenyl]-2-yl]carbonyl]hydrazide.

- 35. Conjugate of Claim 33 which is N²-acetyl-N-5 [[2-butyl-5-chloro-1-[[2'-(1H-tetrazol-5-yl)]1,1'-biphenyl]-4-yl]methyl]-1H-imidazol-4-yl]methyl]-L-glutamine.
- 36. Conjugate of Claim 33 which is N-acetyl-L-glutamic acid, 5-[2-butyl-5-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazol-4-yl]acetylhydrazide.
- 37. Conjugate of Claim 13 wherein said
 15 angiotensin II antagonist compound is 4'-[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-ylmethyl][1,1'-biphenyl]-2-carboxylic acid.
- 38. Conjugate of Claim 37 which is N-acetyl-L20 glutamic acid, 5-[[4'-[2-butyl-4-chloro-5-(hydroxymethyl)1H-imidazol-1-ylmethyl][1,1'-biphenyl]-2yl]carbonyl]hydrazide.
- 39. Conjugate of Claim 37 which is N²-acetyl-N-25 [[2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazol-5-yl]methyl]-L-glutamine.
- 40. Conjugate of Claim 37 which is N-acetyl-L-glutamic acid, 5-[2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazol-5-yl]acetylhydrazide.

- 41. A pharmaceutical composition comprising one or more pharmaceutically-acceptable carriers or diluents and a therapeutically-effective amount of a renal-selective conjugate, said conjugate comprising a residue of an angiotensin II antagonist compound.
- 42. The composition of Claim 41 wherein said conjugate comprises first residue and a second residue, said first and second residues connected together by a cleavable bond, wherein said first residue is provided by an angiotensin II antagonist compound, and wherein said second residue is capable of being cleaved from said first residue.
- first and second residues are provided by precursor compounds wherein the precursor compound of one of said first and second residues has a reactable carboxylic acid moiety and the precursor of the other of said first and second residues has a reactable amino moiety or a moiety convertible to a reactable amino moiety, whereby a cleavable bond may be formed between said carboxylic acid moiety and said amino moiety.
- 25 44. The composition of Claim 43 wherein said angiotensin II antagonist compound providing said first residue is selected from biphenylmethyl 1H-substituted-1,3-imidazole compounds.
- 30 45. The composition of Claim 44 wherein said angiotensin II antagonist compound is selected from a class of compounds defined by Formula I:

WO 92/02257 PCT/US91/05476

313

wherein m is a number selected from one to four, inclusive;

wherein each of R⁰ through R¹¹ is independently selected from hydrido, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, formyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, pitro, garbonyl

cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl, mercaptothiocarbonyl, mercaptoalkyl, alkoxycarbonyloxy,

alkylthio, cycloalkylthio, alkylthiocarbonyl, alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio, alkylthiothiocarbonyl, alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy,

arylthiocarbonylthio, arylthiothiocarbonyl, arylthiothiocarbonylthio, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyl, aralkylthiocarbonyl io, a'kylthiocarbonyl, aralkylthiocarbonyl io, murcapto, alkylsulfinyl,

alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cyclohetero-containing

30 groups has one or more ring atoms selected from oxygen,

20

25

30

sulfur atoms;

sulfur and nitrogen atoms, and wherein each of ${\rm R}^{\,0}$ through ${\rm R}^{11}$ may be further independently selected from amino and amido radicals of the formula

wherein X is oxygen atom or sulfur atom;

10 wherein each n is a number independently selected from zero to six, inclusive;

wherein each of R^{12} through R^{24} is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R^{12} and R^{13} taken together, R^{14} and R^{15} taken together, R^{16} and R^{17} taken together, R^{19} and R^{20} taken together and R^{21} and R^{22} taken together may each form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical and which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein \mathbf{R}^{12} and \mathbf{R}^{13} taken together, \mathbf{R}^{14} and R^{15} taken together, R^{19} and R^{20} taken together and R^{21} and \mathbb{R}^{22} taken together may each form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino or amido radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and

WO 92/02257 PCT/US91/05476

315

and wherein each of \mathbb{R}^3 through \mathbb{R}^{11} may be further independently selected from hydrido and haloalkyl, and from acidic moieties of the formula

5

10

15

 $-Y_nA$

wherein n is a number selected from zero through three, inclusive, and wherein A is an acidic group selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms;

and wherein any of the foregoing \mathbb{R}^1 through \mathbb{R}^{24} , Y and A groups having a substitutable position may be substituted with one or more groups selected from hydroxy, alkyl, 20 alkenyl, alkynyl, aralkyl, hydroxyalkyl, trifluoromethyl, difluoroalkyl, oxo, alkoxy, aryloxy, aralkoxy, aralkylthio, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aroyl, cycloalkenyl, cyano, cyanoamino, nitro, alkylcarbonyloxy, alkoxycarbonyloxy, alkylcarbonyl, alkoxycarbonyl, carboxyl, 25 mercapto, mercaptocarbonyl, alkylthio, arylthio, alkylthiocarbonyl, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and amino 30 and amido radicals of the formula

$$X$$
 \parallel
 $-C-R^{25}$, $-N$
 R^{26}
 R^{27}
and $-NC-R^{28}$

wherein X is selected from oxygen atom and sulfur atom;

wherein R²⁵ is selected from hydrido, alkyl, cycloalkyl, cycloalkyl, aralkyl, aryl, DR³⁰ and



wherein D is selected from oxygen atom and sulfur atom and R³⁰ is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R²⁵, R²⁶, R²⁷, R²⁸, R²⁹, R³¹ and R³² is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl, arylsulfonyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein each of R²⁶, R²⁷, R²⁸, R²⁹, R³¹ and R³² is further independently selected from amino and amido radicals of the formula

$$-N \underset{\mathbb{R}^{34}}{\overset{X}{\swarrow}}, \quad \overset{X}{\overset{X}{\longleftarrow}} \underset{\mathbb{R}^{36}}{\overset{X}{\Longrightarrow}} \quad \text{and} \quad \overset{X}{\underset{\mathbb{R}^{38}}{\overset{X}{\longleftarrow}}}$$

wherein X is oxygen atom or sulfur atom;

wherein each of \mathbb{R}^{33} , \mathbb{R}^{34} , \mathbb{R}^{35} , \mathbb{R}^{36} , \mathbb{R}^{37} and \mathbb{R}^{38} is 20 independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein R^{26} and ${\rm R}^{27}$ taken together and ${\rm R}^{28}$ and ${\rm R}^{29}$ taken together may each 25 form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be 30 saturated or partially unsaturated; wherein R^{26} and R^{27} taken together and \mathbb{R}^{31} and \mathbb{R}^{32} taken together may each form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino or amido radical

WO 92/02257 PCT/US91/05476

317

and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms;

- with the proviso that at least one of said R¹ through R²⁴, Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;
- or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
- 46. The composition of Claim 45 wherein m is one; wherein each of R⁰ through R¹¹ is independently selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl,
- 20 carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl, mercaptothiocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, alkylthiocarbonyl,
- alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio, alkylthiothiocarbonyl, alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy, arylthiocarbonylthio, arylthiothiocarbonyl, arylthiothiocarbonylthio,
- aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy, aralkylthiocarbonylthio, aralkylthiocarbonyl, aralkylthiocarbonylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, phthalimido,
- phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has

one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of ${\bf R}^{\,0}$ through ${\bf R}^{\,11}$ may be further independently selected from amino and amido radicals of the formula

wherein X is selected from oxygen atom or sulfur atom;

wherein each n is a number independently selected from zero to six, inclusive;

wherein each of R¹² through R²⁴ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl;

and wherein each of R³ through R¹¹ may be further

20 independently selected from hydrido and haloalkyl, and from acidic moieties of the formula

$$-Y_nA$$

wherein n is a number selected from zero through three, inclusive; wherein A is an acidic group selected from acids containing one or more atoms selected from oxygen, sulfur, phosphorus and nitrogen atoms, and wherein said acidic group is selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl,

cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms;

and wherein any of the foregoing R¹ through R²⁴, Y and A groups having a substitutable position may be substituted with one or more groups selected from alkyl, alkenyl, aralkyl, hydroxyalkyl, trifluoromethyl, difluoroalkyl, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, mercaptocarbonyl, alkylthio, alkylthiocarbonyl, and amino and amido radicals of the formula

$$X$$
 \parallel
 $-C-R^{25}$, $-N$
 R^{26}
 R^{27}
and $-NC-R^{28}$
 R^{29}

15

wherein X is selected from oxygen atom and sulfur atom; wherein R^{25} is selected from hydrido, alkyl, cycloalkyl, cycloalkyl, aralkyl, aryl, and DR 30 and

$$-N < R^{31}$$

20

25

30

wherein D is selected from oxygen atom and sulfur atom, and R^{30} is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R^{26} , R^{27} , R^{28} , R^{29} , R^{31} and R^{32} is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkanoyl, alkoxycarbonyl, carboxyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein each of R^{26} , R^{27} , R^{28} , R^{29} , R^{31} and R^{32} is further independently selected from amino and amido radicals of the formula

wherein X is selected from oxygen atom or sulfur atom;

wherein each of R²⁶ through R³¹ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl;

10

15

with the proviso that at least one of said R¹ through R²⁴, Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

47. The composition of Claim 46 wherein m is one; wherein each of R⁰ through R¹¹ is independently selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl,

- alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, mercaptocarbonyl, alkoxycarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonyloxyalkyl, aralkylcarbonyloxyalkyl, alkylthio, cycloalkylthio,
- arylthio, aralkylthio, aralkylthiocarbonylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and
- 35 cycloheteroalklylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has one

or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R^0 through R^{11} may be further independently selected from amino and amido radicals of the formula

5

wherein X is selected from oxygen taom or sulfur atom;

10

wherein each n is a number independently selected from zero to six, inclusive;

- wherein each of ${\bf R}^{12}$ through ${\bf R}^{24}$ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, 15 monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl;
- and wherein each of \mathbb{R}^3 through \mathbb{R}^{11} may be an acidic moiety further independently selected from hydrido and haloalkyl, 20 and from acidic moieties of the formula

$$-Y_nA$$

25

wherein n is a number selected from zero through three, inclusive;

wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from

30

wherein each W is independently selected from oxygen atom, sulfur atom and NR 43 ; wherein each of R 39 , R 40 , R 41 , R 42 and \mathbb{R}^{43} is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, cycloalkylalkyl, aryl and aralkyl; wherein each of \mathbb{R}^{39} , \mathbb{R}^{40} , \mathbb{R}^{41} and \mathbb{R}^{42} may be further independently selected from amino radicals of the formula

10

15

20

30

5

$$-N$$
 R^{44}
 R^{45}

wherein each of \mathbb{R}^{44} and \mathbb{R}^{45} is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein ${\it R}^{44}$ and ${\it R}^{45}$ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein \mathbf{R}^{44} and \mathbf{R}^{45} taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more 25 hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; wherein each of \mathbf{R}^{40} and \mathbf{R}^{41} may be further independently selected from hydroxy, alkoxy, alkylthio, aryloxy, arylthio, aralkylthio and aralkoxy; and the amide, ester and salt derivatives of said acidic groups;

wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of

10

15

20

25

heterocyclic rings of four to about nine ring members, which heterocyclic ring contains at least one hetero atom selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R³ through R¹¹ or may be attached at any two adjacent positions selected from R³ through R¹¹ so as to form a fused-ring system with one of the phenyl rings of the biphenyl moiety of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups;

wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl;

and wherein any of the foregoing R¹ through R²⁴, Y and A groups having a substitutable position may be substituted by one or more groups selected from alkyl, difluoroalkyl, alkenyl, aralkyl, hydroxyalkyl, trifluoromethyl, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, mercaptocarbonyl, alkylthio, alkylthiocarbonyl, and amino and amido radicals of the formula

wherein X is selected from oxygen atom and sulfur atom; wherein R²⁵ is selected from hydrido, alkyl, cycloalkyl, cycloalkyl, aralkyl, aryl and DR³⁰ and

wherein D is selected from oxygen atom and sulfur atom, wherein R^{30} is selected from hydrido, alkyl, cycloalkyl, cycloalkyl, aralkyl and aryl;

wherein each of R²⁶, R²⁷, R²⁸, R²⁹, R³¹ and R³² is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkanoyl, alkoxycarbonyl, carboxyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl;

with the proviso that at least one of said R^1 through R^{24} , Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary

or secondary amino moiety;

15

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

48. The composition of Claim 47 wherein m is

20 one; wherein each of R⁰, R¹ and R² is independently selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl, mercaptoalkyl,

alkoxycarbonyloxy, alkylthio, cycloalkylthio, arylthio,
aralkylthio, mercapto, alkylsulfinyl, alkylsulfonyl,
aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl,
arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl,
heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl
and cycloheteroalkylcarbonylalkyl wherein each of said

35 heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R⁰ through R¹¹ may be

15

30

further independently selected from amino and amido radicals of the formula

wherein X is selected from oxygen atom and sulfur atom;

wherein each n is a number independently selected from zero to six, inclusive;

wherein each of R¹² through R²⁴ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl;

wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, al.oxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, alkylthio, aralkylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfinyl, arylsulfinyl, arylsulfonyl and heteroaryl having one or more ring atoms

and wherein each of \mathbb{R}^3 through \mathbb{R}^{11} may be an acidic moiety further independently selected from acidic moieties of the formula

 $-Y_nA$

selected from oxygen, sulfur and nitrogen atoms;

wherein n is a number selected from zero through three, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from

wherein each W is independently selected from oxygen atom, sulfur atom and NR 43 ; wherein each of R 39 , R 42 and R 43 is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, cycloalkylalkyl, aryl and aralkyl; wherein each of R 39 and R 42 may be further independently selected from amino radical of the formula

$$-N$$
 R^{44}
 R^{45}

15

20

25

30

35

5

10

wherein each of \mathbf{R}^{44} and \mathbf{R}^{45} is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein ${
m R}^{44}$ and ${
m R}^{45}$ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms, and which heterocyclic group may be saturated or partially unsaturated; wherein \mathbf{R}^{44} and \mathbf{R}^{45} taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one

WO 92/02257 PCT/US91/05476

327

hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R³ through R¹¹ or may be attached at any two adjacent positions selected from R³ through R¹¹ so as to form a fused-ring system with one of the phenyl rings of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups;

10

wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl;

wherein each of R¹ through R²⁴, Y and A independently may be substituted at any substitutable position with one or more groups selected from alkyl, cycloalkyl, cycloalkylalkyl, hydroxy, oxo, trifluoromethyl, difluoroalkyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy;

with the proviso that at least one of said R¹ through R²⁴, Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

30

35

25

49. The composition of Claim 48 wherein m is one; wherein each of R⁰, R¹ and R² is independently selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, benzoyl, phenoxy, phenoxyalkyl, phenalkyloxy, phenylthio, phenalkylthio, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy,

10

alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R⁰ through R¹¹ may be further independently selected from amino and amido radicals of the formula

15

wherein X is selected from oxygen atom and sulfur atom;

wherein each n is a number independently selected from zero to six, inclusive;

20

- wherein each of R^{12} through R^{24} is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl;
- wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenalkyl, phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio, mercapto and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms;

and wherein each of ${\bf R}^3$ through ${\bf R}^{11}$ may be an acidic moiety further independently selected from acidic moieties of the formula

 $-y_nA$

10

15

25

30

35

wherein n is a number selected from zero through two, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from

wherein each W is independently selected from oxygen atom, sulfur atom and NR 43 ; wherein each of R³⁹, R⁴² and R⁴³ is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, phenyl and benzyl; wherein each of R³⁹ and R⁴² may be further independently selected from amino radical of the formula

20 -N < R⁴⁴

wherein each of R^{44} and R^{45} is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, alkoxyalkyl, benzyl and phenyl; and the amide, ester and salt derivatives of said acidic groups;

wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R³ through R¹¹ or may be attached at any two adjacent positions selected from R³

WO 92/02257 PCT/US91/05476

through R^{11} so as to form a fused-ring system with one of the phenyl rings of the biphenyl moiety of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups;

5

wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, phenyl, phenyl, and aralkyl;

wherein each of R¹ through R²⁴, Y and A and independently may be substituted at any substitutable position with one or more groups selected from alkyl, cycloalkyl, cycloalkylalkyl, hydroxy, oxo, trifluoromethyl, difluoroalkyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy;

with the proviso that at least one of said R^1 through R^{24} , Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

25

30

35

20

50. The composition of Claim 49 wherein m is one; wherein R⁰ is selected from alkyl, alkenyl, phenyl, alkylthio, cycloalkyl, cycloalkylalkyl and cycloalkylthio; wherein each of R¹ and R² is independently selected from alkyl, aminoalkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, benzoyl, phenoxy, phenoxyalkyl, phenalkyloxy, phenylthio, phenalkylthio, aralkoxy, alkoxyalkyl, acetyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, mercaptoalkyl, mercaptocarbonyl, alkoxycarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl,

20

phthalimido, phthalimidoalkyl, imidazoalkyl, tetrazole, tetrazolealkyl, alkylthio, cycloalkylthio, and amino and amido radicals of the formula

wherein X is selected from oxygen atom and sulfur atom;

wherein each n is a number independently selected from zero 10 to six, inclusive;

wherein each of R^{12} through R^{24} is independently selected from hydrido, alkyl, cycl lkyl, cyano, amino, hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl;

wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenalkyl, phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, acetyl, alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio and mercapto;

and wherein each of R^3 through R^{11} may be an acidic moiety further independently selected from acidic moieties consisting of CO_2H , CO_2CH_3 , SH, CH_2SH , C_2H_4SH , PO_3H_2 , $NHSO_2CF_3$, $NHSO_2C_6F_5$, SO_3H , $CONHNH_2$, $CONHNHSO_2CF_3$, $CONHOCH_3$, $CONHOC_2H_5$, $CONHCF_3$, OH, CH_2OH , C_2H_4OH , OPO_3H_2 , OSO_3H ,

wherein each of R^{46} , R^{47} and R^{48} is independently selected from H, Cl, CN, NO₂, CF₃, C₂F₅, C₃F₇, CHF₂, CH₂F, CO₂CH₃, CO₂CC₂H₅, SO₂CH₃, SO₂CF₃ and SO₂C₆F₅; wherein Z is selected from O, S, NR⁴⁹ and CH₂; wherein R⁴⁹ is selected from hydrido, CH₃ and CH₂C₆H₅; and wherein said acidic moiety may be a heterocyclic acidic group attached at any two adjacent positions of R³ through R¹¹ so as to form a fused ring system so as to include one of the phenyl rings of the biphenyl moiety of Formula I, said biphenyl fused ring system selected from

and the esters, amides and salts of said acidic moieties;

- with the proviso that at least one of said R¹ through R²⁴ substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;
- or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
 - 51. The composition of Claim 50 wherein m is one; wherein ${\tt R}^0$ is selected from C4H9(n), CH3CH2CH=CH,
- 15 $C_{3H7}(N)$, SC_{3H7} , C_{H2} , C_{H2} , C_{H2} , C_{H3} , C_{H2} , $C_{H11}(n)$, $C_{H13}(n)$, SC_{H9} , C_{H2} , C_{H3} CH=CH and C_{H3} CH2CH=CH=CH; wherein each of R^1 and R^2 is independently selected from amino, aminomethyl, aminoethyl, aminopropyl, C_{H2} OH2OH4, C_{H2} OCOCH3, C_{H2} CH2CH3, C_{H2} CH2OCH3, C_{H2} CH2OCH4, C_{H

$$CH_2CO_2H$$
, $CH(CH_3)CO_2H$, NO_2 , $C1$, H

-CH₂OCOCH₂CH₂
$$\longrightarrow$$
, -CO₂CH₃, -CONH₂, -CONHCH₃, CON(CH₃)₂,

-CH₂-NHCO₂C₂H₅, -CH₂NHCO₂
$$\longrightarrow$$
 , -CH₂NHCO₂CH₃, -CH₂NHCO₂C3H₇,

5 -CH2NHCO2CH2(CH3)2, -CH2NHCO2C4H9, CH2NHCO2-adamantyl, -CH2NHCO2-(1-napthyl), -CH2NHCONHCH3, -CH2NHCONHC2H5, -CH 2NHCONHC 3H7, -CH2NHCONHC 4H9, -CH2NHCONHCH (CH3) 2, -CH2NHCONH(1-napthyl), -CH2NHCONH(1-adamantyl), CO2H,

-CH2CH2F, -CH2OCONHCH3, -CH2OCSNHCH3, -CH2NHCSOC3H7, 10

pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, 1-oxoethyl, 1-oxopropyl, 1oxobutyl, 1-oxopentyl, 1,1-dimethoxypropyl, 1,1dimethoxybutyl, 1,1-dimethoxypentyl, hydroxyalkyl, halo, difluoromethyl, 1,1-difluoroethyl, 1,1-difluoropropyl, 1,1difluorobutyl and 1,1-difluoropentyl; wherein each of R3 through 11 is hydrido, with the proviso that at least one of R^5 , R^6 , R^8 and R^9 is an acidic group selected from CO_2H , SH, PO₃H₂, SO₃H, CONHNH₂, CONHNHSO₂CF₃, OH,

25

15

20

wherein each of R^{46} and R^{47} is independently selected from Cl, CN, NO₂, CF₃, CO₂CH₃ and SO₂CF₃;

with the proviso that at least one of said R¹ through R¹¹

5 substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;

or a tautomer thereof or a pharmaceutically-acceptable salt 10 thereof.

52. The composition of Claim 51 wherein m is one; wherein ${\tt R}^0$ is selected from C4H9(n), CH3CH2CH=CH,

 $C_{3H7}(N)$, SC_{3H7} , C_{2H5} , $C_{5H11}(n)$,


- 15 $C_{6H13}(n)$, SC_{4H9} , $C_{H2}S$, $C_{H3}C_{H2}C_{H3}C_{H3}C_{H2}C_{H2}C_{H2}C_{H2}C_{H3}C_{H2}C_{H3$
- 20 -CH₂-NHCO₂C₂H₅, -CH₂NHCO₂ -CH₂NHCO₂CH₃,
 CH₂NHCO₂C₃H₇, -CH₂NHCO₂CH₂(CH₃)₂, -CH₂NHCO₂C₄H₉, CH₂NHCO₂
 adamantyl, -CH₂NHCO₂-(1-napthyl), -CH₂NHCONHCH₃,
 CH₂NHCONHC₂H₅, -CH₂NHCONHC₃H₇, -CH₂NHCONHC₄H₉,
 CH₂NHCONHCH (CH₃)₂, -CH₂NHCONH (1-napthyl), -CH₂NHCONH (1-
- 25 adamantyl), CO_2H , $-CH_2CH_2-CO-N$, $-CH_2CH_2CH_2CO_2H$,

-CH₂CH₂F, -CH₂OCONHCH₃, -CH₂CH₂CH₂F, -CH₂SH and -CH₂O-O; wherein R² is selected from H, Cl, NO₂, CF₃, CH₂OH, Br, F, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl,

phenyl, benzyl, phenethyl, clohexyl, cyclohexylmethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl, 1,1-dimethoxypropyl, 1,1-dimethoxybutyl, 1,1-dimethoxypentyl, hydroxyalkyl, halo, difluoromethyl, 1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl and 1,1-difluoropentyl;

wherein each of R^3 through 11 is hydrido, with the proviso that at least one of R^5 , R^6 , R^8 and R^9 is an acidic group selected from CO_2H , SH, PO_3H_2 , SO_3H , $CONHNH_2$, $CONHNHSO_2CF_3$, OH,

5



wherein each of R^{46} and R^{47} is independently selected from C1, CN, NO₂, CF₃, CO₂CH₃ and SO₂CF₃;

10

with the proviso that at least one of said R^1 through R^{11} substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;

15

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

53. The composition of Claim 51 wherein m is one; wherein R^0 is selected from C4H9(n), CH3CH2CH=CH, C3H7(N), SC3H7, CH_2 , CH_2 , CH_2 , CH_3

 $C_{6}H_{13}(n)$, $SC_{4}H_{9}$, $CH_{2}S$, $CH_{3}CH=CH$ and $CH_{3}CH_{2}CH=CH=CH$

i,
wherein R¹ is selected from H, Cl, NO₂, CF₃, CH₂OH, Br, F,
I, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl,
isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl,
phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, 1oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl, 1,1dimethoxypropyl, 1,1-dimethoxybutyl, 1,1-dimethoxypentyl,
hydroxyalkyl, halo, difluoromethyl, 1,1-difluoroethyl, 1,1-

difluoropropyl, 1,1-difluorobutyl and 1,1-difluoropentyl; wherein R² is selected from amino, aminomethyl, aminoethyl,

30

5 -CH₂-NHCO₂C₂H₅, -CH₂NHCO₂ , -CH₂NHCO₂CH₃, -CH₂NHCO₂C₃H₇,

-CH2NHCO2CH2(CH3)2, -CH2NHCO2C4H9, CH2NHCO2-adamantyl,


-CH2NHCO2-(1-napthyl), -CH2NHCONHCH3, -CH2NHCONHC2H5,

-CH 2NHCONHC 3H7, -CH2NHCONHC 4H9, -CH2NHCONHCH (CH3) 2,

10 -CH2NHCONH(1-napthyl), -CH2NHCONH(1-adamantyl), CO2H,

 $CH_2CH_2CH_2F$, $-CH_2SH$ and $-CH_2O$

wherein each of R^3 through 11 is hydrido, with the proviso that at least one of R^5 , R^6 , R^8 and R^9 is an acidic group selected from CO_2H , SH, PO_3H_2 , SO_3H , $CONHNH_2$, $CONHNHSO_2CF_3$, OH,



20 wherein each of R^{46} and R^{47} is independently selected from Cl, CN, NO₂, CF₃, CO₂CH₃ and SO₂CF₃;

with the proviso that at least one of said R¹ through R¹¹ substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

54. The composition of Claim 43 wherein said second residue forms a kidney-enzyme-cleavable amide bond

with the residue of said angiotensin II antagonist compound.

55. The composition of Claim 54 wherein said 5 second residue is provided by a compound of Formula II:

$$\begin{array}{c|c}
O & O \\
C - G \\
C - G \\
\gamma & \beta & \alpha \end{array}$$

$$\begin{array}{c}
C - G \\
R^{50} \\
R^{51}
\end{array}$$
(II)

wherein each of R⁵⁰ and R⁵¹ may be independently selected from hydrido, alkylcarbonyl, alkoxycarbonyl, alkoxyalkyl, hydroxyalkyl and haloalkyl; and wherein G is selected from hydroxyl, halo, mercapto, -OR⁵², -SR⁵³ and NR⁵⁴ with each of R⁵², R⁵³ and R⁵⁴ independently selected from hydrido and alkyl; with the proviso that said Formula II compound is selected such that formation of the cleavable amide bond occurs at carbonyl moiety attached at the gamma-position carbon of said Formula II compound.

- 56. The composition of Claim 55 wherein each G 20 substituent is hydroxy.
 - 57. The composition of Claim 56 wherein each G substituent is hydroxy; wherein ${\bf R}^{50}$ is hydrido; and wherein ${\bf R}^{51}$ is selected from

O \parallel -CR⁵⁵ wherein R⁵⁵ is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, neopentyl, n-hexyl and chloromethyl.

30 58. The composition of Claim 57 wherein said second residue is

WO 92/02257 PCT/US91/05476

339

- 59. The composition of Claim 43 wherein said first residue is an angiotensin II antagonist compound containir a terminal primary or secondary amino moiety selected from amino and linear or branched aminoalkyl moieties containing linear or branched alkyl groups selected from aminomethyl, aminoethyl, aminopropyl, aminoisopropyl, aminobutyl, aminosecbutyl, aminoisobutyl, aminotertbutyl, aminopentyl, aminoisopentyl and aminoneopentyl.
- 60. The composition of Claim 43 wherein said first residue is an angiotensin II antagonist compound containing a moiety convertible to a primary or secondary amino terminal moiety.
 - 61. The composition of Claim 60 wherein said moiety convertible to an amino terminal moiety is a carboxylic acid group reactable with an amino moiety of a diamino-terminated linker group to provide a terminal amino moiety which may then be further reacted with a carboxylic acid moiety of a compound providing said second residue so as to form a hydrolyzable amide bond.

25

20

62. The composition of Claim 61 wherein said diamino-terminated linker group is a divalent radical of Formula III:

$$-\frac{\stackrel{R^{200}}{\stackrel{}{\mid}} CH_2}{\stackrel{}{\mid}} \frac{\stackrel{R^{201}}{\stackrel{}{\mid}} }{N} -$$
 (III)

30

wherein each of R^{200} and R^{201} may be independently selected from hydrido, a kyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, hydroxyalkyl, aralkyl, aryl, haloalkyl, amino,

monoalkylamino, dialkylamino, cyanoamino, carboxyalkyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl and arylsulfonyl; and wherein n is zero or a number selected from three through seven, inclusive.

5

- $\,$ 63. The composition of Claim 62 wherein each of $_{\rm R200~and~R}201$ is hydrido.
- 64. The composition of Claim 61 wherein said diamino-terminated linker group is a divalent radical of Formula IV:




15 wherein each of Q and T is one or more groups independently selected from



- wherein each of R²⁰² through R²⁰⁵ is independently selected from hydrido, hydroxy, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, alkoxy, aralkoxy, aryloxy, alkoxyalkyl, haloalkyl, hydroxyalkyl, halo, cyano, amino, monoalkylamino, dialkylamino, carboxy, carboxyalkyl, alkanoyl, alkenyl, cycloalkenyl and alkynyl.
 - 65. The composition of Claim 64 wherein said diamino-terminated linker group is a divalent radical of Formula V:

30



wherein each of R²⁰² and R²⁰³ is independently selected from hydrido, hydroxy, alkyl, phenalkyl, phenyl, alkoxy, benzyloxy, phenoxy, alkoxyalkyl, hydroxyalkyl, halo, amino, monoalkylamino, dialkylamino, carboxy, carboxyalkyl and alkanoyl; and wherein each of p and q is a number independently selected from one through six, inclusive; with the proviso that when each of R²⁰² and R²⁰³ is selected from halo, hydroxy, amino, monoalkylamino and dialkylamino, then the carbon to which R²⁰² or R²⁰³ is attached in Formula V is not adjacent to a nitrogen atom of Formula V.

66. The composition of Claim 65 wherein each of R²⁰² and R²⁰³ is independently selected from hydrido, hydroxy, alkyl, alkoxy, amino, monoalkylamino, carboxy, carboxyalkyl and alkanoyl; and wherein each of p and q is a number independently selected from two through four, inclusive.

20

25

- 67. The composition of Claim 66 wherein each of R^{202} and R^{203} is independently selected from hydrido, amino, monoalkylamino and carboxyl; and wherein each of p and q is independently selected from the numbers two and three.
- $\,$ 68. The composition of Claim 67 wherein each of $\rm R^{202}$ and $\rm R^{203}$ is hydrido; and wherein each of p and q is two.

69. The composition of Claim 61 wherein said diamino-terminated linker group is a divalent radical of Formula VI:

5

$$\begin{array}{c|c}
R^{214} & R^{216} \\
-N & C \\
R^{217} \\
\end{array}$$

$$\begin{array}{c}
R^{215} \\
N \\
\end{array}$$
(VI)

wherein each of R²¹⁴ through R²¹⁷ is independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, aralkyl, aryl, haloalkyl, amino, monoalkylamino, dialkylamino, cyanoamino, carboxyalkyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl and arylsulfonyl; and wherein p is a number selected from one through six inclusive.

15

20

25

10

- 70. The composition of Claim 69 wherein each of R^{214} and R^{215} is hydrido; wherein each of R^{216} and R^{217} is independently selected from hydrido, alkyl, phenalkyl, phenyl, alkoxyalkyl, hydroxyalkyl, haloalkyl and carboxyalkyl; and wherein p is two or three.
- 71. The composition of Claim 70 wherein each of R^{214} and R^{215} is hydrido; wherein each of R^{216} and R^{217} is independently selected from hydrido and alkyl; and wherein p is two.
- 72. The composition of Claim 71 wherein each of R214, R215, R216 and R217 is hydrido; and wherein p is two.
- 30 73. The composition of Claim 52 wherein said angiotensin II antagonist compound is 4'-[2-butyl-5-chloro-4-(hydroxymethyl)-1H-imidazol-1-ylmethyl][1,1'-biphenyl]-2-carboxylic acid.

WO 92/02257 PCT/US91/05476

343

74. The composition of Claim 73 wherein said conjugate is N-acetyl-L-glutamic acid, 5-[[4'-[2-butyl-5-chloro-4-(hydroxymethyl)-1H-imidazol-1-ylmethyl][1,1'-biphenyl]-2-yl]carbonyl]hydrazide.

5

75. The composition of Claim 73 wherein said conjugate is N^2 -acetyl-N-[[2-butyl-5-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazol-4-yl]methyl]-L-glutamine.

10

76. The composition of Claim 73 which is N-acetyl-L-glutamic acid, 5-[2-butyl-5-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazol-4-yl]acetylhydrazide.

15

77. The composition of Claim 53 wherein said angiotensin II antagonist compound is 4'-[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-ylmethyl][1,1'-biphenyl]-2-carboxylic acid.

20

78. The composition of Claim 77 which is N-acetyl-L-glutamic acid, 5-[[4'-[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-ylmethyl][1,1'-biphenyl]-2-yl]carbonyl]hydrazide.

25

79. The composition of Claim 77 which is N^2 -acetyl-N-[[2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazol-5-yl]methyl]-L-glutamine.

30

80. The composition of Claim 77 which is N-acetyl-L-glutamic aci⁻¹, 5-[2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazol-5-yl]acetylhydrazide.

35

81. A method for treating a hypertensiverelated disorder or a sodium-retaining disorder, said method comprising administering to a patient afflicted with

or susceptible to said disorder a therapeutically-effective amount of a renal-selective conjugate, said conjugate comprising a residue of an angiotensin II antagonist compound.

5

10

- 82. The method of Claim 81 wherein said conjugate comprises a first residue and a second residue, said first and second residues connected together by a cleavable bond, wherein said first residue is provided by an angiotensin II antagonist compound, and wherein said second residue is capable of being cleaved from said first residue.
- and second residues are provided by precursor compounds wherein the precursor compound of one of said first and second residues has a reactable carboxylic acid moiety and the precursor of the other of said first and second residues has a reactable amino moiety or a moiety convertible to a reactable amino moiety, whereby a cleavable bond may be formed between said carboxylic acid moiety and said amino moiety.
- 84. The method of Claim 83 wherein said
 25 angiotensin II antagonist compound providing said first
 residue is selected from biphenylmethyl 1H-substituted-1,3imidazole compounds.
- 85. The method of Claim 84 wherein said
 30 angiotensin II antagonist compound is selected from a class of compounds defined by Formula I:

wherein m is a number selected from one to four, inclusive;

- wherein each of R⁰ through R¹¹ is independently selected from hydrido, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, formyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkenyl,
- cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl, mercaptothiocarbonyl, mercaptoalkyl, alkoxycarbonyloxy,
- alkylthio, cycloalkylthio, alkylthiocarbonyl, alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio, alkylthiothiocarbonyl, alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy,
- arylthiocarbonylthio, arylthiothiocarbonyl, arylthiothiocarbonylthio, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy, aralkylthiocarbonylthio, alkylthiocarbonyl, aralkylthiocarbonylthio, mercapto, alkylsulfinyl,
- alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cyclohetero-containing
- $\mathfrak 3$ groups has one or more ring atoms selected from oxygen,

20

25

30

sulfur atoms;

sulfur and nitrogen atoms, and wherein each of ${\bf R}^0$ through ${\bf R}^{11}$ may be further independently selected from amino and amido radicals of the formula

wherein X is oxygen atom or sulfur atom;

10 wherein each n is a number independently selected from zero to six, inclusive;

wherein each of R^{12} through R^{24} is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R^{12} and R^{13} taken together, R^{14} and R^{15} taken together, R^{16} and ${\bf R}^{17}$ taken together, ${\bf R}^{19}$ and ${\bf R}^{20}$ taken together and ${\bf R}^{21}$ and R^{22} taken together may each form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical and which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein \mathbf{R}^{12} and \mathbf{R}^{13} taken together, \mathbf{R}^{14} and R^{15} taken together, R^{19} and R^{20} taken together and R^{21} and R^{22} taken together may each form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino or amido radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and

WO 92/02257 PCT/US91/05476

347

and wherein each of \mathbb{R}^3 through \mathbb{R}^{11} may be further independently selected from hydrido and haloalkyl, and from acidic moieties of the formula

5

10

15

20


25

30

 $-Y_nA$

wherein n is a number selected from zero through three, inclusive, and wherein A is an acidic group selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, aralayl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms;

and wherein any of the foregoing R¹ through R²⁴, Y and A groups having a substitutable position may be substituted with one or more groups selected from hydroxy, alkyl, alkenyl, alkynyl, aralkyl, hydroxyalkyl, trifluoromethyl, difluoroalkyl, oxo, alkoxy, aryloxy, aralkoxy, aralkylthio, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aroyl, cycloalkenyl, cyano, cyanoamino, nitro, alkylcarbonyloxy, alkoxycarbonyloxy, alkylcarbonyl, alkoxycarbonyl, carboxyl, mercapto, mercaptocarbonyl, alkylthio, arylthio, arylthio, alkylthiocarbonyl, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfinyl, arylsulfinyl, arylsulfinyl, arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and amino and amido radicals of the formula



wherein X is selected from oxygen atom and sulfur atom; 35 wherein R^{25} is selected from hydrido, alkyl, cycloalkyl, cycloalkyl, aralkyl, aryl, DR^{30} and



wherein D is selected from oxygen atom and sulfur atom and R³⁰ is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R²⁵, R²⁶, R²⁷, R²⁸, R²⁹, R³¹ and R³² is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl, arylsulfonyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein each of R²⁶, R²⁷, R²⁸, R²⁹, R³¹ and R³² is further independently selected from amino and amido radicals of the formula

$$-N$$
 $\stackrel{R^{33}}{\underset{R^{34}}{\stackrel{\times}{=}}}$, $\stackrel{X}{\underset{-CN}{\stackrel{\times}{=}}}$ $\stackrel{R^{35}}{\underset{R^{36}}{\stackrel{\times}{=}}}$ and $\stackrel{X}{\underset{R^{38}}{\stackrel{\times}{=}}}$

wherein X is oxygen atom or sulfur atom;

wherein each of R^{33} , R^{34} , R^{35} , R^{36} , R^{37} and R^{38} is 20 independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein R^{26} and $\rm R^{27}$ taken together and $\rm R^{28}$ and $\rm R^{29}$ taken together may each 25 form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be 30 saturated or partially unsaturated; wherein R^{26} and R^{27} taken together and \mathbf{R}^{31} and \mathbf{R}^{32} taken together may each form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino or amido radical

and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms;

- with the proviso that at least one of said R¹ through R²⁴, Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;
- or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
- 86. The method of Claim 85 wherein m is one; wherein each of R⁰ through R¹¹ is independently selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl,
- 20 alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl, mercaptothiocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, alkylthiocarbonyl,
- alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio, alkylthiothiocarbonyl, alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy, arylthiocarbonylthio, arylthiothiocarbonyl, arylthiothiocarbonylthio,
- aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy, aralkylthiocarbonylthio, aralkylthiocarbonyl, aralkylthiocarbonylthio, me-capto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, phthalimido,
- 35 phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has

one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of ${\bf R}^0$ through ${\bf R}^{11}$ may be further independently selected from amino and amido radicals of the formula

wherein X is selected from oxygen atom or sulfur atom;

wherein each n is a number independently selected from zero to six, inclusive;

wherein each of R¹² through R²⁴ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl;

and wherein each of \mathbb{R}^3 through \mathbb{R}^{11} may be further 20 independently selected from hydrido and haloalkyl, and from acidic moieties of the formula

$$-Y_nA$$

wherein n is a number selected from zero through three, inclusive; wherein A is an acidic group selected from acids containing one or more atoms selected from oxygen, sulfur, phosphorus and nitrogen atoms, and wherein said acidic group is selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl,

cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ing atoms selected from oxygen, sulfur and nitrogen atoms;

and wherein any of the foregoing R¹ through R²⁴, Y and A groups having a substitutable position may be substituted with one or more groups selected from alkyl, alkenyl, aralkyl, hydroxyalkyl, trifluoromethyl, difluoroalkyl, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, mercaptocarbonyl, alkylthio, alkylthiocarbonyl, and amino and amido radicals of the formula

$$X$$
 \parallel
 $-C-R^{25}$, $-N$
 R^{26}
 R^{27}
and $-NC-R^{28}$
 R^{29}

15

wherein X is selected from oxygen atom and sulfur atom; wherein R^{25} is selected from hydrido, alkyl, cycloalkyl, cycloalkyl, aralkyl, aryl, and DR^{30} and

20

25

30

wherein D is selected from oxygen atom and sulfur atom, and R^{30} is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R^{26} , R^{27} , R^{28} , R^{29} , R^{31} and R^{32} is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkanoyl, alkoxycarbonyl, carboxyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein each of R^{26} , R^{27} , R^{28} , R^{29} , R^{31} and R^{32} is further independently selected from amino and amido radicals of the formula

 $-N \stackrel{R^{33}}{\underset{R^{34}}{\overset{X}{\longrightarrow}}} , \stackrel{X}{\underset{-CN}{\overset{X}{\longrightarrow}}} \stackrel{R^{35}}{\underset{R^{36}}{\overset{X}{\longrightarrow}}} \text{ and } \stackrel{NC-R^{37}}{\underset{R^{38}}{\overset{X}{\longrightarrow}}}$

wherein X is selected from oxygen atom or sulfur atom;

wherein each of R²⁶ through R³¹ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl;

with the proviso that at least one of said R¹ through R²⁴, Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;

15

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

87. The method of Claim 86 wherein m is one;
20 wherein each of R⁰ through R¹¹ is independently selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, mercaptocarbonyl, alkoxycarbonyloxy,

alkylcarbonyloxy, mercaptocarbonyl, alkoxycarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, alkylthio, cycloalkylthio, arylthio, mercapto, alkylsulfinyl,

aralkylthiocarbonylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-

35 wherein each of said heteroaryl- and cycloheteroalkylcontaining groups has one or more hetero ring atoms

selected from oxygen, sulfur and nitrogen atoms, and wherein each of ${\bf R}^0$ through ${\bf R}^{11}$ may be further independently selected from amino and amido radicals of the formula

wherein X is selected from oxygen taom or sulfur atom;

10 wherein each n is a number independently selected from zero to six, inclusive;

wherein each of R¹² through R²⁴ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl;

and erein each of R^3 through R^{11} may be an acidic moiety further independently selected from hydrido and haloalkyl, and from acidic moieties of the formula

$$-Y_nA$$

15

20

30

wherein n is a number selected from zero through three, inclusive;

wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from

-OH, -SH, -NR³⁹, -C-WH, -S-WH, -S-WH, -P-WH, -P-NH and -P-WH
$$\mathbb{R}^{4\mathbb{C}}$$
 $\mathbb{R}^{4\mathbb{C}}$ $\mathbb{R}^{4\mathbb{C}}$

wherein each W is independently selected from oxygen atom, sulfur atom and NR 43 ; wherein each of R³⁹, R⁴⁰, R⁴¹, R⁴² and R⁴³ is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, cycloalkylalkyl, aryl and aralkyl; wherein each of R³⁹, R⁴⁰, R⁴¹ and R⁴² may be further independently selected from amino radicals of the formula

-N R^{44} R^{45}

10

15

20

25

30

35

wherein each of \mathbf{R}^{44} and \mathbf{R}^{45} is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein ${\rm R}^{44}$ and ${\rm R}^{45}$ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein \mathbf{R}^{44} and \mathbf{R}^{45} taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; wherein each of ${\rm R}^{\,40}$ and ${\rm R}^{\,41}$ may be further independently selected from hydroxy, alkoxy, alkylthio, aryloxy, arylthio, aralkylthio and aralkoxy; and the amide, ester and salt derivatives of said acidic groups;

wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which heterocyclic ring contains at least one hetero atom selected from oxygen, sulfur and nitrogen atoms, which

heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R3 through R11 or may be attached at any two adjacent positions selected from \mathbb{R}^3 through \mathbb{R}^{11} so as to form a fused-ring system with one of the phenyl rings of the biphenyl moiety of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups;

10 wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl;

and wherein any of the foregoing R^1 through R^{24} , Y and A groups having a substitutable position may be substituted 15 by one or more groups selected from alkyl, difluoroalkyl, alkenyl, aralkyl, hydroxyalkyl, trifluoromethyl, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, mercaptocarbonyl, alkylthio, alkylthiocarbonyl, and amino and amido radicals of the formula

25 wherein X is selected from oxygen atom and sulfur atom; wherein R^{25} is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl and DR^{30} and

30

20

wherein D is selected from oxygen atom and sulfur atom, wherein R^{30} is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, arallyl and aryl;

wherein each of R²⁶, R²⁷, R²⁸, R²⁹, R³¹ and R³² is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkanoyl, alkoxycarbonyl, carboxyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl;

with the proviso that at least one of said R¹ through R²⁴, Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

15

10

5

The method of Claim 87 wherein m is one; wherein each of \mathbb{R}^0 , \mathbb{R}^1 and \mathbb{R}^2 is independently selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, 20 alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl, mercaptoalkyl, 25 alkoxycarbonyloxy, alkylthio, cycloalkylthio, arylthio, aralkylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl 30 and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of ${\bf R}^0$ through ${\bf R}^{11}$ may be further independently selected from amino and amido 35

radicals of the formula

WO 92/02257 PCT/US91/05476

wherein X is selected from oxygen atom and sulfur atom;

5

wherein each n is a number independently selected from zero to six, inclusive;

- wherein each of R¹² through R²⁴ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl;
- wherein each of R³ through R¹¹ is independently selected
 from hydrido, hydroxy, alkyl, hydroxyalkyl, halo,
 haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl,
 aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl,
 alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl,
 cycloalrynyl, cyano, nitro, carboxyl, alkylthio,
- aralkylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms;
- 25 and wherein each of \mathbb{R}^3 through \mathbb{R}^{11} may be an acidic moiety further independently selected fr \mathbb{R}^3 acidic moieties of the formula

 $-Y_nA$

30 wherein n is a number selected from zero through three, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from

wherein each W is independently selected from oxygen atom, sulfur atom and NR 43 ; wherein each of R 39 , R 42 and R 43 is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, cycloalkylalkyl, aryl and aralkyl; wherein each of \mathbb{R}^{39} and ${
m R}^{42}$ may be further independently selected from amino radical of the formula

5

10

15

20

25

$$-N$$
 R^{44}
 R^{45}

wherein each of \mathbf{R}^{44} and \mathbf{R}^{45} is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein ${\rm R}^{44}$ and ${\rm R}^{45}$ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms, and which heterocyclic group may be saturated or partially unsaturated; wherein \mathbf{R}^{44} and \mathbf{R}^{45} taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of carboxylic acid may be further selected from heterocyclic 30 acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which 35

359

heterocyclic ring may be attached at a single position selected from \mathbb{R}^3 through \mathbb{R}^{11} or may be attached at any two adjacent positions selected from \mathbb{R}^3 through \mathbb{R}^{11} so as to form a fused-ring system with one of the phenyl rings of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups;

wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl;

10

wherein each of R^1 through R^{24} , Y and A independently may be substituted at any substitutable position with one or more groups selected from alkyl, cycloalkyl,

- 15 cycloalkylalkyl, hydroxy, oxo, trifluoromethyl, difluoroaikyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy;
- 20 with the proviso that at least one of said R¹ through R²⁴, Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;
- or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
- 89. The method of Claim 88 wherein m is one; wherein each of R⁰, R¹ and R² is independently selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, benzoyl, phenoxy, phenoxyalkyl, phenalkyloxy, phenylthio, phenalkylthio, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalke yl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkoxycarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, phthalimido, alkoxycarbonyloxy, alkylthio, cycloalkylthio, phthalimido,

360

phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl— and cycloheteroalkyl—containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R⁰ through R¹¹ may be further independently selected from amino and amido radicals of the formula

wherein X is selected from oxygen atom and sulfur atom;

wherein each n is a number independently selected from zero to six, inclusive;

wherein each of R^{12} through R^{24} is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,

20 hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl;

wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenalkyl, phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio, mercapto and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms;

25

5

and wherein each of ${\bf R}^3$ through ${\bf R}^{11}$ may be an acidic moiety further independently selected from acidic moieties of the formula

$$-Y_nA$$

5

wherein n is a number selected from zero through two, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from

10

15

wherein each W is independently selected from oxygen atom, sulfur atom and NR 43 ; wherein each of R 39 , R 42 and R 43 is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, phenyl and benzyl; wherein each of R 39 and R 42 may be further independently selected from amino radical of the formula

20

wherein each of R^{44} and R^{45} is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, alkoxyalkyl, benzyl and phenyl; and the amide, ester and salt derivatives of said acidic groups;

25

30

35

wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from \mathbb{R}^3 through \mathbb{R}^{11} or may be attached at any two adjacent positions selected from \mathbb{R}^3 through \mathbb{R}^{11} so as to form a fused-ring system with one of

20

the phenyl rings of the biphenyl moiety of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups;

- 5 wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, phenyl, phenalkyl and aralkyl;
- wherein each of R¹ through R²⁴, Y and A and independently

 may be substituted at any substitutable position with one
 or more groups selected from alkyl, cycloalkyl,
 cycloalkylalkyl, hydroxy, oxo, trifluoromethyl,
 difluoroalkyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl,
 haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and
 aralkoxy;

with the proviso that at least one of said R^1 through R^{24} , Y and A substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

90. The method of Claim 89 wherein m is one; wherein R⁰ is selected from alkyl, alkenyl, phenyl, alkylthio, cycloalkyl, cycloalkylalkyl and cycloalkylthio; wherein each of R¹ and R² is independently selected from alkyl, aminoalkyl, hydroxyalkyl, halo, haloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, benzoyl, phenoxy, phenoxyalkyl, phenalkyloxy, phenylthio, phenalkylthio, aralkoxy, alkoxyalkyl, acetyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, mercaptoalkyl, mercaptocarbonyl, alkoxycarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,

aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl,

phthalimido, phthalimidoalkyl, imidazoalkyl, tetrazole,

tetrazolealkyl, alkylthio, cycloalkylthio, and amino and amido radicals of the formula

5

wherein X is selected from oxygen atom and sulfur atom;

wherein each n is a number independently selected from zero to six, inclusive;

10

wherein each of R^{12} through R^{24} is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl;

- wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenalkyl, phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, acetyl, alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl,
- 20 alkylthio and mercapto;

and wherein each of R^3 through R^{11} may be an acidic moiety further independently selected from acidic moieties consisting of CO_2H , CO_2CH_3 , SH, CH_2SH , C_2H_4SH , PO_3H_2 , $NHSO_2CE_3$, $NHSO_2CE_5$, SO_3H , $CONHNH_3$, $CONHNH_5O_2CE_3$, $CONHOCH_3$

NHSO $_2$ CF $_3$, NHSO $_2$ C $_6$ F $_5$, SO $_3$ H, CONHNH $_2$, CONHNHSO $_2$ CF $_3$, CONHOCH $_3$, CONHOC $_2$ H $_5$, CONHCF $_3$, OH, CH $_2$ OH, C $_2$ H $_4$ OH, OPO $_3$ H $_2$, OSO $_3$ H,

5

10

wherein each of R^{46} , R^{47} and R^{48} is independently selected from H, Cl, CN, NO₂, CF₃, C₂F₅, C₃F₇, CHF₂, CH₂F, CO₂CH₃, CO₂C₂H₅, SO₂CH₃, SO₂CF₃ and SO₂C₆F₅; wherein Z is selected from O, S, NR⁴⁹ and CH₂; wherein R^{49} is selected from hydrido, CH₃ and CH₂C₆H₅; and wherein said acidic moiety may be a heterocyclic acidic group attached at any two adjacent positions of R^3 through R^{11} so as to form a fused ring system so as to include one of the phenyl rings of the biphenyl moiety of Formula I, said biphenyl fused ring system selected from

and the esters, amides and salts of said acidic moieties;

- with the proviso that at least one of said R¹ through R²⁴ substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;
- or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
 - 91. The method of Claim 90 wherein m is one; wherein R^0 is selected from C4H9(n), CH3CH2CH=CH, C3H7(N),
- SC3H7, CH_2 , C_2H_5 , C_5H_{11} (n), C_6H_{13} (n

CH₂CO₂H, CH(CH₃)CO₂H, NO₂, Cl,
$$\stackrel{N-N}{\downarrow}_{N}$$

-CH₂OCOCH₂CH₂
$$\longrightarrow$$
 , -CO₂CH₃, -CONH₂, -CONHCH₃, CON (CH₃)₂,

-CH₂-NHCO₂C₂H₅, -CH₂NHCO₂—
$$\left\langle -\text{CH}_{2}\text{NHCO}_{2}\text{CH}_{3}, -\text{CH}_{2}\text{NHCO}_{2}\right\rangle$$

CH2NHCO2C3H7,

15

20

5 -CH2NHCO2CH2(CH3)2, -CH2NHCO2C4H9, CH2NHCO2-adamantyl, -CH2NHCO2-(1-napthyl), -CH2NHCONHCH3, -CH2NHCONHC2H5, -CH2NHCONHC3H7, -CH2NHCONHC4H9, -CH2NHCONHCH(CH3)2, -CH2NHCONH(1-napthyl), -CH2NHCONH(1-adamantyl), CO2H,

-CH₂CH₂-CO-N
$$\bigcirc$$
O, -CH₂CH₂CO-N \bigcirc , -CH₂CH₂CH₂CO₂H,

10 $-CH_2CH_2F$, $-CH_2OCONHCH_3$, $-CH_2OCSNHCH_3$, $-CH_2NHCSOC_3H_7$,

-CH₂-N
-CH₂CH₂CH₂F, -CH₂ONO₂, , -CH₂SH, -CH₂O-O,
92. Cl, NO₂, CF₃, CH₂OH, Br, F, I, methyl, ethyl, n-propyl,
isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, npentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl,
cyclohexyl, cyclohexylmethyl, 1-oxoethyl, 1-oxopropyl, 1oxobutyl, 1-oxopentyl, 1,1-dimethoxypropyl, 1,1dimethoxybutyl, 1,1-dimethoxypentyl, hydroxyalkyl, halo,
difluoromethyl, 1,1-difluoroethyl, 1,1-difluoropropyl, 1,1difluorobutyl and 1,1-difluoropentyl; wherein each of R³
through 11 is hydrido, with the proviso that at least one
of R⁵, R⁶, R⁸ and R⁹ is an acidic group selected from CO₂H,
SH, PO₃H₂, SO₃H, CONHNH₂, CONHNHSO₂CF₃, OH,

wherein each of R^{46} and R^{47} is independently selected from Cl, CN, NO₂, CF₃, CO₂CH₃ and SO₂CF₃;

with the proviso that at least one of said R¹ through R¹¹

5 substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;

or a tautomer thereof or a pharmaceutically-acceptable salt 10 thereof.

- 92. The method of Claim 91 wherein m is one; wherein R^0 is selected from C4H9(n), CH3CH2CH=CH, C3H7(N),
- $SC_{3}H_{7}$, $C_{2}H_{5}$, $C_{5}H_{11}(n)$, $C_{6}H_{13}(n)$,
- SC₄H₉, CH₂S, CH₃CH=CH and CH₃CH₂CH₂CH=CH-; wherein R¹ is selected from amino, aminomethyl, aminoethyl, aminopropyl, CH₂OH, CH₂OCOCH₃, CH₂Cl, Cl, CH₂OCH₃, CH₂OCH(CH₃)₂, I, CHO, CH₂CO₂H, CH(CH₃)₂CO₂H, -CO₂CH₃, -CONH₂, -CONHCH₃, CON(CH₃)₂,
- 20 -CH₂-NHCO₂C₂H₅, -CH₂NHCO₂ , -CH₂NHCO₂CH₃,
 CH₂NHCO₂C₃H₇, -CH₂NHCO₂CH₂(CH₃)₂, -CH₂NHCO₂C₄H₉, CH₂NHCO₂
 adamantyl, -CH₂NHCO₂-(1-napthyl), -CH₂NHCONHCH₃,
 CH₂NHCONHC₂H₅, -CH₂NHCONHC₃H₇, -CH₂NHCONHC₄H₉,
 CH₂NHCONHCH (CH₃)₂, -CH₂NHCONH (1-napthyl), -CH₂NHCONH (1-
- 25 adamantyl), CO_2H , $-CH_2CH_2-CO-N$, $-CH_2CH_2CH_2CO_2H$,
 - -CH₂CH₂F, -CH₂OCONHCH₃, -CH₂CH₂CH₂F, -CH₂SH and -CH₂O-O, wherein R² is selected from H, Cl, NO₂, CF₃, CH₂OH, Br, F, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl,
- phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl, 1,1-dimethoxypropyl, 1,1-dimethoxybutyl, 1,1-dimethoxypentyl, hydroxyalkyl, halo, difluoromethyl, 1,1-difluoroethyl, 1,1-difluoropentyl;

wherein each of \mathbb{R}^3 through 11 is hydrido, with the proviso that at least one of R^5 , R^6 , R^8 and R^9 is an acidic group selected from CO₂H, SH, PO₃H₂, SO₃H, CONHNH₂, CONHNHSO₂CF₃, OH,

5

wherein each of \mathbf{R}^{46} and \mathbf{R}^{47} is independently selected from Cl, CN, NO₂, CF₃, CO₂CH₃ and SO₂CF₃;

10

with the proviso that at least one of said ${\bf R}^{\bf 1}$ through ${\bf R}^{\bf 11}$ substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;

15

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

20

93. The method of Claim 91 wherein m is one; wherein R^0 is selected from C4H9(n), CH3CH2CH=CH, C3H7(N), SC_3H_7 , C_2H_5 , C_5H_{11} (n), C_6H_{13} (n), SC_4H_9 , CH_2S , $CH_3CH=CH$ and $CH_3CH_2CH=CH=;$ wherein R¹ is selected from H, Cl, NO₂, CF₃, CH₂OH, Br, F, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, 25 phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, 1oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl, 1,1dimethoxypropyl, 1,1-dimethoxybutyl, 1,1-dimethoxypentyl, hydroxyalkyl, halo, difluoromethyl, 1,1-difluoroethyl, 1,1difluoropropyl, 1,1-difluorobutyl and 1,1-difluoropentyl; 30

SUBSTITUTE SHEET

wherein R² is selected from amino, aminomethyl, aminoethyl,

aminopropyl, CH2OH, CH2OCOCH3, CH2Cl, Cl, CH2OCH3,

CH2OCH (CH3) 2, I, CHO,

CH₂CO₂H, CH(CH₃)CO₂H, , -CO₂CH₃, -CONH₂, -CONHCH₃, CON(CH₃)₂,

CH2NHCO2C3H7,

5 -CH2NHCO2CH2(CH3)2, -CH2NHCO2C4H9, CH2NHCO2-adamantyl,

- -CH₂NHCO₂-(1-napthyl), -CH₂NHCONHCH₃, -CH₂NHCONHC₂H₅,
- -CH 2NHCONHC 3H7, -CH2NHCONHC 4H9, -CH2NHCONHCH (CH3) 2,
- -CH2NHCONH(1-napthyl), -CH2NHCONH(1-adamantyl), CO2H,

10 $CH_2CH_2CH_2F$, $-CH_2SH$ and $-CH_2O$;

wherein each of R^3 through 11 is hydrido, with the proviso that at least one of R^5 , R^6 , R^8 and R^9 is an acidic group selected from CO₂H, SH, PO₃H₂, SO₃H, CONHNH₂, CONHNHSO₂CF₃, OH,

15

wherein each of R^{46} and R^{47} is independently selected from Cl, CN, NO₂, CF₃, CO₂CH₃ and SO₂CF₃;

20

with the proviso that at least one of said R^1 through R^{11} substituents contains a terminal primary or secondary amino moiety or a moiety convertible to a primary or secondary amino moiety;

25

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

94. The method of Claim 83 wherein said second residue forms a kidney-enzyme-cleavable amide bond with the residue of said angiotensin II antagonist compound.

95. The method of Claim 94 wherein said second residue is provided by a compound of Formula II:

$$\begin{array}{c|c}
O & O \\
C-G \\
C-G \\
\gamma & \beta & \alpha
\end{array}$$

$$\begin{array}{c}
O \\
C-G \\
R^{50} \\
R^{51}
\end{array}$$
(II)

5

wherein each of R^{50} and R^{51} may be independently selected from hydrido, alkylcarbonyl, alkoxycarbonyl, alkoxyalkyl, hydroxyalkyl and haloalkyl; and wherein G is selected from hydroxyl, halo, mercapto, $-OR^{52}$, $-SR^{53}$ and

10

with each of R⁵², R⁵³ and R⁵⁴ independently selected from hydrido and alkyl; with the proviso that said Formula II compound is selected such that formation of the cleavable amide bond occurs at carbonyl moiety attached at the gamma-position carbon of said Formula II compound.

15

96. The method of Claim 95 wherein each G substituent is hydroxy.

20

97. The method of Claim 96 wherein each G substituent is hydroxy; wherein R^{50} is hydrido; and wherein R^{51} is selected from \int_{-CR}^{0} wherein R^{55} is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, neopentyl, n-hexyl and chloromethyl.

25

98. The method of Claim 97 wherein said second residue is

$$\begin{array}{cccc} \text{O} & \text{COOH} \\ \parallel & \parallel \\ -\text{CCH}_2\text{CH}_2\text{CHNHCCH}_3 \\ \gamma & \beta & \alpha & \parallel \\ & \text{O} \end{array}$$

5

- 99. The method of Claim 83 wherein said first residue is an angiotensin II antagonist compound containing a terminal primary or secondary amino moiety selected from amino and linear or branched aminoalkyl moieties containing linear or branched alkyl groups selected from aminomethyl, aminoethyl, aminopropyl, aminoisopropyl, aminobutyl, aminosecbutyl, aminoisobutyl, aminotertbutyl, aminopentyl, aminoisopentyl and aminoneopentyl.
- 100. The method of Claim 83 wherein said first residue is an angiotensin II antagonist compound containing a moiety convertible to a primary or secondary amino terminal moiety.
- 101. The method of Claim 100 wherein said moiety convertible to an amino terminal moiety is a carboxylic acid group reactable with an amino moiety of a diamino-terminated linker group to provide a terminal amino moiety which may then be further reacted with a carboxylic acid moiety of a compound providing said second residue so as to form a hydrolyzable amide bond.
- 102. The method of Claim 101 wherein said diamino-terminated linker group is a divalent radical of 25 Formula III:

$$-\frac{R^{200}}{N} + \frac{R^{201}}{CH_2} + \frac{R^{201}}{N}$$
(III)

wherein each of R²⁰⁰ and R²⁰¹ may be independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalk, hydroxyalkyl, aralkyl, aryl, haloalkyl, amino, monoalkylamino, dialkylamino, cyanoamino, carboxyalkyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl and arylsulfonyl; and wherein n is zero or a number selected from three through seven, inclusive.

\$103.\$ The method of Claim 102 wherein each of $$\rm R200$$ and $$\rm R^{201}$$ is hydrido.

104. The method of Claim 101 wherein said 5 diamino-terminated linker group is a divalent radical of Formula IV:




10 wherein each of Q and T is one or more groups independently selected from



wherein each of R²⁰² through R²⁰⁵ is independently selected from hydrido, hydroxy, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, alkoxy, aralkoxy, aryloxy, alkoxyalkyl, haloalkyl, hydroxyalkyl, halo, cyano, amino, monoalkylamino, dialkylamino, carboxy, carboxyalkyl, alkanoyl, alkenyl, cycloalkenyl and alkynyl.

105. The method of Claim 104 wherein said diamino-terminated linker group is a divalent radical of Formula V:

373



wherein each of R²⁰² and R²⁰³ is independently selected from hydrido, hydroxy, alkyl, phenalkyl, phenyl, alkoxy, benzyloxy, phenoxy, alkoxyalkyl, hydroxyalkyl, halo, amino, monoalkylamino, dialkylamino, carboxy, carboxyalkyl and alkanoyl; and wherein each of p and q is a number independently selected from one through six, inclusive; with the proviso that when each of R²⁰² and R²⁰³ is selected from halo, hydroxy, amino, monoalkylamino and dialkylamino, then the carbon to which R²⁰² or R²⁰³ is attached in Formula V is not adjacent to a nitrogen atom of Formula V.

106. The method of Claim 105 wherein each of R²⁰² and R²⁰³ is independently selected from hydrido, hydroxy, alkyl, alkoxy, amino, monoalkylamino, carboxy, carboxyalkyl and alkanoyl; and wherein each of p and q is a number independently selected from two through four, inclusive.

20

25

 1×7 . The method of Claim 106 wherein each of R²⁰² and R²⁰³ is independently selected from hydrido, amino, monoalkylamino and carboxyl; and wherein each of p and q is independently selected from the numbers two and three.

 $$108$. The method of Claim 107 wherein each of <math display="inline">$R^{202}$$ and $$R^{203}$$ is hydrido; and wherein each of p and q is two.

109. The method of Claim 101 wherein said diamino-terminated linker group is a divalent radical of Formula VI:

5

$$-\frac{R^{214}}{N} = \begin{bmatrix} R^{216} \\ 1 \\ C \\ R^{217} \end{bmatrix}_{p} R^{215}$$
 (VI)

wherein each of R²¹⁴ through R²¹⁷ is independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, aralkyl, aryl, haloalkyl, amino, monoalkylamino, dialkylamino, cyanoamino, carboxyalkyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl and arylsulfonyl; and wherein p is a number selected from one through six inclusive.

15

20

- 110. The method of Claim 109 wherein each of R^{214} and R^{215} is hydrido; wherein each of R^{216} and R^{217} is independently selected from hydrido, alkyl, phenalkyl, phenyl, alkoxyalkyl, hydroxyalkyl, haloalkyl and carboxyalkyl; and wherein p is two or three.
- 111. The method of Claim 110 wherein each of R^{214} and R^{215} is hydrido; wherein each of R^{216} and R^{217} is independently selected from hydrido and alkyl; and wherein p is two.
 - 112. The method of Claim 111 wherein each of R214, R215, R216 and R217 is hydrido; and wherein p is two.
- 30 113. The method of Claim 92 wherein said angiotensin II antagonist compound is 4'-[2-butyl-5-chloro-4-(hydroxymethyl)-1H-imidazol-1-ylmethyl][1,1'-biphenyl]-2-carboxylic acid.

114. The method of Claim 113 wherein said conjugate is N-acetyl-L-glutamic acid, 5-[[4'-[2-butyl-5-chloro-4-(hydroxymethyl)-1H-imidazol-1-ylmethyl][1,1'-biphenyl]-2-yl]carbonyl]hydrazide.

5

115. The method of Claim 113 wherein said conjugate is N^2 -acetyl-N-[[2-butyl-5-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazol-4-yl]methyl]-L-glutamine.

10

116. The method of Claim 113 which is N-acetyl-L-glutamic acid, 5-[2-butyl-5-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazol-4-yl]acetylhydrazide.

15

117. The method of Claim 93 wherein said angiotensin II antagonist compound is 4'-[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-ylmethyl][1,1'-biphenyl]-2-carboxylic acid.

20

118. The method of Claim 117 which is N-acetyl-L-glutamic acid, 5-[[4'-[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-ylmethyl][1,1'-biphenyl]-2-yl]carbonyl]hydrazide.

25

119. The method of Claim 117 which is N^2 -acetyl-N-[[2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazol-5-yl]methyl]-L-glutamine.

30

120. The sthod of Claim 117 which is N-acetyl-L-glutamic acid, 5-[2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazol-5-yl]acetylhydrazide.

35

121. The method of Claim 81 wherein said hypertensive-related disorder is chronic hypertension.

376

- 122. The method of Claim 81 wherein said sodium-retaining disorder is congestive heart failure.
- 123. The method of Claim 81 wherein said 5 sodium-retaining disorder is cirrhosis.
 - 124. The method of Claim 81 wherein said sodium-retaining disorder is nephrosis.

1/4

Chronic Infusion of Example #81 Conjugate




Figure 1

2/4

Acute Angiotensin II Pressor Response During Chronic Infusion of Example #81 Conjugate




Figure 2




Figure 3

Mean Arterial Pressure Responses to Acute Angiotensin II Infusion




Figure 4